10-Q

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 10-Q

(Mark One)

☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934.

For the quarterly period ended March 31, 2017.

OR

☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the transition period from             to             

Commission file number 001-08895

HCP, INC.

(Exact name of registrant as specified in its charter)

Maryland	33-0091377
(State or other jurisdiction of incorporation or organization)	(I.R.S. Employer Identification No.)

1920 Main Street, Suite 1200

Irvine, CA 92614

(Address of principal executive offices)

(949) 407-0700

(Registrant’s telephone number, including area code)

(Former name, former address and former fiscal year, if changed since last report)

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.  YES ☒ NO ☐

Indicate by check mark whether the registrant has submitted electronically and posted on its corporate Web site, if any, every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or such shorter period that the registrant was required to submit and post such files).  YES ☒ NO ☐

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, smaller reporting company or an emerging growth company. See definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company” and “emerging growth company” in Rule 12b-2 of the Exchange Act.

Large Accelerated Filer ☒	Accelerated Filer ☐
Non-accelerated Filer ☐	Smaller Reporting Company ☐
(Do not check if a smaller reporting company)
	Emerging Growth Company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.    ☐

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act)  YES ☐ NO ☒

At April 28, 2017, there were 468,572,028 shares of the registrant’s $1.00 par value common stock outstanding.

HCP, INC.

INDEX

PART I. FINANCIAL INFORMATION
Item 1.	Financial Statements (Unaudited):
	Consolidated Balance Sheets	3
	Consolidated Statements of Operations	4
	Consolidated Statements of Comprehensive Income	5
	Consolidated Statements of Equity	6
	Consolidated Statements of Cash Flows	7
	Notes to the Consolidated Financial Statements	8
Item 2.	Management’s Discussion and Analysis of Financial Condition and Results of Operations	31
Item 3.	Quantitative and Qualitative Disclosures About Market Risk	50
Item 4.	Controls and Procedures	51
PART II. OTHER INFORMATION
Item 1.	Legal Proceedings	52
Item 1A.	Risk Factors	52
Item 2.	Unregistered Sales of Equity Securities and Use of Proceeds	53
Item 5.	Other Information	54
Item 6.	Exhibits	55
Signatures		56

2

HCP, Inc.

CONSOLIDATED BALANCE SHEETS

(In thousands, except share and per share data)

(Unaudited)

	March 31,		December 31,
	2017		2016
ASSETS
Real estate:
Buildings and improvements	$	11,008,771	$	11,692,654
Development costs and construction in progress		430,007		400,619
Land		1,772,174		1,881,487
Accumulated depreciation and amortization		(2,577,248)		(2,648,930)
Net real estate		10,633,704		11,325,830
Net investment in direct financing leases		712,540		752,589
Loans receivable, net		788,486		807,954
Investments in and advances to unconsolidated joint ventures		827,202		571,491
Accounts receivable, net of allowance of $3,941 and $4,459, respectively		31,500		45,116
Cash and cash equivalents		764,114		94,730
Restricted cash		60,806		42,260
Intangible assets, net		432,109		479,805
Assets held for sale, net		—		927,866
Other assets, net		605,407		711,624
Total assets	$	14,855,868	$	15,759,265
LIABILITIES AND EQUITY
Bank line of credit	$	492,421	$	899,718
Term loans		274,103		440,062
Senior unsecured notes		7,136,336		7,133,538
Mortgage debt		147,329		623,792
Other debt		91,263		92,385
Intangible liabilities, net		54,472		58,145
Liabilities of assets held for sale, net		—		3,776
Accounts payable and accrued liabilities		344,908		417,360
Deferred revenue		141,561		149,181
Total liabilities		8,682,393		9,817,957
Commitments and contingencies
Common stock, $1.00 par value: 750,000,000 shares authorized; 468,446,208 and 468,081,489 shares issued and outstanding, respectively		468,446		468,081
Additional paid-in capital		8,203,778		8,198,890
Cumulative dividends in excess of earnings		(2,802,218)		(3,089,734)
Accumulated other comprehensive loss		(28,658)		(29,642)
Total stockholders’ equity		5,841,348		5,547,595
Joint venture partners		154,161		214,377
Non-managing member unitholders		177,966		179,336
Total noncontrolling interests		332,127		393,713
Total equity		6,173,475		5,941,308
Total liabilities and equity	$	14,855,868	$	15,759,265

See accompanying Notes to the Consolidated Financial Statements.

3

HCP, Inc.

CONSOLIDATED STATEMENTS OF OPERATIONS

(In thousands, except per share data)

(Unaudited)

	Three Months Ended March 31,
	2017		2016
Revenues:
Rental and related revenues	$	286,218	$	290,380
Tenant recoveries		33,675		31,375
Resident fees and services		140,232		165,763
Income from direct financing leases		13,712		14,910
Interest income		18,331		18,029
Total revenues		492,168		520,457
Costs and expenses:
Interest expense		86,718		122,062
Depreciation and amortization		136,554		139,855
Operating		159,081		175,957
General and administrative		22,478		25,451
Acquisition and pursuit costs		1,057		2,475
Total costs and expenses		405,888		465,800
Other income (expense):
Gain on sales of real estate, net		317,258		—
Other income, net		51,208		1,292
Total other income, net		368,466		1,292
Income before income taxes and equity income (loss) from unconsolidated joint ventures		454,746		55,949
Income tax benefit (expense)		6,162		(3,704)
Equity income (loss) from unconsolidated joint ventures		3,269		(908)
Income from continuing operations		464,177		51,337
Discontinued operations:
Income before income taxes		—		117,742
Income taxes		—		(49,334)
Total discontinued operations		—		68,408
Net income		464,177		119,745
Noncontrolling interests’ share in earnings		(3,032)		(3,626)
Net income attributable to HCP, Inc.		461,145		116,119
Participating securities’ share in earnings		(770)		(357)
Net income applicable to common shares	$	460,375	$	115,762
Basic earnings per common share:
Continuing operations	$	0.98	$	0.10
Discontinued operations		—		0.15
Net income applicable to common shares	$	0.98	$	0.25
Diluted earnings per common share:
Continuing operations	$	0.97	$	0.10
Discontinued operations		—		0.15
Net income applicable to common shares	$	0.97	$	0.25
Weighted average shares used to calculate earnings per common share:
Basic		468,299		466,074
Diluted		475,173		466,262
Dividends declared per common share	$	0.37	$	0.575

See accompanying Notes to the Consolidated Financial Statements.

4

HCP, Inc.

CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME

(In thousands)

(Unaudited)

	Three Months Ended March 31,
	2017		2016
Net income	$	464,177	$	119,745
Other comprehensive income (loss):
Change in net unrealized gains (losses) on securities		9		(15)
Change in net unrealized gains (losses) on cash flow hedges:
Unrealized losses		(302)		(690)
Reclassification adjustment realized in net income		213		169
Change in Supplemental Executive Retirement Plan obligation		74		70
Foreign currency translation adjustment		990		(737)
Total other comprehensive income (loss)		984		(1,203)
Total comprehensive income		465,161		118,542
Total comprehensive income attributable to noncontrolling interests		(3,032)		(3,626)
Total comprehensive income attributable to HCP, Inc.	$	462,129	$	114,916

See accompanying Notes to the Consolidated Financial Statements.

5

HCP, Inc.

CONSOLIDATED STATEMENTS OF EQUITY

(In thousands, except per share data)

(Unaudited)

						Cumulative		Accumulated
				Additional		Dividends		Other		Total		Total
	Common Stock			Paid-In		In Excess		Comprehensive		Stockholders’		Noncontrolling		Total
	Shares	Amount		Capital		Of Earnings		Loss		Equity		Interests		Equity
January 1, 2017	468,081	$	468,081	$	8,198,890	$	(3,089,734)	$	(29,642)	$	5,547,595	$	393,713	$	5,941,308
Net income	—		—		—		461,145		—		461,145		3,032		464,177
Other comprehensive income	—		—		—		—		984		984		—		984
Issuance of common stock, net	427		427		3,045		—		—		3,472		—		3,472
Conversion of DownREIT units to common stock	54		54		1,494		—		—		1,548		(1,548)		—
Repurchase of common stock	(116)		(116)		(3,416)		—		—		(3,532)		—		(3,532)
Amortization of deferred compensation	—		—		3,765		—		—		3,765		—		3,765
Common dividends ($0.37 per share)	—		—		—		(173,629)		—		(173,629)		—		(173,629)
Distributions to noncontrolling interests	—		—		—		—		—		—		(5,659)		(5,659)
Issuance of noncontrolling interests	—		—		—		—		—		—		650		650
Deconsolidation of noncontrolling interests	—		—		—		—		—		—		(58,061)		(58,061)
March 31, 2017	468,446	$	468,446	$	8,203,778	$	(2,802,218)	$	(28,658)	$	5,841,348	$	332,127	$	6,173,475

						Cumulative		Accumulated
				Additional		Dividends		Other		Total		Total
	Common Stock			Paid-In		In Excess		Comprehensive		Stockholders’		Noncontrolling		Total
	Shares	Amount		Capital		Of Earnings		Loss		Equity		Interests		Equity
January 1, 2016	465,488	$	465,488	$	11,647,039	$	(2,738,414)	$	(30,470)	$	9,343,643	$	402,674	$	9,746,317
Net income	—		—		—		116,119		—		116,119		3,626		119,745
Other comprehensive loss	—		—		—		—		(1,203)		(1,203)		—		(1,203)
Issuance of common stock, net	1,428		1,428		33,978		—		—		35,406		—		35,406
Conversion of DownREIT units to common stock	—		—		—		—		—		—		(4,136)		(4,136)
Repurchase of common stock	(102)		(102)		(3,526)		—		—		(3,628)		—		(3,628)
Exercise of stock options	111		111		2,741		—		—		2,852		—		2,852
Amortization of deferred compensation	—		—		5,345		—		—		5,345		—		5,345
Common dividends ($0.575 per share)	—		—		—		(268,186)		—		(268,186)		—		(268,186)
Distributions to noncontrolling interests	—		—		(36)		—		—		(36)		(4,853)		(4,889)
Issuance of noncontrolling interests	—		—		—		—		—		—		2,200		2,200
Deconsolidation of noncontrolling interests	—		—		—		435		—		435		67		502
March 31, 2016	466,925	$	466,925	$	11,685,541	$	(2,890,046)	$	(31,673)	$	9,230,747	$	399,578	$	9,630,325

See accompanying Notes to the Consolidated Financial Statements.

6

HCP, Inc.

CONSOLIDATED STATEMENTS OF CASH FLOWS

(In thousands)

(Unaudited)

	Three Months Ended March 31,
	2017		2016
Cash flows from operating activities:
Net income	$	464,177	$	119,745
Adjustments to reconcile net income to net cash provided by operating activities:
Depreciation and amortization of real estate, in-place lease and other intangibles:
Continuing operations		136,554		139,855
Discontinued operations		—		1,467
Amortization of deferred compensation		3,765		5,345
Amortization of deferred financing costs		3,858		5,280
Straight-line rents		(5,007)		(7,576)
Equity (income) loss from unconsolidated joint ventures		(3,269)		908
Distributions of earnings from unconsolidated joint ventures		7,842		1,589
Gain on sales of real estate, net		(317,258)		—
Deferred income tax (benefit) expense		(8,130)		49,156
Foreign exchange and other gains, net		(77)		(89)
Gain on sale of marketable securities		(50,895)		—
Other non-cash items		(583)		(922)
Changes in:
Accounts receivable, net		3,467		3,705
Other assets, net		(2,331)		(6,847)
Accounts payable and accrued liabilities		(38,984)		(42,999)
Net cash provided by operating activities		193,129		268,617
Cash flows from investing activities:
Acquisitions of real estate		—		(94,271)
Development of real estate		(75,166)		(99,096)
Leasing costs and tenant and capital improvements		(22,693)		(19,964)
Proceeds from sales of real estate, net		1,166,265		—
Contributions to unconsolidated joint ventures		(8,109)		(10,136)
Distributions in excess of earnings from unconsolidated joint ventures		870		5,336
Net proceeds from the RIDEA II transaction (Note 4)		480,613		—
Proceeds from the sales of Four Seasons investments		135,538		—
Principal repayments on direct financing leases, loans receivable and other		49,826		155,320
Investments in loans receivable and other		(15,000)		(117,282)
Decrease in restricted cash		3,073		14,336
Net cash provided by (used in) investing activities		1,715,217		(165,757)
Cash flows from financing activities:
Net (repayments) borrowings under bank line of credit		(375,812)		422,897
Repayments under bank line of credit		(37,032)		—
Repayment of term loan		(169,113)		—
Repayments of senior unsecured notes		—		(500,000)
Repayments of mortgage and other debt		(478,314)		(36,918)
Issuance of common stock and exercise of options		3,472		34,122
Repurchase of common stock		(3,532)		(3,628)
Dividends paid on common stock		(173,629)		(268,186)
Issuance of noncontrolling interests		650		2,200
Distributions to noncontrolling interests		(5,659)		(4,889)
Net cash used in financing activities		(1,238,969)		(354,402)
Effect of foreign exchange on cash and cash equivalents		7		(293)
Net increase (decrease) in cash and cash equivalents		669,384		(251,835)
Cash and cash equivalents, beginning of period		94,730		346,500
Cash and cash equivalents, end of period	$	764,114	$	94,665
Less: cash and cash equivalents of discontinued operations		—		(3,578)
Cash and Cash equivalents of continuing operations, end of period	$	764,114	$	91,087

See accompanying Notes to the Consolidated Financial Statements.

7

HCP, Inc.

NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS

(Unaudited)

NOTE 1.  Business

HCP, Inc., a Standard & Poor’s (“S&P”) 500 company, is a Maryland corporation that is organized to qualify as a real estate investment trust (“REIT”) which, together with its consolidated entities (collectively, “HCP” or the “Company”), invests primarily in real estate serving the healthcare industry in the United States (“U.S.”). The Company acquires, develops, leases, manages and disposes of healthcare real estate and provides financing to healthcare providers. The Company’s diverse portfolio is comprised of investments in the following reportable healthcare segments: (i) senior housing triple-net (“SH NNN”); (ii) senior housing operating portfolio (“SHOP”); (iii) life science and (iv) medical office.

NOTE 2.  Summary of Significant Accounting Policies

Basis of Presentation

The accompanying unaudited consolidated financial statements have been prepared in accordance with U.S. generally accepted accounting principles (“GAAP”) for interim financial information. Management is required to make estimates and assumptions in the preparation of financial statements in conformity with GAAP. These estimates and assumptions affect the reported amounts of assets and liabilities and the disclosure of contingent assets and liabilities at the date of the consolidated financial statements and the reported amounts of revenue and expenses during the reporting period. Actual results could differ from management’s estimates.

The consolidated financial statements include the accounts of HCP, Inc., its wholly-owned subsidiaries, joint ventures (“JVs”) and VIEs that it controls through voting rights or other means. Intercompany transactions and balances have been eliminated upon consolidation. In the opinion of management, all adjustments (consisting of normal recurring adjustments) necessary to present fairly the Company’s financial position, results of operations and cash flows have been included. Operating results for the three months ended March 31, 2017 are not necessarily indicative of the results that may be expected for the year ending December 31, 2017. The accompanying unaudited interim financial information should be read in conjunction with the consolidated financial statements and notes thereto for the year ended December 31, 2016 included in the Company’s Annual Report on Form 10-K filed with the U.S. Securities and Exchange Commission (“SEC”).

Real Estate

On January 1, 2017 the Company adopted Accounting Standards Update (“ASU”) No. 2017-01, Clarifying the Definition of a Business (“ASU 2017-01”) which narrows the Financial Accounting Standards Board’s (“FASB”) definition of a business and provides a framework that gives entities a basis for making reasonable judgments about whether a transaction involves an asset, or a group of assets, or a business. ASU 2017-01 states that when substantially all of the fair value of the gross assets acquired (or disposed of) is concentrated in a single identifiable asset or group of similar identifiable assets, the set is not a business. If this initial test is not met, a set cannot be considered a business unless it includes an acquired input and a substantive process that together significantly contribute to the ability to create outputs. In addition, ASU 2017-01 clarifies the requirements for a set of activities to be considered a business and narrows the definition of an output. This ASU is to be applied prospectively and the Company expects that a majority of its future real estate acquisitions and dispositions will be deemed asset transactions rather than business combinations. As a result, for asset acquisitions the Company will record identifiable assets acquired, liabilities assumed and any associated noncontrolling interests at cost on a relative fair value basis. In addition, for such asset acquisitions, no goodwill will be recognized, third party transaction costs will be capitalized and any associated contingent consideration will be recorded when the contingency is resolved.

Segment Reporting

The Company’s reportable segments, based on how it evaluates its business and allocates resources, are as follows: (i) SH NNN, (ii) SHOP, (iii) life science and (iv) medical office.

8

Prior to the third quarter of 2016, the Company had five reportable segments: (i) senior housing, (ii) post-acute/skilled nursing, (iii) life science, (iv) medical office and (v) hospital. During the third quarter of 2016, primarily as a result of the planned spin-off of Quality Care Properties, Inc. (“QCP”) (NYSE:QCP), the Company revised its operating analysis structure and changed its reportable segments. The Company believes the change to its reportable segments is appropriate and consistent with how its chief operating decision makers review the Company’s operating results and determine resource allocations. Accordingly, all prior period segment information has been reclassified to conform to the current period presentation.

Reclassifications

Certain amounts in the Company’s consolidated financial statements have been reclassified for prior periods to conform to the current period presentation. Certain prior period amounts have been reclassified on consolidated statements of operations for discontinued operations (see Note 4). See Segment Reporting above for additional reclassifications.

Recent Accounting Pronouncements

In February 2017, the FASB issued ASU No. 2017-05, Clarifying the Scope of Asset Derecognition Guidance and Accounting for Partial Sales of Nonfinancial Assets (“ASU 2017-05”). The amendments in ASU 2017-05 clarify the scope of the FASB’s recently established guidance on nonfinancial asset derecognition which applies to the derecognition of all nonfinancial assets and in-substance nonfinancial assets. In addition, ASU 2017-05 clarifies the accounting for partial sales of nonfinancial assets and in-substance nonfinancial assets to align with the new revenue recognition standard (see below). ASU 2017-05 is effective for annual periods beginning after December 15, 2017, including interim periods within, and must be adopted in conjunction with the Revenue ASUs (as defined below). ASU 2017-05 can be adopted using a full retrospective approach or a modified retrospective approach, resulting in a cumulative-effect adjustment to equity as of the beginning of the fiscal year in which the guidance is effective. Under either transition election, the Company will reassess its partial sale of RIDEA II, completed in the first quarter of 2017, and record its retained 40% equity interest at fair value as of the sale completion date. The Company estimates the fair value of its retained equity investment as of the sale completion date to be approximately $107 million which upon adoption, will increase the Company’s gain on sales of real estate, net for the period ended March 31, 2017 by the same amount. See Note 4 for further information on the RIDEA II transaction.

In June 2016, the FASB issued ASU No. 2016-13, Measurement of Credit Losses on Financial Instruments (“ASU 2016-13”). ASU 2016-13 is intended to improve financial reporting by requiring timelier recognition of credit losses on loans and other financial instruments held by financial institutions and other organizations. The amendments in ASU 2016-13 eliminate the “probable” initial threshold for recognition of credit losses in current accounting guidance and, instead, reflect an entity’s current estimate of all expected credit losses over the life of the financial instrument. Previously, when credit losses were measured under current accounting guidance, an entity generally only considered past events and current conditions in measuring the incurred loss. The amendments in ASU 2016-13 broaden the information that an entity must consider in developing its expected credit loss estimate for assets measured either collectively or individually. The use of forecasted information incorporates more timely information in the estimate of expected credit loss. ASU 2016-13 is effective for fiscal years, and interim periods within, beginning after December 15, 2019. Early adoption is permitted for fiscal years, and interim periods within, beginning after December 15, 2018. A reporting entity is required to apply the amendments in ASU 2016-13 using a modified retrospective approach by recording a cumulative-effect adjustment to equity as of the beginning of the fiscal year of adoption. A prospective transition approach is required for debt securities for which an other-than-temporary impairment had been recognized before the effective date. Upon adoption of ASU 2016-13, the Company is required to reassess its financing receivables, including direct finance leases and loans receivable, and expects that application of ASU 2016-13 may result in the Company recognizing credit losses at an earlier date than would otherwise be recognized under current accounting guidance. The Company is evaluating the impact of the adoption of ASU 2016-13 on January 1, 2020 to its consolidated financial position and results of operations.

In February 2016, the FASB issued ASU No. 2016-02, Leases (“ASU 2016-02”). ASU 2016-02 amends the current accounting for leases to: (i) require lessees to put most leases on their balance sheets, but continue recognizing expenses on their income statements in a manner similar to requirements under current accounting guidance, (ii) eliminate current real estate specific lease provisions and (iii) modify the classification criteria and accounting for sales-type leases for lessors. ASU 2016-02 is effective for fiscal years, and interim periods within, beginning after December 15, 2018. Early adoption is permitted. The transition method required by ASU 2016-02 varies based on the specific amendment being

9

adopted. As a result of adopting ASU 2016-02, the Company will recognize all of its operating leases for which it is the lessee, including corporate office leases and ground leases, on its consolidated balance sheets and will capitalize fewer legal costs related to the drafting and execution of its lease agreements. In addition, the Company expects that it will have to bifurcate lease agreements into lease components and certain non-lease components. Lease components will continue to be recognized on a straight-line basis over the lease term and certain non-lease components will be accounted for under the new revenue recognition guidance in ASU 2014-09. The Company is evaluating the impact of the adoption of ASU 2016-02 on January 1, 2019 to its consolidated financial position and results of operations.

Between May 2014 and May 2016, the FASB issued three ASUs changing the requirements for recognizing and reporting revenue (together, herein referred to as the “Revenue ASUs”): (i) ASU No. 2014-09, Revenue from Contracts with Customers (“ASU 2014-09”), (ii) ASU No. 2016-08, Principal versus Agent Considerations (Reporting Revenue Gross versus Net) (“ASU 2016-08”) and (iii) ASU No. 2016-12, Narrow-Scope Improvements and Practical Expedients (“ASU 2016-12”). ASU 2014-09 provides guidance for revenue recognition to depict the transfer of promised goods or services to customers in an amount that reflects the consideration to which the entity expects to be entitled in exchange for those goods or services. ASU 2016-08 is intended to improve the operability and understandability of the implementation guidance on principal versus agent considerations. ASU 2016-12 provides practical expedients and improvements on the previously narrow scope of ASU 2014-09. In August 2015, the FASB issued ASU No. 2015-14, Revenue from Contracts with Customers (Topic 606): Deferral of the Effective Date (“ASU 2015-14”). ASU 2015-14 defers the effective date of ASU 2014-09 by one year to fiscal years, and interim periods within, beginning after December 15, 2017. All subsequent ASUs related to ASU 2014-09, including ASU 2016-08 and ASU 2016-12, assumed the deferred effective date enforced by ASU 2015-14. Early adoption of the Revenue ASUs is permitted for annual periods, and interim periods within, beginning after December 15, 2016. A reporting entity may apply the amendments in the Revenue ASUs using either a modified retrospective approach, by recording a cumulative-effect adjustment to equity as of the beginning of the fiscal year of adoption or full retrospective approach. The Company has not yet elected a transition method and is evaluating the complete impact of the adoption of the Revenue ASUs on January 1, 2018 to its consolidated financial position, results of operations and disclosures. The Company expects to complete its evaluation of the impacts of the Revenue ASUs during the second half of 2017. As the primary source of revenue for the Company is generated through leasing arrangements, which are excluded from the Revenue ASUs,the Company expects that it will be impacted in its recognition and disclosure of non-lease revenue, such as certain resident fees in its RIDEA structures (a portion of which are not generated through leasing arrangements), non-lease components of revenue from lease agreements (upon adoption of ASU 2016-02) and its recognition of real estate sale transactions. Under ASU 2014-09, revenue recognition for real estate sales is largely based on the transfer of control versus continuing involvement under current guidance. As a result, the Company generally expects that the new guidance will result in more transactions qualifying as sales of real estate and revenue being recognized at an earlier date than under current accounting guidance.

The following ASUs have been issued, but not yet adopted, and the Company does not expect a material impact to its consolidated financial position, results of operations, cash flows, or disclosures upon adoption:

· ASU No. 2017-04, Simplifying the Test for Goodwill Impairment (“ASU 2017-04”). ASU 2017-04 is effective for fiscal years, including interim periods within, beginning after December 15, 2019 (upon the first goodwill impairment test performed during that fiscal year). Early adoption is permitted for interim or annual goodwill impairment tests performed on testing dates after January 1, 2017. A reporting entity must apply the amendments in ASU 2017-04 using a prospective approach.

· ASU No. 2016-18, Restricted Cash (“ASU 2016-18”). ASU 2016-18 is effective for fiscal years, and interim periods within, beginning after December 15, 2017. Early adoption is permitted. A reporting entity must apply the amendments in ASU 2016-18 using a full retrospective approach.

· ASU No. 2016-15, Classification of Certain Cash Receipts and Cash Payments (“ASU 2016-15”). ASU 2016-15 is effective for fiscal years, and interim periods within, beginning after December 15, 2017. Early adoption is permitted. A reporting entity must apply the amendments in ASU 2016-15 using a full retrospective approach.

· ASU No. 2016-01, Recognition and Measurement of Financial Assets and Financial Liabilities (“ASU 2016-01”). ASU 2016-01 is effective for fiscal years, and interim periods within, beginning after December 15, 2017. Early adoption is permitted only for updates to certain disclosure requirements. A reporting entity is required to

10

apply the amendments in ASU 2016-01 using a modified retrospective approach by recording a cumulative-effect adjustment to equity as of the beginning of the fiscal year of adoption.

· ASU No. 2016-16, Intra-Entity Transfers of Assets Other Than Inventory (“ASU 2016-16”). ASU 2016-16 is effective for fiscal years, and interim periods within, beginning after December 15, 2017. Early adoption is permitted as of the first interim period presented in any year following issuance. A reporting entity must apply the amendments in ASU 2016-16 using a modified retrospective approach by recording a cumulative-effect adjustment to equity as of the beginning of the fiscal year of adoption. 

NOTE 3.  Real Estate Property Investments

The following table summarizes the Company’s real estate acquisitions for the three months ended March 31, 2016 (in thousands):

	Consideration				Assets Acquired
	Cash Paid/		Liabilities				Net
Segment	Debt Settled		Assumed		Real Estate		Intangibles
SH NNN	$	76,362	$	1,200	$	71,875	$	5,687
Other non-reportable segments		17,909		—		16,596		1,313
	$	94,271	$	1,200	$	88,471	$	7,000

There were no real estate acquisitions for the three months ended March 31, 2017.

NOTE 4.  Discontinued Operations and Dispositions of Real Estate

Discontinued Operations - Quality Care Properties, Inc.

On October 31, 2016, the Company completed the spin-off (the “Spin-Off”) of its subsidiary, QCP. The Spin-Off included 338 properties, primarily comprised of the HCR ManorCare, Inc. (“HCRMC”) direct financing lease (“DFL”) investments and an equity investment in HCRMC. QCP is an independent, publicly-traded, self-managed and self-administrated REIT.

In connection with the Spin-Off, the Company entered into a Transition Services Agreement (“TSA”) with QCP. Per the terms of the TSA, the Company has agreed to provide certain administrative and support services to QCP on a transitional basis for established fees. The TSA will terminate on the expiration of the term of the last service provided under the agreement, which will be on or prior to October 30, 2017. The TSA provides that QCP generally has the right to terminate a transition service upon thirty days notice to the Company. The TSA contains provisions under which the Company will, subject to certain limitations, be obligated to indemnify QCP for losses incurred by QCP resulting from the Company’s breach of the TSA.

11

Summarized financial information for discontinued operations for the three months ended March 31, 2016 is as follows (in thousands):

	Three Months Ended
	March 31, 2016
Revenues:
Rental and related revenues	$	6,814
Tenant recoveries		362
Income from direct financing leases		113,058
Total revenues		120,234
Costs and expenses:
Depreciation and amortization		(1,467)
Operating		(998)
General and administrative		(48)
Other income, net		21
Income before income taxes		117,742
Income tax expense		(49,334)
Net income from discontinued operations	$	68,408

HCR ManorCare, Inc.

Discontinued operations is primarily comprised of QCP’s HCRMC DFL investments. During the three months ended March 31, 2016, the Company recognized DFL income and received cash payments of $113 million from the HCRMC DFL investments.

No accretion related to its HCRMC DFL investments was recognized in 2016 due to the Company utilizing a cash basis method of accounting beginning January 1, 2016.

The Company’s acquisition of the HCRMC DFL investments in 2011 was subject to federal and state built-in gain tax of up to $2 billion, if all the assets were sold within 10 years of the acquisition date. At the time of acquisition, the Company intended to hold the assets for at least 10 years, at which time the assets would no longer be subject to the built-in gain tax. In December 2015, the U.S. Federal Government passed legislation which permanently reduced the holding period, for federal tax purposes, to five years, which the Company satisfied in April 2016. This legislation was not extended to certain states, which maintain a 10 year requirement. During the three months ended March 31, 2016, the Company determined that it may sell assets during the next five years and, therefore, recorded a deferred tax liability of $49 million representing its estimated exposure to state built-in gain tax.

Dispositions of Real Estate

Held for Sale

At December 31, 2016, 64 SH NNN facilities, four life science facilities and a SHOP facility were classified as held for sale, with an aggregate carrying value of $928 million, primarily comprised of real estate assets of $809 million. All facilities held for sale at December 31, 2016 were sold during the first quarter of 2017.

At March 31, 2017, there were no assets classified as held for sale.

2017 Dispositions

In January 2017, the Company sold four life science facilities in Salt Lake City, Utah for $76 million, resulting in a net gain on sale of $45 million.

Also in January 2017, the Company completed the contribution of its ownership interest in RIDEA II to an unconsolidated JV owned by HCP and an investor group led by Columbia Pacific Advisors, LLC (“HCP/CPA PropCo” and “HCP/CPA OpCo,” together, the “HCP/CPA JV”). In addition, RIDEA II was recapitalized with $602 million of debt, of which $360 million was provided by a third-party and $242 million was provided by HCP. In return, for both transaction elements the Company received combined proceeds of $480 million from the HCP/CPA JV and $242 million in note receivables and

12

retained an approximately 40% beneficial interest in RIDEA II (the note receivable and 40% beneficial interest are herein referred to as the “RIDEA II Investments”). This transaction resulted in the Company deconsolidating the net assets of RIDEA II and recognizing a net gain on sale of $99 million. The RIDEA II Investments are now recognized and accounted for as equity method investments.

In March 2017, the Company sold 64 SH NNN assets, previously under triple-net leases with Brookdale Senior Living Inc. (“Brookdale”), for $1.125 billion to affiliates of Blackstone Real Estate Partners VIII, L.P., resulting in a net gain on sale of $170 million.

Subsequent Dispositions

In April 2017, the Company sold a land parcel in San Diego, California for $27 million.

NOTE 5.  Net Investment in Direct Financing Leases

Net investment in DFLs consisted of the following (dollars in thousands):

	March 31,		December 31,
	2017		2016
Minimum lease payments receivable	$	1,095,233	$	1,108,237
Estimated residual values		500,368		539,656
Less unearned income		(883,061)		(895,304)
Net investment in direct financing leases	$	712,540	$	752,589
Properties subject to direct financing leases		29		30

Certain DFLs contain provisions that allow the tenants to elect to purchase the properties during or at the end of the lease terms for the aggregate initial investment amount plus adjustments, if any, as defined in the lease agreements. Certain leases also permit the Company to require the tenants to purchase the properties at the end of the lease terms.

In March 2017, the Company sold a hospital in Palm Beach Gardens, Florida for $43 million to the current tenant.

Direct Financing Lease Internal Ratings

The following table summarizes the Company’s internal ratings for DFLs at March 31, 2017 (dollars in thousands):

	Carrying		Percentage of	Internal Ratings
Segment	Amount		DFL Portfolio	Performing DFLs		Watch List DFLs		Workout DFLs
SH NNN	$	627,936	88	$	268,350	$	359,586	$	—
Other non-reportable segments		84,604	12		84,604		—		—
	$	712,540	100	$	352,954	$	359,586	$	—

Beginning September 30, 2013, the Company placed a 14 property senior housing triple-net DFL (the “DFL Watchlist Portfolio”) on nonaccrual status and “Watch List” status. The Company determined that the collection of all rental payments was and continues to be no longer reasonably assured; therefore, rental revenue for the DFL Watchlist Portfolio has been recognized on a cash basis.

During both the three months ended March 31, 2017 and 2016, the Company recognized DFL income of $3 million and received cash payments of $4 million from the DFL Watchlist Portfolio. The carrying value of the DFL Watchlist Portfolio was $360 million and $361 million at March 31, 2017 and December 31, 2016, respectively.

13

NOTE 6.  Loans Receivable

The following table summarizes the Company’s loans receivable (in thousands):

	March 31, 2017						December 31, 2016
	Real Estate		Other				Real Estate		Other
	Secured		Secured		Total		Secured		Secured		Total
Mezzanine(1) (2)	$	—	$	625,116	$	625,116	$	—	$	615,188	$	615,188
Other(3)		166,595		—		166,595		195,946		—		195,946
Unamortized discounts, fees and costs		—		(3,225)		(3,225)		413		(3,593)		(3,180)
	$	166,595	$	621,891	$	788,486	$	196,359	$	611,595	$	807,954

(1) At March 31, 2017, included £280 million ($350 million) outstanding and £2 million ($2 million) of associated unamortized discounts, fees and costs, both related to the HC-One Facility. At December 31, 2016, included £282 million ($348 million) outstanding and £2 million ($3 million) of associated unamortized discounts, fees and costs, both related to the HC-One Facility.

(2) At March 31, 2017, the Company had £29 million ($36 million) remaining under its commitments to fund development projects and capital expenditures under its United Kingdom (“U.K.”)  development projects.

(3) At March 31, 2017, included £116 million ($145 million) outstanding related to Maria Mallaband loans.

Loans Receivable Internal Ratings

The following table summarizes the Company’s internal ratings for loans receivable at March 31, 2017 (dollars in thousands):

	Carrying		Percentage of	Internal Ratings
Investment Type	Amount		Loan Portfolio	Performing Loans		Watch List Loans		Workout Loans
Real estate secured	$	166,595	21	$	166,595	$	—	$	—
Other secured		621,891	79		365,318		256,573		—
	$	788,486	100	$	531,913	$	256,573	$	—

Real Estate Secured Loans

Four Seasons Health Care. In March 2017, the Company sold its investment in Four Seasons Health Care’s (“Four Seasons”) senior secured term loan at par plus accrued interest for £29 million ($35 million).

Other Secured Loans

Tandem Health Care Loan. On July 31, 2012, the Company closed a mezzanine loan facility to lend up to $205 million to Tandem Health Care (“Tandem”), as part of the recapitalization of a post-acute/skilled nursing portfolio (the “Tandem Portfolio”). The Company funded $100 million (the “First Tranche”) at closing and funded an additional $102 million (the “Second Tranche”) in June 2013. In May 2015, the Company increased and extended the mezzanine loan facility with Tandem to: (i) fund $50 million (the “Third Tranche”) and $5 million (the “Fourth Tranche”), which proceeds were used to repay a portion of Tandem’s existing senior and mortgage debt, respectively; (ii) extend its maturity to October 2018; and (iii) extend the prepayment penalty period through January 2017. The tranches (collectively, the “Tandem Mezzanine Loan”) bear interest at fixed annual rates of 12%, 14%,  6% and 6% per annum for the First, Second, Third and Fourth Tranches, respectively. The blended rate for the Tandem Mezzanine Loan is 11.5% per year. Due to a decline in the Tandem Portfolio’s operating performance, at September 30, 2016, the Company assigned an internal rating of “Watch List” to the Tandem Mezzanine Loan.At March 31, 2017, the Tandem Mezzanine Loan had an outstanding balance of $257 million and was subordinate to approximately $372 million of senior mortgage debt.

Tandem leases the entire Tandem Portfolio to Consulate Health Care (“Consulate”) under a master lease (the “Tandem and Consulate Lease”). At March 31, 2017, as a result of the Tandem Portfolio’s operating performance there are outstanding events of default under the Tandem and Consulate Lease (“Events of Default”) due to: (i) Consulate’s failure to meet certain financial covenants under the Tandem and Consulate Lease; and (ii) events of default under Consulate’s working capital facility, which, through a cross-default provision, are Events of Default. Additionally, Consulate failed to pay the full amount of its April 2017 rent under the Tandem and Consulate Lease which triggered another Event of Default. Through cross-default provisions, these Events of Default are also events of default under the Tandem Mezzanine Loan

14

and Tandem’s senior mortgage debt (each, a “Loan Event of Default”). The Tandem Mezzanine Loan requires Tandem to pay default interest at a rate of 16.5% per year, during periods in which there is an outstanding Loan Event of Default. Tandem did not pay the additional 5% default interest rate spread above the 11.5%  and, therefore created a monetary event of default under the Tandem Mezzanine Loan.

Although Tandem continues to remain current on its non-default interest payment obligations under the Tandem Mezzanine Loan, the Company believes that it is probable it will be unable to collect all interest and principal payments according to the contractual terms of the Tandem Mezzanine Loan. Because the Tandem Mezzanine Loan is deemed collateral-dependent, and the fair value of the underlying collateral, net of the fair value of the senior mortgage debt, at March 31, 2017, exceeds the carrying amount of the Tandem Mezzanine Loan, the Company has not recorded an impairment write-down at March 31, 2017. The Company will continue to monitor the fair value of the collateral, and other factors, to determine whether it will be required to record an impairment write-down in future periods. Additionally, beginning in the first quarter of 2017, the Company elected to recognize interest income on a cash basis. During both the three months ended March 31, 2017 and 2016, the Company recognized interest income and received cash payments of $7 million from Tandem.

The Company entered into a forbearance agreement with Tandem on May 1, 2017, pursuant to which it agreed to forbear from exercising remedies, including waiving default interest, with respect to the above-described Loan Events of Default under the Tandem Mezzanine Loan until June 30, 2017, subject to the satisfaction of certain conditions. Under the forbearance terms, among other conditions, Tandem is required to make timely non-default interest payments in full for each of May and June 2017, and no additional Event of Default or Loan Event of Default may occur. The Company’s forbearance is contingent on the senior mortgage lender also agreeing to forebear from exercising remedies, including waiving default interest, with respect to the above-described Loan Events of Default under the senior mortgage debt. The Company expects Tandem and Tandem’s senior mortgage lender to enter into such forbearance agreement in the near term.  

NOTE 7.  Investments in and Advances to Unconsolidated Joint Ventures

The Company owns interests in the following entities that are accounted for under the equity method at March 31, 2017 (dollars in thousands):

					Carrying Amount
					March 31,		December 31,
Entity(1)	Segment	Ownership%			2017		2016
CCRC JV(2)	SHOP		49		$	434,649	$	439,449
RIDEA II(6)	SHOP		40			263,180		—
HCP Life Science(4)	Life science	50	–	63		65,490		67,879
MBK JV(3)	SHOP		50			39,088		38,909
HCP Ventures IV, LLC	Medical office		20			7,338		7,277
Vintage Park Development JV	SHOP		85			6,953		7,486
Suburban Properties, LLC	Medical office		67			4,618		4,628
MBK Development JV(3)	SHOP		50			2,464		2,463
K&Y(5)	Other non-reportable segments		80			1,380		1,342
Advances to unconsolidated JVs, net and other						2,042		2,058
					$	827,202	$	571,491

(1) These entities are not consolidated because the Company does not control, through voting rights or other means, the JVs.

(2) Includes two unconsolidated JVs in a RIDEA structure (CCRC PropCo and CCRC OpCo).

(3) Includes two unconsolidated JVs in a RIDEA structure.

(4) Includes the following unconsolidated partnerships (and the Company’s ownership percentage): (i) Torrey Pines Science Center, LP (50%); (ii) Britannia Biotech Gateway, LP (55%) and (iii) LASDK, LP (63%).

(5) Includes three unconsolidated JVs.

(6) Includes three unconsolidated JVs in a RIDEA structure (HCP/CPA PropCo, HCP/CPA OpCo, and RIDEA II PropCo).

See Note 4 for further information on the deconsolidation of RIDEA II.

15

NOTE 8.  Intangibles

The following tables summarize the Company’s intangible lease assets and liabilities (in thousands):

	March 31,		December 31,
Intangible lease assets	2017		2016
Gross intangible lease assets	$	841,905	$	911,697
Accumulated depreciation and amortization		(409,796)		(431,892)
Intangible assets, net	$	432,109	$	479,805

	March 31,		December 31,
Intangible lease liabilities	2017		2016
Gross intangible lease liabilities	$	151,890	$	163,924
Accumulated depreciation and amortization		(97,418)		(105,779)
Intangible liabilities, net	$	54,472	$	58,145

NOTE 9.  Other Assets

The following table summarizes the Company’s other assets (in thousands):

	March 31,		December 31,
	2017		2016
Straight-line rent receivables, net of allowance of $25,173 and $25,059, respectively	$	316,125	$	311,776
Marketable debt securities, net		18,330		68,630
Leasing costs and inducements, net		87,553		156,820
Goodwill		47,019		42,386
Other		136,380		132,012
Total other assets	$	605,407	$	711,624

Four Seasons Health Care Senior Notes

In March 2017, pursuant to a shift in the Company’s investment strategy, the Company sold its £138.5 million par value Four Seasons senior notes (the “Four Seasons Notes”) for £83 million ($101 million).  The disposition of the Four Seasons Notes generated a £42 million ($51 million) gain on sale, recognized in other income, net, as the sales price was above the previously-impaired carrying value of £41 million ($50 million).  

NOTE 10.  Debt

Bank Line of Credit and Term Loans

The Company’s $2.0 billion unsecured revolving line of credit facility (the “Facility”) matures on March 31, 2018 and contains a committed one-year extension option, at a cost of 30 basis points. Borrowings under the Facility accrue interest at LIBOR plus a margin that depends on the Company’s credit ratings. The Company pays a facility fee on the entire revolving commitment that depends on its credit ratings. Based on the Company’s credit ratings at March 31, 2017, the margin on the Facility was 1.05% and the facility fee was 0.20%. The Facility also includes a feature that allows the Company to increase the borrowing capacity by an aggregate amount of up to $500 million, subject to securing additional commitments from existing lenders or new lending institutions. During the three months ended March 31, 2017, the Company repaid $440 million primarily using proceeds from the RIDEA II joint venture disposition (see Note 4). At March 31, 2017, the Company had £394 million ($492 million) outstanding under the Facility with a weighted average effective interest rate of 1.65%.

On July 30, 2012, the Company entered into a credit agreement with a syndicate of banks for a £137 million unsecured term loan (the “2012 Term Loan”). In March 2017, the Company repaid the 2012 Term Loan primarily using proceeds from the sale of the Four Seasons investments (see Notes 6 and 9).

16

On January 12, 2015, the Company entered into a credit agreement with a syndicate of banks for a £220 million ($275 million at March 31, 2017) four-year unsecured term loan (the “2015 Term Loan”) that accrues interest at a rate of GBP LIBOR plus 1.15%, subject to adjustments based on the Company’s credit ratings. The 2015 Term Loan matures on January 12, 2019 and contains a one-year committed extension option. Concurrently, the Company entered into a three-year interest rate swap contract that fixed the interest rate of the 2015 Term Loan (1.966% at March 31, 2017) (see Note 19).

The Facility and 2015 Term Loan contain certain financial restrictions and other customary requirements, including cross-default provisions to other indebtedness. Among other things, these covenants, using terms defined in the agreements: (i) limit the ratio of Consolidated Total Indebtedness to Consolidated Total Asset Value to 60%; (ii) limit the ratio of Secured Debt to Consolidated Total Asset Value to 30%; (iii) limit the ratio of Unsecured Debt to Consolidated Unencumbered Asset Value to 60%; and (iv) require a minimum Fixed Charge Coverage ratio of 1.5 times. The Facility and Term Loan also require a Minimum Consolidated Tangible Net Worth of $6.5 billion at March 31, 2017. At March 31, 2017, the Company was in compliance with each of these restrictions and requirements of the Facility and Term Loan.

Senior Unsecured Notes

At March 31, 2017, the Company had senior unsecured notes outstanding with an aggregate principal balance of $7.2 billion. The senior unsecured notes contain certain covenants including limitations on debt, maintenance of unencumbered assets, cross-acceleration provisions and other customary terms. The Company believes it was in compliance with these covenants at March 31, 2017.

The following table summarizes the Company’s senior unsecured notes payoffs for the year ended December 31, 2016 (dollars in thousands):

Date	Amount		Coupon Rate
February 1, 2016	$	500,000		3.750	%
September 15, 2016	$	400,000		6.300	%
November 30, 2016	$	500,000		6.000	%
November 30, 2016	$	600,000		6.700	%

There were no senior unsecured note payoffs for the three months ended March 31, 2017.

There were no senior unsecured notes issuances for the year ended December 31, 2016 and three months ended March 31, 2017.

Mortgage Debt

At March 31, 2017, the Company had $142 million in aggregate principal of mortgage debt outstanding, which is secured by 17 healthcare facilities (including redevelopment properties) with a carrying value of $311 million. In March 2017, the Company paid off $472 million of mortgage debt primarily using proceeds from the sale of 64 SH NNN facilities (see Note 4).

17

Debt Maturities

The following table summarizes the Company’s stated debt maturities and scheduled principal repayments at March 31, 2017 (in thousands):

					Senior
	Bank Line of				Unsecured		Mortgage
Year	Credit(1)		Term Loan(2)		Notes(3)		Debt(4)		Total(5)
2017 (nine months)	$	—	$	—	$	250,000	$	2,604	$	252,604
2018		492,421		—		—		3,641		496,062
2019		—		274,956		450,000		3,839		728,795
2020		—		—		800,000		3,907		803,907
2021		—		—		1,200,000		11,277		1,211,277
Thereafter		—		—		4,500,000		116,481		4,616,481
		492,421		274,956		7,200,000		141,749		8,109,126
(Discounts), premiums and debt costs, net		—		(853)		(63,664)		5,580		(58,937)
	$	492,421	$	274,103	$	7,136,336	$	147,329	$	8,050,189

(1) Represents £394 million translated into U.S. dollar (“USD”).

(2) Represents £220 million translated into USD.

(3) Effective interest rates on the notes ranged from 2.79% to 6.88% with a weighted average effective interest rate of 4.34% and a weighted average maturity of six years.

(4) Interest rates on the mortgage debt ranged from 2.99% to 7.51% with a weighted average effective interest rate of 4.24% and a weighted average maturity of 20 years.

(5) Excludes $91 million of other debt that have no scheduled maturities.

Subsequent Event

In April 2017, the Company repaid an additional £105 million of the Facility.

On May 1, 2017, the Company repaid $250 million of maturing senior unsecured notes.

NOTE 11.  Commitments and Contingencies

Commitments

HCP is the sole lender to QCP of an unsecured revolving credit facility (the "Unsecured Revolving Credit Facility") which has a total commitment of $36 million as of February 28, 2017. The Unsecured Revolving Credit Facility is available to be drawn upon by QCP through October 31, 2017 and matures on October 31, 2018. Commitments under the Unsecured Revolving Credit Facility will automatically and permanently decrease each calendar month by an amount equal to 50% of QCP's and its restricted subsidiaries’ retained cash flow for the prior calendar month. All borrowings under the Unsecured Revolving Credit Facility will be subject to the satisfaction of certain conditions, including (i) QCP’s senior secured revolving credit facility being unavailable, (ii) the failure of HCRMC to pay rent and (iii) other customary conditions, including the absence of a default and the accuracy of representations and warranties. QCP may only draw on the Unsecured Revolving Credit Facility prior to the one-year anniversary of the completion of the Spin-Off. Borrowings under the Unsecured Revolving Credit Facility will bear interest at a rate equal to LIBOR, subject to a 1.00% floor, plus an applicable margin of 6.25%. In addition to paying interest on outstanding principal under the Unsecured Revolving Credit Facility, QCP is required to pay a facility fee equal to 0.50% per annum of the unused capacity under the Unsecured Revolving Credit Facility to HCP, payable quarterly. Through March 31, 2017, no amounts had been drawn on the Unsecured Revolving Credit Facility.

Legal Proceedings

From time to time, the Company is a party to legal proceedings, lawsuits and other claims. Except as described below, the Company is not aware of any legal proceedings or claims that it believes may have, individually or taken together, a material adverse effect on the Company’s financial condition, results of operations or cash flows. The Company’s policy is to expense legal costs as they are incurred.

18

Class Action

On May 9, 2016, a purported stockholder of the Company filed a putative class action complaint, Boynton Beach Firefighters’ Pension Fund v. HCP, Inc., et al., Case No. 3:16-cv-01106-JJH, in the U.S. District Court for the Northern District of Ohio against the Company, certain of its officers, HCRMC, and certain of its officers, asserting violations of the federal securities laws. The suit asserts claims under sections 10(b) and 20(a) of the Securities Exchange Act of 1934 and alleges that the Company made certain false or misleading statements relating to the value of and risks concerning its investment in HCRMC by allegedly failing to disclose that HCRMC had engaged in billing fraud, as alleged by the U.S. Department of Justice in a pending suit against HCRMC arising from the False Claims Act. The plaintiff in the suit demands compensatory damages (in an unspecified amount), costs and expenses (including attorneys’ fees and expert fees), and equitable, injunctive, or other relief as the Court deems just and proper. As the Boynton Beach action is in its early stages and a lead plaintiff has not yet been named, the defendants have not yet responded to the complaint. The Company believes the suit to be without merit and intends to vigorously defend against it.

Derivative Actions

On June 16, 2016 and July 5, 2016, purported stockholders of the Company filed two derivative actions, respectively Subodh v. HCR ManorCare Inc., et al., Case No. 30-2016-00858497-CU-PT-CXC and Stearns v. HCR ManorCare, Inc., et al., Case No. 30-2016-00861646-CU-MC-CJC, in the Superior Court of California, County of Orange, against certain of the Company’s current and former directors and officers and HCRMC. The Company is named as a nominal defendant. As both derivative actions contained substantially the same allegations, they have been consolidated into a single action. The consolidated action alleges that the defendants engaged in various acts of wrongdoing, including, among other things, breaching fiduciary duties by publicly making false or misleading statements of fact regarding HCRMC’s finances and prospects, and failing to maintain adequate internal controls. As the Subodh/Stearns action is in the early stages, defendants have not yet responded to the complaint. On April 18, 2017, the Court approved the parties’ stipulation staying the action pending further developments, including in the related securities class action litigation. The Court also adjourned the status conference scheduled for April 27, 2017 to January 10, 2018.

On April 10, 2017, a purported stockholder of the Company filed a derivative action, Weldon v. Martin et al., Case No. 3:17-cv-755, in federal court in the Northern District of Ohio, Western Division, against certain of the Company’s current and former directors and officers and HCRMC. The Company is named as a nominal defendant. The Weldon complaint asserts similar claims to those asserted in the California derivative actions. In addition, the complaint asserts a claim under Section 14(a) of the Securities Exchange Act of 1934, alleging that the Company made false statements in its 2016 proxy statement by not disclosing that the Company’s performance issues in 2015 were the direct result of billing fraud at HCRMC. On April 18, 2017, the Court re-assigned and transferred this action to the judge presiding over the related federal securities class action. Defendants have not yet been served or responded to the complaint.

The Company is unable to estimate the ultimate individual or aggregate amount of monetary liability or financial impact amount of loss or range of reasonable possible losses with respect to matters discussed above at March 31, 2017.

NOTE 12.  Equity

Accumulated Other Comprehensive Loss

The following table summarizes the Company’s accumulated other comprehensive loss (in thousands):

	March 31,		December 31,
	2017		2016
Cumulative foreign currency translation adjustment	$	(21,827)	$	(22,817)
Unrealized losses on cash flow hedges, net		(3,731)		(3,642)
Supplemental Executive Retirement Plan minimum liability		(3,055)		(3,129)
Unrealized losses on available for sale securities		(45)		(54)
Total accumulated other comprehensive loss	$	(28,658)	$	(29,642)

19

NOTE 13.  Segment Disclosures

The Company evaluates its business and allocates resources based on its reportable business segments: (i) SH NNN, (ii) SHOP, (iii) life science and (iv) medical office. Under the medical office segment, the Company invests through the acquisition and development of MOBs, which generally require a greater level of property management. Otherwise, the Company primarily invests, through the acquisition and development of real estate, in single tenant and operator properties. The Company has non-reportable segments that are comprised primarily of the Company’s debt investments, hospital properties and U.K. care homes. The accounting policies of the segments are the same as those in Note 2 to the Consolidated Financial Statements in the Company’s 2016 Annual Report on Form 10-K filed with the SEC, as amended by Note 2 herein. During the year ended December 31, 2016, 17 SH NNN facilities were transitioned to a RIDEA structure (reported in the Company’s SHOP segment). During the three months ended March 31, 2017, one SH NNN facility was transitioned to a RIDEA structure. The Company evaluates performance based upon: (i) property net operating income from continuing operations (“NOI”) and (ii) adjusted NOI of the combined consolidated and unconsolidated investments in each segment.

Non-segment assets consist primarily of corporate assets, including cash and cash equivalents, restricted cash, accounts receivable, net, marketable equity securities and, if any, real estate held for sale. Interest expense, depreciation and amortization, and non-property specific revenues and expenses are not allocated to individual segments in evaluating the Company’s segment-level performance. See Note 17 for other information regarding concentrations of credit risk.

20

The following tables summarize information for the reportable segments (in thousands):

For the three months ended March 31, 2017:

					Life		Medical		Other		Corporate
	SH NNN		SHOP		Science		Office		Non-reportable		Non-segment		Total
Rental revenues(1)	$	100,034	$	140,228	$	85,321	$	118,371	$	29,883	$	—	$	473,837
HCP share of unconsolidated JV revenues		—		76,364		1,940		489		418		—		79,211
Operating expenses		(1,111)		(94,539)		(17,319)		(44,864)		(1,248)		—		(159,081)
HCP share of unconsolidated JV operating expenses		—		(59,527)		(371)		(142)		(19)		—		(60,059)
NOI		98,923		62,526		69,571		73,854		29,034		—		333,908
Adjustments to NOI(2)		(1,839)		3,508		(256)		(969)		(1,012)		—		(568)
Adjusted NOI		97,084		66,034		69,315		72,885		28,022		—		333,340
Addback adjustments		1,839		(3,508)		256		969		1,012		—		568
Interest income		—		—		—		—		18,331		—		18,331
Interest expense		(627)		(4,596)		(104)		(129)		(1,997)		(79,265)		(86,718)
Depreciation and amortization		(26,411)		(26,358)		(33,791)		(42,729)		(7,265)		—		(136,554)
General and administrative		—		—		—		—		—		(22,478)		(22,478)
Acquisition and pursuit costs		—		—		—		—		—		(1,057)		(1,057)
Gain on sales of real estate, net		268,464		366		44,633		—		3,795		—		317,258
Other income, net		—		—		—		—		—		51,208		51,208
Income tax benefit		—		—		—		—		—		6,162		6,162
Less: HCP share of unconsolidated JV NOI		—		(16,837)		(1,569)		(347)		(399)		—		(19,152)
Equity income in unconsolidated JVs		—		1,993		770		269		237		—		3,269
Net income (loss)	$	340,349	$	17,094	$	79,510	$	30,918	$	41,736	$	(45,430)	$	464,177

21

For the three months ended March 31, 2016:

					Life		Medical		Other		Corporate
	SH NNN		SHOP		Science		Office		Non-reportable		Non-segment		Total
Rental revenues(1)	$	106,889	$	165,763	$	88,948	$	108,023	$	32,805	$	—	$	502,428
HCP share of unconsolidated JV revenues		—		52,277		1,810		479		407		—		54,973
Operating expenses		(2,074)		(114,003)		(16,743)		(41,949)		(1,188)		—		(175,957)
HCP share of unconsolidated JV operating expenses		—		(42,088)		(374)		(149)		(3)		—		(42,614)
NOI		104,815		61,949		73,641		66,404		32,021		—		338,830
Adjustments to NOI(2)		(5,443)		5,032		(673)		(795)		(571)		—		(2,450)
Adjusted NOI		99,372		66,981		72,968		65,609		31,450		—		336,380
Addback adjustments		5,443		(5,032)		673		795		571		—		2,450
Interest income		—		—		—		—		18,029		—		18,029
Interest expense		(4,166)		(7,855)		(638)		(1,665)		(2,327)		(105,411)		(122,062)
Depreciation and amortization		(33,506)		(26,297)		(33,596)		(38,719)		(7,737)		—		(139,855)
General and administrative		—		—		—		—		—		(25,451)		(25,451)
Acquisition and pursuit costs		—		—		—		—		—		(2,475)		(2,475)
Other income, net		—		—		—		—		—		1,292		1,292
Income tax expense		—		—		—		—		—		(3,704)		(3,704)
Less: HCP share of unconsolidated JV NOI		—		(10,189)		(1,436)		(330)		(404)		—		(12,359)
Equity (loss) income in unconsolidated JVs		—		(2,478)		709		658		203		—		(908)
Discontinued operations		—		—		—		—		—		68,408		68,408
Net income (loss)	$	67,143	$	15,130	$	38,680	$	26,348	$	39,785	$	(67,341)	$	119,745

(1) Represents rental and related revenues, tenant recoveries, resident fees and services, and income from DFLs.

(2) Represents straight-line rents, DFL non-cash interest, amortization of market lease intangibles, net, lease termination fees and non-refundable entrance fees as the fees are collected by the Company’s CCRC JV, net of CCRC JV entrance fee amortization.

The following table summarizes the Company’s revenues by segment (in thousands):

	Three Months Ended March 31,
Segment	2017		2016
SH NNN	$	100,034	$	106,889
SHOP		140,228		165,763
Life science		85,321		88,948
Medical office		118,371		108,023
Other non-reportable segments		48,214		50,834
Total revenues	$	492,168	$	520,457

See Notes 3 and 4 for significant transactions impacting the Company’s segment assets during the periods presented.

22

NOTE 14.  Earnings Per Common Share

The following table illustrates the computation of basic and diluted earnings per share (in thousands, except per share amounts):

	Three Months Ended March 31,
	2017		2016
Numerator
Net income from continuing operations	$	464,177	$	51,337
Noncontrolling interests’ share in earnings		(3,032)		(3,626)
Net income attributable to HCP, Inc.		461,145		47,711
Participating securities’ share in earnings		(770)		(357)
Income from continuing operations applicable to common shares		460,375		47,354
Discontinued operations		—		68,408
Net income applicable to common shares	$	460,375	$	115,762
Numerator - Dilutive
Net income applicable to common shares	$	460,375	$	115,762
Add: distributions on dilutive convertible units		2,803		—
Dilutive net income available to common shares	$	463,178	$	115,762
Denominator
Basic weighted average common shares		468,299		466,074
Dilutive potential common shares - equity awards		229		188
Dilutive potential common shares - DownREIT units		6,645		—
Diluted weighted average common shares		475,173		466,262
Basic earnings per common share
Continuing operations	$	0.98	$	0.10
Discontinued operations		—		0.15
Net income applicable to common shares	$	0.98	$	0.25
Diluted earnings per common share
Continuing operations	$	0.97	$	0.10
Discontinued operations		—		0.15
Net income applicable to common shares	$	0.97	$	0.25

Restricted stock and certain performance restricted stock units are considered participating securities, because dividend payments are not forfeited even if the underlying award does not vest, and require use of the two-class method when computing basic and diluted earnings per share.

Options to purchase 1 million shares of common stock were excluded from the computation of diluted earnings per share for both the three months ended March 31, 2017 and 2016 because they are anti-dilutive. Additionally, 6 million shares, issuable upon conversion of 4 million DownREIT units during the three months ended March 31, 2016, were not included because they are anti-dilutive.

23

NOTE 15.  Supplemental Cash Flow Information

The following table provides supplemental cash flow information (in thousands):

	Three Months Ended March 31,
	2017		2016
Supplemental cash flow information:
Interest paid, net of capitalized interest	$	108,232	$	171,422
Income taxes paid		1,105		1,213
Capitalized interest		3,090		3,128
Supplemental schedule of non-cash investing and financing activities:
Accrued construction costs		51,498		56,972
Non-cash acquisitions and dispositions settled with receivables and restricted cash held in connection with Section 1031 transactions		39,991		91,605
Tenant-funded tenant improvements owned by HCP		3,120		9,178
Vesting of restricted stock units		293		248
Conversion of non-managing member units into common stock		1,548		4,136
Mortgages and other liabilities assumed with real estate acquisitions		—		1,200
Unrealized losses on available-for-sale securities and derivatives designated as cash flow hedges, net		(45)		(705)

NOTE 16.  Variable Interest Entities

Unconsolidated Variable Interest Entities

At March 31, 2017, the Company had investments in: (i) four unconsolidated VIE JVs, (ii) 48 properties leased to VIE tenants, (iii) marketable debt securities of one VIE and (iv) two loans to VIE borrowers. The Company has determined that it is not the primary beneficiary of and therefore does not consolidate these VIEs because it does not have the ability to control the activities that most significantly impact their economic performance. Except for the Company’s equity interest in the unconsolidated JVs (CCRC OpCo, RIDEA II PropCo, Vintage Park Development JV and the LLC investment discussed below), it has no formal involvement in these VIEs beyond its investments.

The Company holds a 49% ownership interest in CCRC OpCo, a joint venture entity formed in August 2014 that operates senior housing properties in a RIDEA structure and has been identified as a VIE (see Note 7). The equity members of CCRC OpCo “lack power” because they share certain operating rights with Brookdale, as manager of the CCRCs. The assets of CCRC OpCo primarily consist of the CCRCs that it owns and leases, resident fees receivable, notes receivable, and cash and cash equivalents; its obligations primarily consist of operating lease obligations to CCRC PropCo, debt service payments and capital expenditures for the properties, and accounts payable and expense accruals associated with the cost of its CCRCs’ operations. Assets generated by the CCRC operations (primarily rents from CCRC residents) of CCRC OpCo may only be used to settle its contractual obligations (primarily from debt service payments, capital expenditures, and rental costs and operating expenses incurred to manage such facilities).

In January 2017, as a result of the partial sale of its interest in RIDEA II, the Company concluded that it should deconsolidate RIDEA II as it is no longer the primary beneficiary of the joint venture. The HCP/CPA JV is the primary beneficiary of both RIDEA II PropCo and RIDEA II OpCo as it controls the significant activities of RIDEA II PropCo and, of the group that controls the significant activities of RIDEA II OpCo, is most closely associated to the entity. Furthermore, control over the HCP/CPA JV is shared between HCP and CPA, and as such, the Company does not consolidate the HCP/CPA JV. Subsequent to the partial sale of its interest in RIDEA II, the Company continues to hold a direct investment in RIDEA II PropCo, which has been identified as a VIE as Brookdale, the non-managing member, does not have any substantive participating rights or kick-out rights over the managing member, HCP/CPA PropCo (see Notes 4 and 7). The assets of RIDEA II PropCo primarily consist of leased properties (net real estate), rents receivable, and cash and cash equivalents; its obligations primarily consist of a combination of third-party and HCP debt (see Note 4). Assets generated by RIDEA II PropCo (primarily from RIDEA II OpCo lease payments) may only be used to settle its contractual obligations (primarily debt service payments on the third-party and HCP debt).

24

The Company holds an 85% ownership interest in Vintage Park Development JV (see Note 7), which has been identified as a VIE as power is shared with a member that does not have a substantive equity investment at risk. The assets of Vintage Park Development JV primarily consist of an in-progress independent living facility development project that it owns and cash and cash equivalents; its obligations primarily consist of accounts payable and expense accruals associated with the cost of its development obligations. Any assets generated by Vintage Park Development JV may only be used to settle its contractual obligations (primarily development expenses and debt service payments).

The Company holds a limited partner ownership interest in an unconsolidated LLC that has been identified as a VIE. The Company’s involvement in the entity is limited to its equity investment as a limited partner, and it does not have any substantive participating rights or kick-out rights over the general partner. The assets and liabilities of the entity primarily consist of those associated with its senior housing real estate and development activities. Any assets generated by the entity may only be used to settle its contractual obligations (primarily development expenses and debt service payments).

The Company leases 48 properties to a total of seven tenants that have also been identified as VIEs (“VIE tenants”). These VIE tenants are “thinly capitalized” entities that rely on the operating cash flows generated from the senior housing facilities to pay operating expenses, including the rent obligations under their leases.

The Company holds commercial mortgage-backed securities (“CMBS”) issued by Federal Home Loan Mortgage Corporation (commonly referred to as Freddie MAC) through a special purpose entity that has been identified as a VIE because it is “thinly capitalized.” The CMBS issued by the VIE are backed by mortgage debt obligations on real estate assets.

The Company provided a £105 million ($131 million at closing) bridge loan to Maria Mallaband Care Group Ltd. (“MMCG”) to fund the acquisition of a portfolio of care homes in the U.K. MMCG created a special purpose entity to acquire the portfolio and funded it entirely using the Company’s bridge loan. As such, the special purpose entity has been identified as a VIE because it is “thinly capitalized.” The Company retains a three-year call option to acquire all the shares of the special purpose entity, which it can only exercise upon the occurrence of certain events.

The Company provided seller financing of $10 million related to its sale of seven SH NNN facilities. The financing was provided in the form of a secured five-year mezzanine loan to a “thinly capitalized” borrower created to acquire the facilities.

The classification of the related assets and liabilities and the maximum loss exposure as a result of the Company’s involvement with these VIEs at March 31, 2017 was as follows (in thousands):

		Maximum Loss
		Exposure
		and Carrying
VIE Type	Asset/Liability Type	Amount(1)
VIE tenants—DFLs(2)	Net investment in DFLs	$	600,348
VIE tenants—operating leases(2)	Lease intangibles, net and straight-line rent receivables		6,721
CCRC OpCo	Investments in unconsolidated JVs		217,655
RIDEA II PropCo	Investments in unconsolidated JVs		257,534
Vintage Park Development JV	Investments in unconsolidated JVs		6,953
Loan—senior secured	Loans receivable, net		131,916
Loan—seller financing	Loans receivable, net		10,000
CMBS and LLC investment	Marketable debt and cost method investment		33,391

(1) The Company’s maximum loss exposure represents the aggregate carrying amount of such investments (including accrued interest).

(2) The Company’s maximum loss exposure may be mitigated by re-leasing the underlying properties to new tenants upon an event of default.

At March 31, 2017, the Company had not provided, and is not required to provide, financial support through a liquidity arrangement or otherwise, to its unconsolidated VIEs, including circumstances in which it could be exposed to further losses (e.g., cash shortfalls). See Notes 4, 6, and 7 for additional descriptions of the nature, purpose and operating activities of the Company’s unconsolidated VIEs and interests therein.

25

Consolidated Variable Interest Entities

HCP, Inc.’s consolidated total assets and total liabilities at March 31, 2017 and December 31, 2016 include certain assets of variable interest entities (“VIEs”) that can only be used to settle the liabilities of the related VIE. The VIE creditors do not have recourse to HCP, Inc. Total assets at March 31, 2017 and December 31, 2016 include VIE assets as follows (in thousands):

	March 31, 2017		December 31, 2016
Assets
Buildings and improvements	$	2,787,845	$	3,522,310
Development costs and construction in progress		23,837		31,953
Land		214,963		327,241
Accumulated depreciation and amortization		(535,012)		(676,276)
Net real estate		2,491,633		3,205,228
Investments in and advances to unconsolidated joint ventures		3,108		3,641
Accounts receivable		9,609		19,996
Cash and cash equivalents		37,005		35,844
Restricted cash		42,009		22,624
Intangible assets, net		139,281		169,027
Other assets, net		55,049		69,562
Total assets	$	2,777,694	$	3,525,922
Liabilities
Mortgage debt		45,245		520,870
Intangible liabilities, net		8,734		8,994
Liabilities of assets held for sale, net		92,640		120,719
Deferred revenue		16,077		23,456
Total liabilities	$	162,696	$	674,039

RIDEA I.  The Company holds a 90% ownership interest in JV entities formed in September 2011 that own and operate senior housing properties in a RIDEA structure (“RIDEA I”). The Company has historically classified RIDEA I OpCo as a VIE and, as a result of the adoption of ASU No. 2015-02, Amendments to the Consolidation Analysis (“ASU 2015-02”), also classifies RIDEA I PropCo as a VIE due to the non-managing member lacking substantive participation rights in the management of RIDEA I PropCo or kick-out rights over the managing member. The Company consolidates RIDEA I PropCo and RIDEA I OpCo as the primary beneficiary because it has the ability to control the activities that most significantly impact these VIEs’ economic performance. The assets of RIDEA I PropCo primarily consist of leased properties (net real estate), rents receivable, and cash and cash equivalents; its obligations primarily consist of notes payable to a non-VIE consolidated subsidiary of the Company. The assets of RIDEA I OpCo primarily consist of leasehold interests in senior housing facilities (operating leases), resident fees receivable, and cash and cash equivalents; its obligations primarily consist of lease payments to RIDEA I PropCo and operating expenses of its senior housing facilities (accounts payable and accrued expenses). Assets generated by the senior housing operations (primarily from senior housing resident rents) of the RIDEA I structure may only be used to settle its contractual obligations (primarily from the rental costs, operating expenses incurred to manage such facilities and debt costs).

RIDEA III.  The Company holds a 90% ownership interest in JV entities formed in June 2015 that own and operate senior housing properties in a RIDEA structure. The Company has historically classified RIDEA III OpCo as a VIE and, as a result of the adoption of ASU 2015-02, also classifies RIDEA III PropCo as a VIE due to the non-managing member lacking substantive participation rights in the management of RIDEA III PropCo or kick-out rights over the managing member. The Company consolidates RIDEA III PropCo and RIDEA III OpCo as the primary beneficiary because it has the ability to control the activities that most significantly impact these VIEs’ economic performance. The assets of RIDEA III PropCo primarily consist of leased properties (net real estate), rents receivable, and cash and cash equivalents; its obligations primarily consist of a note payable to a non-VIE consolidated subsidiary of the Company. The assets of RIDEA III OpCo primarily consist of leasehold interests in senior housing facilities (operating leases), resident fees receivable,

26

and cash and cash equivalents; its obligations primarily consist of lease payments to RIDEA III PropCo and operating expenses of its senior housing facilities (accounts payable and accrued expenses). Assets generated by the senior housing operations (primarily from senior housing resident rents) of the RIDEA III structure may only be used to settle its contractual obligations (primarily from the rental costs, operating expenses incurred to manage such facilities and debt costs).

HCP Ventures V, LLC.  The Company holds a 51% ownership interest in and is the managing member of a JV entity formed in October 2015 that owns and leases MOBs (“HCP Ventures V”). Upon adoption of ASU 2015-02, the Company classified HCP Ventures V as a VIE due to the non-managing member lacking substantive participation rights in the management of HCP Ventures V or kick-out rights over the managing member. The Company consolidates HCP Ventures V as the primary beneficiary because it has the ability to control the activities that most significantly impact the VIE’s economic performance. The assets of HCP Ventures V primarily consist of leased properties (net real estate), rents receivable, and cash and cash equivalents; its obligations primarily consist of capital expenditures for the properties. Assets generated by HCP Ventures V may only be used to settle its contractual obligations (primarily from capital expenditures).

Vintage Park JV.  The Company holds a 90% ownership interest in a JV entity formed in January 2015 that owns an 85% interest in an unconsolidated development VIE (“Vintage Park JV”). Upon adoption of ASU 2015-02, the Company classified Vintage Park JV as a VIE due to the non-managing member lacking substantive participation rights in the management of the Vintage Park JV or kick-out rights over the managing member. The Company consolidates Vintage Park JV as the primary beneficiary because it has the ability to control the activities that most significantly impact the VIE’s economic performance. The assets of Vintage Park JV primarily consist of an investment in the Vintage Park Development JV and cash and cash equivalents; its obligations primarily consist of funding the ongoing development of the Vintage Park Development JV. Assets generated by the Vintage Park JV may only be used to settle its contractual obligations (primarily from the funding of the Vintage Park Development JV).

DownREITs.  The Company holds a controlling ownership interest in and is the managing member of five DownREITs. Upon adoption of ASU 2015-02, the Company classified the DownREITs as VIEs due to the non-managing members lacking substantive participation rights in the management of the DownREITs or kick-out rights over the managing member. The Company consolidates the DownREITs as the primary beneficiary because it has the ability to control the activities that most significantly impact these VIEs’ economic performance. The assets of the DownREITs primarily consist of leased properties (net real estate), rents receivable, and cash and cash equivalents; their obligations primarily consist of debt service payments and capital expenditures for the properties. Assets generated by the DownREITs (primarily from resident rents) may only be used to settle their contractual obligations (primarily from debt service and capital expenditures).

Other Consolidated Real Estate Partnerships.  The Company holds a controlling ownership interest in and is the general partner (or managing member) of multiple partnerships that own and lease real estate assets (the “Partnerships”). Upon adoption of ASU 2015-02, the Company classified the Partnerships as VIEs due to the limited partners (non-managing members) lacking substantive participation rights in the management of the Partnerships or kick-out rights over the general partner (managing member). The Company consolidates the Partnerships as the primary beneficiary because it has the ability to control the activities that most significantly impact these VIEs’ economic performance. The assets of the Partnerships primarily consist of leased properties (net real estate), rents receivable, and cash and cash equivalents; their obligations primarily consist of debt service payments and capital expenditures for the properties. Assets generated by the Partnerships (primarily from resident rents) may only be used to settle their contractual obligations (primarily from debt service and capital expenditures).

Other consolidated VIEs.  The Company made a loan to an entity that entered into a tax credit structure (“Tax Credit Subsidiary”) and a loan to an entity that made an investment in a development JV (“Development JV”) both of which are considered VIEs. The Company consolidates the Tax Credit Subsidiary and Development JV as the primary beneficiary because it has the ability to control the activities that most significantly impact the VIEs’ economic performance. The assets and liabilities of the Tax Credit Subsidiary and Development JV substantially consist of a development in progress, notes receivable, prepaid expenses, notes payable, and accounts payable and accrued liabilities generated from their operating activities. Any assets generated by the operating activities of the Tax Credit Subsidiary and Development JV may only be used to settle their contractual obligations.

27

NOTE 17.  Concentration of Credit Risk

Concentrations of credit risk arise when one or more tenants, operators or obligors related to the Company’s investments are engaged in similar business activities, or activities in the same geographic region, or have similar economic features that would cause their ability to meet contractual obligations, including those to the Company, to be similarly affected by changes in economic conditions. The Company regularly monitors various segments of its portfolio to assess potential concentrations of credit risks. The Company does not have significant foreign operations.

The following tables provide information regarding the Company’s concentrations with respect to certain tenants:

	Percentage of Gross Assets				Percentage of Revenues
	Total Company		SH NNN		Total Company		SH NNN
	March 31,	December 31,	March 31,	December 31,	Three Months Ended March 31,		Three Months Ended March 31,
Tenant	2017	2016	2017	2016	2017	2016	2017	2016
Brookdale(1)	11	17	42	69	12	12	60	58

(1) Includes revenues from 64 SH NNN facilities that were classified as held for sale at December 31, 2016 and sold in March 2017. 

At March 31, 2017 and December 31, 2016, Brookdale managed or operated, in the Company’s SHOP segment,  approximately 13% and 18%, respectively, of the Company’s real estate investments based on gross assets. Because an operator manages the Company’s facilities in exchange for the receipt of a management fee, the Company is not directly exposed to the credit risk of its operators in the same manner or to the same extent as its triple-net tenants. At March 31, 2017, Brookdale provided comprehensive facility management and accounting services with respect to 59 of the Company’s SHOP facilities and 65 SHOP facilities owned by its unconsolidated joint ventures, for which the Company or joint venture pay annual management fees pursuant to long-term management agreements. Most of the management agreements have terms ranging from 10 to 15 years, with three to four 5-year renewal periods. The base management fees are 4.5% to 5.0% of gross revenues (as defined) generated by the RIDEA facilities. In addition, there are incentive management fees payable to Brookdale if operating results of the RIDEA properties exceed pre-established EBITDAR (as defined) thresholds.

Brookdale is subject to the registration and reporting requirements of the SEC and is required to file with the SEC annual reports containing audited financial information and quarterly reports containing unaudited financial information. The information related to Brookdale contained or referred to in this report has been derived from SEC filings made by Brookdale or other publicly available information, or was provided to the Company by Brookdale, and the Company has not verified this information through an independent investigation or otherwise. The Company has no reason to believe that this information is inaccurate in any material respect, but the Company cannot assure the reader of its accuracy. The Company is providing this data for informational purposes only, and encourages the reader to obtain Brookdale’s publicly available filings, which can be found on the SEC’s website at www.sec.gov.

To mitigate the credit risk of leasing properties to certain senior housing and post-acute/skilled nursing operators, leases with operators are often combined into portfolios that contain cross-default terms, so that if a tenant of any of the properties in a portfolio defaults on its obligations under its lease, the Company may pursue its remedies under the lease with respect to any of the properties in the portfolio. Certain portfolios also contain terms whereby the net operating profits of the properties are combined for the purpose of securing the funding of rental payments due under each lease.

28

NOTE 18.  Fair Value Measurements

Financial assets and liabilities measured at fair value on a recurring basis at March 31, 2017 in the consolidated balance sheets are immaterial.

The table below summarizes the carrying amounts and fair values of the Company’s financial instruments (in thousands):

	March 31, 2017(4)				December 31, 2016(4)
	Carrying				Carrying
	Value		Fair Value		Value		Fair Value
Loans receivable, net(2)	$	788,486	$	787,067	$	807,954	$	807,505
Marketable debt securities(2)		18,330		18,330		68,630		68,630
Marketable equity securities(1)		85		85		76		76
Warrants(3)		39		39		19		19
Bank line of credit(2)		492,421		492,421		899,718		899,718
Term loans(2)		274,103		274,103		440,062		440,062
Senior unsecured notes(1)		7,136,336		7,445,519		7,133,538		7,386,149
Mortgage debt(2)		147,329		134,605		623,792		609,374
Other debt(2)		91,263		91,263		92,385		92,385
Interest-rate swap liabilities(2)		4,163		4,163		4,857		4,857
Currency swap asset(2)		1,924		1,924		2,920		2,920

(1) Level 1: Fair value calculated based on quoted prices in active markets.  

(2) Level 2: Fair value based on (i) for marketable debt securities, quoted prices for similar or identical instruments in active or inactive markets, respectively, or (ii) or for loans receivable, net, mortgage debt, and swaps, calculated utilizing standardized pricing models in which significant inputs or value drivers are observable in active markets. For bank line of credit, term loans and other debt, the carrying values are a reasonable estimate of fair value because the borrowings are primarily based on market interest rates and the Company’s credit rating.

(3) Level 3: Fair value determined based on significant unobservable market inputs using standardized derivative pricing models.

(4) During the three months ended March 31, 2017 and year ended December 31, 2016, there were no material transfers of financial assets or liabilities within the fair value hierarchy.

NOTE 19.  Derivative Financial Instruments

The following table summarizes the Company’s outstanding interest-rate and foreign currency swap contracts at March 31, 2017 (dollars and GBP in thousands):

			Fixed
		Hedge	Rate/Buy			Floating/Exchange	Notional/
Date Entered	Maturity Date	Designation	Amount			Rate Index	Sell Amount		Fair Value(1)
Interest rate:
July 2005(2)	July 2020	Cash Flow		3.82	%	BMA Swap Index	$	44,300	$	(3,301)
January 2015(3)	October 2017	Cash Flow		1.79	%	1 Month GBP LIBOR+0.975%	£	220,000	$	(862)
Foreign currency:
January 2015(4)	October 2017	Cash Flow	$	11,300		Buy USD/Sell GBP	£	7,500	$	1,924

(1) Derivative assets are recorded in other assets, net and derivative liabilities are recorded in accounts payable and accrued liabilities on the consolidated balance sheets.

(2) Represents three interest-rate swap contracts, which hedge fluctuations in interest payments on variable-rate secured debt due to overall changes in hedged cash flows.

(3) Hedges fluctuations in interest payments on variable-rate unsecured debt due to fluctuations in the underlying benchmark interest rate.

(4) Currency swap contract (buy USD/sell GBP) hedges the foreign currency exchange risk related to the Company’s forecasted GBP denominated interest receipts on its HC-One Facility. Represents a currency swap to sell approximately £1.1 million monthly at a rate of 1.5149 through October 2017.

29

The Company uses derivative instruments to mitigate the effects of interest rate and foreign currency fluctuations on specific forecasted transactions as well as recognized financial obligations or assets. Utilizing derivative instruments allows the Company to manage the risk of fluctuations in interest and foreign currency rates related to the potential impact these changes could have on future earnings and forecasted cash flows. The Company does not use derivative instruments for speculative or trading purposes. Assuming a one percentage point change in the underlying interest rate curve and foreign currency exchange rates, the estimated change in fair value of each of the underlying derivative instruments would not exceed $2 million.

At March 31, 2017, £219 million of the Company’s GBP-denominated borrowings under the Facility and 2015 Term Loan are designated as a hedge of a portion of the Company’s net investments in GBP-functional subsidiaries to mitigate its exposure to fluctuations in the GBP to USD exchange rate. For instruments that are designated and qualify as net investment hedges, the variability in the foreign currency to USD exchange rate of the instrument is recorded as part of the cumulative translation adjustment component of accumulated other comprehensive income (loss). Accordingly, the remeasurement value of the designated £219 million GBP-denominated borrowings due to fluctuations in the GBP to USD exchange rate are reported in accumulated other comprehensive income (loss) as the hedging relationship is considered to be effective. The cumulative balance of the remeasurement value will be reclassified to earnings when the hedged investment is sold or substantially liquidated.

30

Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations

All references in this report to “HCP,” “we,” “us” or “our” mean HCP, Inc., together with its consolidated subsidiaries. Unless the context suggests otherwise, references to “HCP, Inc.” mean the parent company without its subsidiaries.

Cautionary Language Regarding Forward-Looking Statements

Statements in this Quarterly Report on Form 10-Q that are not historical factual statements are “forward-looking statements.” We intend to have our forward-looking statements covered by the safe harbor provisions of the Private Securities Litigation Reform Act of 1995 and include this statement for purposes of complying with those provisions. Forward-looking statements include, among other things, statements regarding our and our officers’ intent, belief or expectation as identified by the use of words such as “may,” “will,” “project,” “expect,” “believe,” “intend,” “anticipate,” “seek,” “forecast,” “plan,” “potential,” “estimate,” “could,” “would,” “should” and other comparable and derivative terms or the negatives thereof. Forward-looking statements reflect our current expectations and views about future events and are subject to known and unknown risks and uncertainties that could significantly affect our future financial condition and results of operations. While forward-looking statements reflect our good faith belief and assumptions we believe to be reasonable based upon current information, we can give no assurance that our expectations or forecasts will be attained. As more fully set forth under “Part II, Item 1A. “Risk Factors” in this Quarterly Report on Form 10-Q, and “Part I, Item 1A. “Risk Factors” in our Annual Report on Form 10-K for the fiscal year ended December 31, 2016, risks and uncertainties that may cause our actual results to differ materially from the expectations contained in the forward-looking statements include, among other things:

· our reliance on a concentration of a small number of tenants and operators for a significant portion of our revenues, with our concentration in Brookdale increasing as a result of the consummation of the Spin-Off of Quality Care Properties, Inc. (“QCP”) on October 31, 2016;

· the financial condition of our existing and future tenants, operators and borrowers, including potential bankruptcies and downturns in their businesses, and their legal and regulatory proceedings, which results in uncertainties regarding our ability to continue to realize the full benefit of such tenants’ and operators’ leases and borrowers’ loans;

· the ability of our existing and future tenants, operators and borrowers to conduct their respective businesses in a manner sufficient to maintain or increase their revenues and to generate sufficient income to make rent and loan payments to us and our ability to recover investments made, if applicable, in their operations;

· competition for tenants and operators, including with respect to new leases and mortgages and the renewal or rollover of existing leases;

· our concentration in the healthcare property sector, particularly in life sciences, medical office buildings and hospitals, which makes our profitability more vulnerable to a downturn in a specific sector that if we were investing in multiple industries;

· availability of suitable properties to acquire at favorable prices, the competition for the acquisition and financing of those properties, and the costs of associated property development;

· our ability to negotiate the same or better terms with new tenants or operators if existing leases are not renewed or we exercise our right to foreclose on loan collateral or replace an existing tenant or operator upon default;

· the risks associated with our investments in joint ventures and unconsolidated entities, including our lack of sole decision making authority and our reliance on our partners’ financial condition and continued cooperation;

· our ability to achieve the benefits of investments within expected time frames or at all, or within expected cost projections;

· operational risks associated with third party management contracts, including the additional regulation and liabilities of our RIDEA lease structures;

· the potential impact on us and our tenants, operators and borrowers from current and future litigation matters, including the possibility of larger than expected litigation costs, adverse results and related developments;

31

· the effect on our tenants and operators of legislation and other legal requirements, including the Affordable Care Act and licensure, certification and inspection requirements, as well as laws addressing entitlement programs and related services, including Medicare and Medicaid, which may result in future reductions in reimbursements;

· changes in federal, state or local laws and regulations, including those affecting the healthcare industry that affect our costs of compliance or increase the costs, or otherwise affect the operations, of our tenants and operators;

· volatility or uncertainty in the capital markets, the availability and cost of capital as impacted by interest rates, changes in our credit ratings, and the value of our common stock, and other conditions that may adversely impact our ability to fund our obligations or consummate transactions, or reduce the earnings from potential transactions;

· changes in global, national and local economic conditions, and currency exchange rates;

· our ability to manage our indebtedness level and changes in the terms of such indebtedness;

· competition for skilled management and other key personnel; and

· our ability to maintain our qualification as a REIT.

Except as required by law, we do not undertake, and hereby disclaim, any obligation to update any forward-looking statements, which speak only as of the date on which they are made.

The information set forth in this Item 2 is intended to provide readers with an understanding of our financial condition, changes in financial condition and results of operations. We will discuss and provide our analysis in the following order:

· Executive Summary

· 2017 Transaction Overview

· Dividends

· Results of Operations

· Liquidity and Capital Resources

· Off-Balance Sheet Arrangements

· Inflation

· Non-GAAP Financial Measures Reconciliations

· Critical Accounting Policies

· Recent Accounting Pronouncements

Executive Summary

HCP, Inc., a Standard & Poor’s (“S&P”) 500 company, invests primarily in real estate serving the healthcare industry in the United States. We are a Maryland corporation organized in 1985 and qualify as a self-administered REIT. We acquire, develop, lease, manage and dispose of healthcare real estates. At March 31, 2017, our portfolio of investments, including properties in our unconsolidated joint ventures (“JVs”), consisted of interests in 801 properties.  

We invest and manage our real estate portfolio for the long-term to maximize the benefit to our stockholders and support the growth of our dividends. The core elements of our strategy are: (i) to acquire, develop, lease, own and manage a diversified portfolio of quality healthcare properties across multiple geographic locations and business segments including senior housing, medical office, and life science, among others; (ii) to align ourselves with leading healthcare companies, operators and service providers, which over the long-term, should result in higher relative rental rates, net operating cash flows and appreciation of property values; (iii) to maintain adequate liquidity with long-term fixed rate debt financing with staggered maturities, which supports the longer-term nature of our investments, while reducing our exposure to interest rate volatility and refinancing risk at any point in the interest rate or credit cycles; and (iv) to continue to manage our balance sheet with a targeted financial leverage of 40% relative to our assets.

32

We believe that our real estate portfolio holds the potential for increased future cash flows as it is well-maintained and in desirable locations within markets where new supply is generally limited by the lack of available sites and the difficulty of obtaining the necessary licensing, other approvals and/or financing. Our strategy for maximizing the benefits from these opportunities is to: (i) work with new or existing tenants and operators to address their space and capital needs and (ii) provide high-quality property management services in order to motivate tenants to renew, expand or relocate into our properties.

The delivery of healthcare services requires real estate and, as a result, tenants and operators depend on real estate, in part, to maintain and grow their businesses. We believe that the healthcare real estate market provides investment opportunities due to the: (i) compelling long-term demographics driving the demand for healthcare services; (ii) specialized nature of healthcare real estate investing; and (iii) ongoing consolidation of the fragmented healthcare real estate sector.

While we emphasize healthcare real estate ownership, we may also provide real estate secured financing to, or invest in equity or debt securities of, healthcare operators or other entities engaged in healthcare real estate ownership. We may also acquire all or substantially all of the securities or assets of other REITs, operating companies or similar entities where such investments would be consistent with our investment strategies. We may co-invest alongside institutional or development investors through partnerships or limited liability companies.

We monitor, but do not limit, our investments based on the percentage of our total assets that may be invested in any one property type, investment vehicle or geographic location, the number of properties that may be leased to a single tenant or operator, or loans that may be made to a single borrower. In allocating capital, we target opportunities with the most attractive risk/reward profile for our portfolio as a whole. We may take additional measures to mitigate risk, including diversifying our investments (by sector, geography, tenant or operator), structuring transactions as master leases, requiring tenant or operator insurance and indemnifications, and obtaining credit enhancements in the form of guarantees, letters of credit or security deposits.

Our REIT qualification requires us to distribute at least 90% of our REIT taxable income (excluding net capital gains); therefore, we do not retain capital. As a result, we regularly access the public equity and debt markets to raise the funds necessary to finance acquisitions and debt investments, develop and redevelop properties, and refinance maturing debt.

We maintain a disciplined balance sheet by actively managing our debt to equity levels and maintaining multiple sources of liquidity. Our debt obligations are primarily long-term fixed rate with staggered maturities.

We finance our investments based on our evaluation of available sources of funding. For short-term purposes, we may utilize our revolving line of credit facility or arrange for other short-term borrowings from banks or other sources. We arrange for longer-term financing by offering debt and equity securities, placing mortgage debt and obtaining capital from institutional lenders and JV partners.

2017 Transaction Overview

Disposition Transactions

In January 2017, we sold four life science facilities in Salt Lake City, Utah for $76 million, resulting in a net gain on sale of $45 million.

In January 2017, we completed the contribution of our ownership interest in RIDEA II to an unconsolidated JV owned by HCP and an investor group led by Columbia Pacific Advisors, LLC (“the HCP/CPA JV”). In addition, RIDEA II was recapitalized with $602 million of debt, of which $360 million was provided by a third-party and $242 million was provided by HCP. In return, we received $480 million in cash proceeds from the HCP/CPA JV and $242 million in note receivables and retained an approximate 40% beneficial interest in RIDEA II (the note receivable and 40% beneficial interest are herein referred to as the “RIDEA II Investments”). This transaction resulted in HCP deconsolidating the net assets of RIDEA II and recognizing a net gain on sale of $99 million.

33

In March 2017,we sold 64 senior housing triple-net assets, previously under triple-net leases with Brookdale Senior Living, Inc. (“Brookdale”), for $1.125 billion to affiliates of Blackstone Real Estate Partners VIII, L.P., resulting in a net gain on sale of $170 million.

In March 2017, we sold our aggregate £138.5 million par value Four Seasons senior notes (“Four Seasons Notes”) for £83 million ($101 million).  The disposition of the Four Seasons Notes generated a £42 million ($51 million) gain on sale as the sales price was above the previously-impaired carrying value of £41 million ($50 million). In addition, we sold our Four Seasons senior secured term loan at par plus accrued interest for £29 million ($35 million).

In March 2017, we sold a hospital in Palm Beach Gardens, Florida for $43 million to the current tenant.

Subsequent to the first quarter of 2017, we sold a land parcel in San Diego, California for $27 million.

Financing Activities

In January 2017, we paid down $440 million on our revolving line of credit facility, primarily using proceeds from our RIDEA II disposition.

In March 2017, we repaid our £137 million unsecured term loan (the “2012 Term Loan”) that was entered into on July 30, 2012 primarily using proceeds from the sale of our Four Seasons investments.

In March 2017, we repaid $472 million of mortgage debt primarily using proceeds from the sale of 64 SH NNN facilities, discussed above.

In April 2017, we paid down £105 million on our revolving line of credit facility.

On May 1, 2017, we repaid $250 million of maturing senior unsecured notes.

Developments and Redevelopments

Through May 2, 2017, we have leased 100% of The Cove Phase I and Phase II.

Dividends

The following table summarizes our common stock cash dividends declared in 2017:

		Amount		Dividend
Declaration Date	Record Date	Per Share		Payable Date
February 2	February 15	$	0.37	March 2
April 27	May 8		0.37	May 23

Results of Operations

We evaluate our business and allocate resources among our reportable business segments: (i) senior housing triple-net (“SH NNN”); (ii) senior housing operating portfolio (“SHOP”); (iii) life science; and (iv) medical office. Under the medical office segment, we invest through the acquisition and development of medical office buildings (“MOBs”), which generally require a greater level of property management. Otherwise, we primarily invest, through the acquisition and development of real estate, in single tenant and operator properties. We have other non-reportable segments that are comprised primarily of our U.K. care homes, debt investments and hospitals. We evaluate performance based upon (i) property net operating income from continuing operations (“NOI”) and (ii) adjusted NOI (cash NOI) of the combined consolidated and unconsolidated investments in each segment. The accounting policies of the segments are the same as those described in the summary of significant accounting policies in Note 2 of the Annual Report on Form 10-K for the year ended December 31, 2016 filed with the U.S. Securities and Exchange Commission (“SEC”).

34

Non-GAAP Financial Measures

Net Operating Income (“NOI”)

NOI and adjusted NOI are non-U.S. generally accepted accounting principles (“GAAP”) supplemental financial measures used to evaluate the operating performance of real estate. We include properties from our consolidated portfolio, as well as our pro-rata share of properties owned by our unconsolidated joint ventures, in our NOI and adjusted NOI. We believe providing this information assists investors and analysts in estimating the economic interest in our total portfolio of real estate. Our pro-rata share information is prepared on a basis consistent with the comparable consolidated amounts, is intended to reflect our proportionate economic interest in the operating results of properties in our portfolio and is calculated by applying our actual ownership percentage for the period. We do not control the unconsolidated joint ventures, and the pro-rata presentations of revenues and expenses included in NOI (see below) do not represent our legal claim to such items. The joint venture members or partners are entitled to profit or loss allocations and distributions of cash flows according to the joint venture agreements, which provide for such allocations generally according to their invested capital.

The presentation of pro-rata information has limitations, which include, but are not limited to, the following (i) the amounts shown on the individual line items were derived by applying our overall economic ownership interest percentage determined when applying the equity method of accounting and do not necessarily represent our legal claim to the assets and liabilities, or the revenues and expenses and (ii) other companies in our industry may calculate their pro-rata interest differently, limiting the usefulness as a comparative measure. Because of these limitations, the pro-rata financial information should not be considered independently or as a substitute for our financial statements as reported under GAAP. We compensate for these limitations by relying primarily on our GAAP financial statements, using the pro-rata financial information as a supplement.

NOI is defined as rental and related revenues, including tenant recoveries, resident fees and services, and income from DFLs, less property level operating expenses; NOI excludes all other financial statement amounts included in net income (loss) as presented in Note 13 to the Consolidated Financial Statements. Management believes NOI provides relevant and useful information because it reflects only income and operating expense items that are incurred at the property level and presents them on an unleveraged basis. Adjusted NOI is calculated as NOI after eliminating the effects of straight-line rents, DFL non-cash interest, amortization of market lease intangibles, non-refundable entrance fees, net of entrance fee amortization and lease termination fees (“adjustments”). Adjusted NOI is oftentimes referred to as “cash NOI.” We use NOI and adjusted NOI to make decisions about resource allocations, to assess and compare property level performance, and to evaluate our same property portfolio (“SPP”), as described below. We believe that net income (loss) is the most directly comparable GAAP measure to NOI. NOI should not be viewed as an alternative measure of operating performance to net income (loss) as defined by GAAP since it does not reflect various excluded items. Further, our definition of NOI may not be comparable to the definition used by other REITs or real estate companies, as they may use different methodologies for calculating NOI. For a reconciliation of NOI and Adjusted NOI to net income (loss) by segment, refer to Note 13 to the Consolidated Financial Statements.

Operating expenses generally relate to leased medical office and life science properties and senior housing RIDEA properties. We generally recover all or a portion of our leased medical office and life science property expenses through tenant recoveries. We present expenses as operating or general and administrative based on the underlying nature of the expense. Periodically, we review the classification of expenses between categories and make revisions based on changes in the underlying nature of the expenses.

Same Property Portfolio

SPP NOI and adjusted NOI information allows us to evaluate the performance of our property portfolio under a consistent population by eliminating changes in the composition of our portfolio of properties. We include properties from our consolidated portfolio, as well as properties owned by our unconsolidated joint ventures in our SPP NOI and adjusted NOI (see NOI above for further discussion regarding our use of pro-rata share information and its limitations). We identify our SPP as stabilized properties that remained in operations and were consistently reported as leased properties or RIDEA properties for the duration of the year-over-year comparison periods presented, excluding assets held for sale. Accordingly, it takes a stabilized property a minimum of 12 months in operations under a consistent reporting structure to be included in our SPP. Newly acquired operating assets are generally considered stabilized at the earlier of lease-up (typically when the tenant(s) control(s) the physical use of at least 80% of the space) or 12 months from the acquisition date. Newly

35

completed developments and redevelopments are considered stabilized at the earlier of lease-up or 24 months from the date the property is placed in service. SPP NOI excludes (i) certain non-property specific operating expenses that are allocated to each operating segment on a consolidated basis and (ii) entrance fees and related activity such as deferred expenses, reserves and management fees related to entrance fees. A property is removed from our SPP when it is classified as held for sale, sold, placed into redevelopment or changes its reporting structure. For a reconciliation of SPP to total portfolio adjusted NOI and other relevant disclosures by segment, refer to our Segment Analysis below.

Funds From Operations (“FFO”)

We believe FFO applicable to common shares, diluted FFO applicable to common shares, and diluted FFO per common share are important supplemental non-GAAP measures of operating performance for a REIT. Because the historical cost accounting convention used for real estate assets utilizes straight-line depreciation (except on land), such accounting presentation implies that the value of real estate assets diminishes predictably over time. Since real estate values instead have historically risen and fallen with market conditions, presentations of operating results for a REIT that use historical cost accounting for depreciation could be less informative. The term FFO was designed by the REIT industry to address this issue.

FFO, as defined by the National Association of Real Estate Investment Trusts (“NAREIT”), is net income (loss) applicable to common shares (computed in accordance with GAAP), excluding gains or losses from sales of depreciable property, including any current and deferred taxes directly associated with sales of depreciable property, impairments of, or related to, depreciable real estate, plus real estate and other depreciation and amortization, and adjustments to compute our share of FFO and FFO as adjusted (see below) from joint ventures. Adjustments for joint ventures are calculated to reflect our pro-rata share of both our consolidated and unconsolidated joint ventures. We reflect our share of FFO for unconsolidated joint ventures by applying our actual ownership percentage for the period to the applicable reconciling items on an entity by entity basis. We reflect our share for consolidated joint ventures in which we do not own 100% of the equity by adjusting our FFO to remove the third party ownership share of the applicable reconciling items based on actual ownership percentage for the applicable periods. Our pro-rata share information is prepared on a basis consistent with the comparable consolidated amounts, is intended to reflect our proportionate economic interest in the operating results of properties in our portfolio and is calculated by applying our actual ownership percentage for the period. We do not control the unconsolidated joint ventures, and the pro-rata presentations of reconciling items included in FFO (see above) do not represent our legal claim to such items. The joint venture members or partners are entitled to profit or loss allocations and distributions of cash flows according to the joint venture agreements, which provide for such allocations generally according to their invested capital. See NOI above for further discussion regarding our use of pro-rata share information and its limitations.

FFO does not represent cash generated from operating activities in accordance with GAAP, is not necessarily indicative of cash available to fund cash needs and should not be considered an alternative to net income (loss). We compute FFO in accordance with the current NAREIT definition; however, other REITs may report FFO differently or have a different interpretation of the current NAREIT definition from ours.

In addition, we present FFO before the impact of non-comparable items including, but not limited to, severance-related charges, litigation provisions, preferred stock redemption charges, impairments (recoveries) of non-depreciable assets, prepayment costs (benefits) associated with early retirement or payment of debt, foreign currency remeasurement losses (gains) and transaction-related items (“FFO as adjusted”). Prepayment costs (benefits) associated with early retirement of debt include the write-off of unamortized deferred financing fees, or additional costs, expenses, discounts, make-whole payments, penalties or premiums incurred as a result of early retirement or payment of debt. Transaction-related items include expensed acquisition and pursuit costs and gains/charges incurred as a result of mergers and acquisitions and lease amendment or termination activities. Management believes that FFO as adjusted provides a meaningful supplemental measurement of our FFO run-rate and is frequently used by analysts, investors and other interested parties in the evaluation of our performance as a REIT. At the same time that NAREIT created and defined its FFO measure for the REIT industry, it also recognized that “management of each of its member companies has the responsibility and authority to publish financial information that it regards as useful to the financial community.” We believe stockholders, potential investors and financial analysts who review our operating performance are best served by an FFO run-rate earnings measure that includes, in addition to adjustments made to arrive at the NAREIT defined measure of FFO, other adjustments to net income (loss). FFO as adjusted is used by management in analyzing our business and the performance of our properties,

36

and we believe it is important that stockholders, potential investors and financial analysts understand this measure used by management. We use FFO as adjusted to: (i) evaluate our performance in comparison with expected results and results of previous periods, relative to resource allocation decisions, (ii) evaluate the performance of our management, (iii) budget and forecast future results to assist in the allocation of resources, (iv) assess our performance as compared with similar real estate companies and the industry in general and (v) evaluate how a specific potential investment will impact our future results. Other REITs or real estate companies may use different methodologies for calculating an adjusted FFO measure, and accordingly, our FFO as adjusted may not be comparable to those reported by other REITs. For a reconciliation of net income (loss) to FFO and FFO as adjusted and other relevant disclosure, refer to “Non-GAAP Financial Measures Reconciliations” below.

Funds Available for Distribution (“FAD”)

FAD is defined as FFO as adjusted after excluding the impact of the following: (i) amortization of acquired market lease intangibles, net, (ii) amortization of deferred compensation expense, (iii) amortization of deferred financing costs, net, (iv) straight-line rents, (v) non-cash interest and depreciation related to DFLs and lease incentive amortization (reduction of straight-line rents) and (vi) deferred revenues, excluding amounts amortized into rental income that are associated with tenant funded improvements owned/recognized by us and up-front cash payments made by tenants to reduce their contractual rents. Also, FAD: (i) is computed after deducting recurring capital expenditures, including leasing costs and second generation tenant and capital improvements, and (ii) includes lease restructure payments and adjustments to compute our share of FAD from our unconsolidated joint ventures and those related to CCRC non-refundable entrance fees. Certain amounts in the “Non-GAAP Financial Measures Reconciliation” below for FAD have been reclassified for prior periods to conform to the current period presentation. More specifically, we have combined wholly-owned and our share from unconsolidated joint ventures recurring capital expenditures, including leasing costs and second generation tenant and capital improvements (previously reported in “other”) into a single line item. In addition, we have combined cash CCRC JV entrance fees with CCRC JV entrance fee amortization into a single line item, separately disclosed deferred income taxes (previously reported in “other”) and collapsed immaterial line items into ‘other’. Adjustments for joint ventures are calculated to reflect our pro-rata share of both our consolidated and unconsolidated joint ventures. We reflect our share of FAD for unconsolidated joint ventures by applying our actual ownership percentage for the period to the applicable reconciling items on an entity by entity basis. We reflect our share for consolidated joint ventures in which we do not own 100% of the equity by adjusting our FAD to remove the third party ownership share of the applicable reconciling items based on actual ownership percentage for the applicable periods (see FFO above for further disclosure regarding our use of pro-rata share information and its limitations). Other REITs or real estate companies may use different methodologies for calculating FAD, and accordingly, our FAD may not be comparable to those reported by other REITs. Although our FAD computation may not be comparable to that of other REITs, management believes FAD provides a meaningful supplemental measure of our performance and is frequently used by analysts, investors, and other interested parties in the evaluation of our performance as a REIT. We believe FAD is an alternative run-rate earnings measure that improves the understanding of our operating results among investors and makes comparisons with: (i) expected results, (ii) results of previous periods and (iii) results among REITS more meaningful. FAD does not represent cash generated from operating activities determined in accordance with GAAP and is not necessarily indicative of cash available to fund cash needs as it excludes the following items which generally flow through our cash flows from operating activities: (i) adjustments for changes in working capital or the actual timing of the payment of income or expense items that are accrued in the period, (ii) transaction-related costs, (iii) litigation settlement expenses, (iv) severance-related expenses and (v) actual cash receipts from interest income recognized on loans receivable (in contrast to our FAD adjustment to exclude non-cash interest and depreciation related to our investments in direct financing leases). Furthermore, FAD is adjusted for recurring capital expenditures, which are generally not considered when determining cash flows from operations or liquidity. FAD is a non-GAAP supplemental financial measure and should not be considered as an alternative to net income (loss) determined in accordance with GAAP. For a reconciliation of net income (loss) to FAD and other relevant disclosure, refer to “Non-GAAP Financial Measures Reconciliations” below.

37

Comparison of the Three Months Ended March 31, 2017 to the Three Months Ended March 31, 2016

Overview

Three Months Ended March 31, 2017 and 2016

The following table summarizes results for the three months ended March 31, 2017 and 2016 (dollars in thousands, except per share data):

	Three Months Ended				Three Months Ended				Per
	March 31, 2017				March 31, 2016				Share
	Amount		Per Share		Amount		Per Share		Change
Net income applicable to common shares	$	460,375	$	0.97	$	115,762	$	0.25	$	0.72
FFO		288,249		0.61		319,266		0.68		(0.07)
FFO as adjusted		240,172		0.51		321,784		0.69		(0.18)
FAD		218,555				309,038

Earnings per share (“EPS”) increased primarily as a result of the following:

· gains on sales of real estate during the first quarter of 2017 compared to none during the first quarter of 2016;

· gain on sale of our Four Seasons Notes;

· a reduction in interest expense as a result of debt repayments, which primarily occurred in the second half of 2016; and

· increased NOI from our 2016 acquisitions, annual rent escalations and developments placed in service.

The increase in EPS was partially offset by the following:

· a reduction in net income from discontinued operations due to the spinoff of QCP on October 31, 2016; and

· a reduction in resident fees and services, partially offset by a reduction in operating expenses due to the partial sale and deconsolidation of RIDEA II during the first quarter of 2017.

FFO decreased primarily as a result of the aforementioned events impacting EPS, excluding gains on sales of real estate, which is an adjustment to our calculation of FFO.

FFO as adjusted decreased primarily as a result of the aforementioned events impacting FFO, excluding the gain on sale of our Four Seasons Notes which is excluded from FFO as adjusted.

FAD decreased primarily as a result of the aforementioned events impacting FFO as adjusted and increased leasing costs and tenant capital improvements and lower lease restructure payments.

Segment Analysis

The tables below provide selected operating information for our SPP and total property portfolio for each of our business segments. Our SPP for the three months ended March 31, 2017 consists of 740 properties representing properties acquired or placed in service and stabilized on or prior to January 1, 2016 and that remained in operation under a consistent reporting structure through March 31, 2017. Our total property portfolio consists of 801 and 862 properties at March 31, 2017 and 2016, respectively.

38

Senior Housing Triple-Net

The following table summarizes results at and for the three months ended March 31, 2017 and 2016 (dollars in thousands, except per unit data):

	SPP							Total Portfolio
	Three Months Ended March 31,							Three Months Ended March 31,
	2017		2016		Change			2017		2016		Change
Rental revenues(1)	$	75,425	$	74,956	$	469		$	100,034	$	106,889	$	(6,855)
Operating expenses		(155)		(174)		19			(1,111)		(2,074)		963
NOI		75,270		74,782		488			98,923		104,815		(5,892)
Adjustments to NOI		(1,515)		(4,590)		3,075			(1,839)		(5,443)		3,604
Adjusted NOI	$	73,755	$	70,192	$	3,563			97,084		99,372		(2,288)
Non-SPP adjusted NOI									(23,329)		(29,180)		5,851
SPP adjusted NOI								$	73,755	$	70,192	$	3,563
Adjusted NOI % change						5.1	%
Property count(2)		204		204					209		209
Average capacity (units)(3)		20,172		20,169					26,435		29,048
Average annual rent per unit	$	14,656	$	13,955				$	14,858	$	13,970

(1) Represents rental and related revenues and income from DFLs.

(2) From our past presentation of SPP for the three months ended March 31, 2016, we removed 74 senior housing properties from SPP that were sold and 18 senior housing properties that we transitioned to SHOP.

(3) Represents average capacity as reported by the respective tenants or operators for the 12-month period and a quarter in arrears from the periods presented.

SPP adjusted NOI increased primarily as a result of the following:

· annual rent escalations; and

· higher cash rent received from our portfolio of assets leased to Sunrise Senior Living. 

Total Portfolio NOI and adjusted NOI decreased primarily as a result of the following Non-SPP impacts:

· SH NNN facilities sold during 2016 and 2017; and

· the transition of 18 SH NNN facilities to a RIDEA structure during the second half of 2016 and first quarter of 2017 (reported in our SHOP segment).

The decrease to Total Portfolio NOI and adjusted NOI is partially offset by (i) increased non-SPP income from five SH NNN facilities acquired in the first quarter of 2016 and (ii) the aforementioned increases to SPP.

39

Senior Housing Operating Portfolio

The following table summarizes results at and for the three months ended March 31, 2017 and 2016 (dollars in thousands, except per unit data):

	SPP							Total Portfolio
	Three Months Ended March 31,							Three Months Ended March 31,
	2017		2016		Change			2017		2016		Change
Resident fees and services	$	93,669	$	92,353	$	1,316		$	140,228	$	165,763	$	(25,535)
HCP share of unconsolidated JV revenues		77,397		75,577		1,820			76,364		52,277		24,087
Operating expenses		(58,580)		(57,784)		(796)			(94,539)		(114,003)		19,464
HCP share of unconsolidated JV of operating expenses		(62,332)		(61,395)		(937)			(59,527)		(42,088)		(17,439)
NOI		50,154		48,751		1,403			62,526		61,949		577
Adjustments to NOI		—		—		—			3,508		5,032		(1,524)
Adjusted NOI	$	50,154	$	48,751	$	1,403			66,034		66,981		(947)
Non-SPP adjusted NOI									(15,880)		(18,230)		2,350
SPP adjusted NOI								$	50,154	$	48,751	$	1,403
Adjusted NOI % change						2.9	%
Property count(1)		123		123					153		153
Average capacity (units)		21,203		16,794					25,515		23,332
Average annual rent per occupied unit	$	50,968	$	45,403				$	52,986	$	48,499

(1) From our past presentation of SPP for the three months ended March 31, 2016, we have recast the components of SPP to reflect our retained 40% equity interest in RIDEA II within HCP share of unconsolidated JV revenues and operating expenses resulting from our deconsolidation of RIDEA II during the first quarter of 2017.

SPP NOI and adjusted NOI increased primarily as a result of the following:

· increased rates for resident fees and services; and

· lower expense growth, partially offset by a decline in occupancy.

Total Portfolio NOI and adjusted NOI increased primarily as a result of the aforementioned increases to SPP and the transition of 18 SH NNN assets to SHOP, partially offset by decreased non-SPP income from our partial sale of RIDEA II.

40

Life Science

The following table summarizes results at and for the three months ended March 31, 2017 and 2016 (dollars and square feet in thousands, except per square foot data):

	SPP									Total Portfolio
	Three Months Ended March 31,									Three Months Ended March 31,
	2017			2016			Change			2017			2016			Change
Rental revenues(1)	$	80,746		$	77,113		$	3,633		$	85,321		$	88,948		$	(3,627)
HCP share of unconsolidated JV revenues		1,912			1,795			117			1,940			1,810			130
Operating expenses		(15,189)			(14,028)			(1,161)			(17,319)			(16,743)			(576)
HCP share of unconsolidated JV of operating expenses		(371)			(374)			3			(371)			(374)			3
NOI		67,098			64,506			2,592			69,571			73,641			(4,070)
Adjustments to NOI		347			(59)			406			(256)			(673)			417
Adjusted NOI	$	67,445		$	64,447		$	2,998			69,315			72,968			(3,653)
Non-SPP adjusted NOI											(1,870)			(8,521)			6,651
SPP adjusted NOI										$	67,445		$	64,447		$	2,998
Adjusted NOI % change								4.7	%
Property count(2)		117			117						120			118
Average occupancy		97.2	%		97.8	%					96.3	%		98.0	%
Average occupied square feet		6,771			6,805						7,005			7,661
Average annual total revenues per occupied square foot	$	50		$	47					$	50		$	48
Average annual base rent per occupied square foot	$	41		$	41					$	42		$	40

(1) Represents rental and related revenues and tenant recoveries.

(2) From our past presentation of SPP for the three months ended March 31, 2016, we removed five life science facilities that were sold.

SPP NOI and adjusted NOI increased primarily as a result of the following:

· mark-to-market lease renewals;

· new leasing activity; and

· specific to adjusted NOI, annual rent escalations.

Total Portfolio NOI and adjusted NOI decreased primarily as a result of the following impacts to Non-SPP:

· decreased income from the sale of life science facilities in 2016 and the first quarter of 2017; partially offset by

· increased income from (i) life science acquisitions in 2016 and (ii) increased occupancy in a development placed in operations during 2016.

The decrease in Total Portfolio NOI and adjusted NOI was also partially offset by the aforementioned increases to SPP. 

During the three months ended March 31, 2017, 91,000 square feet of new and renewal leases commenced at an average annual base rent of $44.30 per square foot, compared to 81,000 square feet of expired leases with an average annual base rent of $34.94 per square foot. During the three months ended March 31, 2017,  we disposed of 324,000 square feet with an average annual base rent of $18.81 per square foot that was held for sale at December 31, 2016.

41

Medical Office

The following table summarizes results at and for the three months ended March 31, 2017 and 2016 (dollars and square feet in thousands, except per square foot data):

	SPP									Total Portfolio
	Three Months Ended March 31,									Three Months Ended March 31,
	2017			2016			Change			2017			2016			Change
Rental revenues(1)	$	104,231		$	101,233		$	2,998		$	118,371		$	108,023		$	10,348
HCP share of unconsolidated JV revenues		467			468			(1)			489			479			10
Operating expenses		(38,411)			(37,475)			(936)			(44,864)			(41,949)			(2,915)
HCP share of unconsolidated JV of operating expenses		(143)			(149)			6			(142)			(149)			7
NOI		66,144			64,077			2,067			73,854			66,404			7,450
Adjustments to NOI		(66)			(810)			744			(969)			(795)			(174)
Adjusted NOI	$	66,078		$	63,267		$	2,811			72,885			65,609			7,276
Non-SPP adjusted NOI											(6,807)			(2,342)			(4,465)
SPP adjusted NOI										$	66,078		$	63,267		$	2,811
Adjusted NOI % change								4.4	%
Property count(2)		217			217						239			227
Average occupancy		92.2	%		92.1	%					92.0	%		91.3	%
Average occupied square feet		14,979			14,940						16,761			15,611
Average annual total revenues per occupied square foot	$	28		$	27					$	28		$	27
Average annual base rent per occupied square foot	$	23		$	23					$	24		$	23

(1) Represents rental and related revenues and tenant recoveries.

(2) From our past presentation of SPP for the three months ended March 31, 2016,  we removed three MOBs that were sold and six MOBs that were placed into redevelopment.

SPP NOI and adjusted NOI increased primarily as a result of increased occupancy. Additionally, SPP adjusted NOI increased as a result of annual rent escalations.

Total Portfolio NOI and adjusted NOI increased primarily as a result of the aforementioned increases to SPP and the following impacts to Non-SPP:

· increased income from 2016 acquisitions; and

· increased occupancy in former redevelopment and development properties that have been placed into operations; partially offset by

· decreased income from the sale of three MOBs during 2016.

During the three months ended March 31, 2017,  575,000 square feet of new and renewal leases commenced at an average annual base rent of $22.56 per square foot, compared to 558,000 square feet of expiring and terminated leases with an average annual base rent of $22.12 per square foot.

Other Income and Expense Items

Tandem Mezzanine Loan

On July 31, 2012, we closed a mezzanine loan facility to lend up to $205 million to Tandem Health Care (“Tandem”), as part of the recapitalization of a post-acute/skilled nursing portfolio (the “Tandem Portfolio”). We funded $100 million (the “First Tranche”) at closing and funded an additional $102 million (the “Second Tranche”) in June 2013. In May 2015, we

42

increased and extended the mezzanine loan facility with Tandem to: (i) fund $50 million (the “Third Tranche”) and $5 million (the “Fourth Tranche”), the proceeds of which were used to repay a portion of Tandem’s existing senior and mortgage debt, respectively; (ii) extend its maturity to October 2018; and (iii) extend the prepayment penalty period through January 2017. The tranches (collectively, the “Tandem Mezzanine Loan”) bear interest at fixed annual rates of 12%, 14%, 6% and 6% per annum for the First, Second, Third and Fourth Tranches, respectively. The blended rate for the Tandem Mezzanine Loan is 11.5% per year. Due to a decline in the Tandem Portfolio’s operating performance, at September 30, 2016, we assigned an internal rating of “Watch List” to the Tandem Mezzanine Loan.At March 31, 2017, the Tandem Mezzanine Loan had an outstanding balance of $257 million and was subordinate to approximately $372 million of senior mortgage debt.

Tandem leases the entire Tandem Portfolio to Consulate Health Care (“Consulate”) under a master lease (the “Tandem and Consulate Lease”). On February 15, 2017, a jury returned an adverse verdict against five Consulate entities (which are not tenants under the Tandem and Consulate Lease) as defendants, resulting in a $348 million judgment. On March 15, 2017, the court stayed the execution of the judgment pending Consulate’s post-trial motion for judgment as a matter of law. It is unclear how the court will ultimately rule or whether the parties will reach an out-of-court settlement. A negative outcome would have a materially adverse effect on Consulate’s financial condition, results of operations or cash flows. This may cause additional declines in the Tandem Portfolio’s operating performance and would likely negatively affect Consulate’s and Tandem’s ability to raise capital. This may further adversely affect Tandem’s ability to meet its debt service obligations to us, which would have a negative impact on our future liquidity. We are currently evaluating our options with respect to the Tandem Mezzanine Loan.

At March 31, 2017, as a result of the Tandem Portfolio’s operating performance there are outstanding events of default under the Tandem and Consulate Lease (“Events of Default”) due to: (i) Consulate’s failure to meet certain financial covenants under the Tandem and Consulate Lease; and (ii) events of default under Consulate’s working capital facility, which, through a cross-default provision, are Events of Default. Additionally, Consulate failed to pay the full amount of its April 2017 rent under the Tandem and Consulate Lease which triggered another Event of Default. Through cross-default provisions, these Events of Default are also events of default under the Tandem Mezzanine Loan and Tandem’s senior mortgage debt (each, a “Loan Event of Default”). The Tandem Mezzanine Loan requires Tandem to pay default interest at a rate of 16.5% per year, during periods in which there is an outstanding Loan Event of Default. Tandem did not pay the additional 5% default interest rate spread above 11.5% and, therefore, created a monetary event of default under the Tandem Mezzanine Loan.

We entered into a forbearance agreement with Tandem on May 1, 2017, pursuant to which we agreed to forbear from exercising our remedies, including waiving default interest with respect to the above-described Loan Events of Default under the Tandem Mezzanine Loan until June 30, 2017, subject to the satisfaction of certain conditions. Under the forbearance terms, among other conditions, Tandem is required to make timely non-default interest payments in full for each of May and June 2017, and no additional Event of Default or Loan Event of Default may occur. Our forbearance is contingent on the senior mortgage lender also agreeing to forebear from exercising remedies, including waiving default interest, with respect to the above-described Loan Events of Default under the senior mortgage debt. We expect Tandem and Tandem’s senior mortgage lender to enter into such forbearance agreement in the near term.   

Although Tandem continues to remain current on its non-default interest payment obligations under the Tandem Mezzanine Loan, we believe that it is probable we will be unable to collect all interest and principal payments according to the contractual terms of the Tandem Mezzanine Loan. Because the Tandem Mezzanine Loan is deemed collateral-dependent, and the fair value of the underlying collateral, net of the fair value of the senior mortgage debt, at March 31, 2017, exceeds the carrying amount of the Tandem Mezzanine Loan, we have not recorded an impairment write-down at March 31, 2017. We will continue to monitor the fair value of the collateral, and other factors, to determine whether we will be required to record an impairment write-down in future periods. Additionally, beginning in the first quarter of 2017, we elected to recognize interest income on a cash basis. During both the three months ended March 31, 2017 and 2016, we recognized interest income and received cash payments of $7 million from Tandem.

43

The following table summarizes our other income and expense items results for the three months ended March 31, 2017 and 2016 (in thousands):

	Three Months Ended March 31,
	2017		2016		Change
Interest income	$	18,331	$	18,029	$	302
Interest expense		86,718		122,062		(35,344)
Depreciation and amortization		136,554		139,855		(3,301)
General and administrative		22,478		25,451		(2,973)
Acquisition and pursuit costs		1,057		2,475		(1,418)
Gain on sales of real estate, net		317,258		—		317,258
Other income, net		51,208		1,292		49,916
Income tax benefit (expense)		6,162		(3,704)		9,866
Equity income (loss) from unconsolidated joint ventures		3,269		(908)		4,177
Total discontinued operations		—		68,408		(68,408)
Noncontrolling interests’ share in earnings		(3,032)		(3,626)		594

Interest expense

Interest expense decreased for the three months ended March 31, 2017 as a result of senior unsecured notes and mortgage debt payoffs which occurred primarily in the second half of 2016.

The following table sets forth information with respect to our debt, excluding premiums and discounts (dollars in thousands):

	At March 31, (1)
	2017			2016
Balance:
Fixed rate	$	7,616,705		$	10,108,396
Variable rate		492,421			810,313
Total	$	8,109,126		$	10,918,709
Percent of total debt:
Fixed rate		93.9	%		92.6	%
Variable rate		6.1	%		7.4	%
Total		100.0	%		100.0	%
Weighted average interest rate at end of period:
Fixed rate		4.26	%		4.71	%
Variable rate		1.65	%		1.68	%
Total		4.10	%		4.48	%

(1) At March 31, 2017 and 2016, excludes $91 million and $95 million, respectively, of other debt that represents non-interest bearing life care bonds and occupancy fee deposits at certain of our senior housing facilities and demand notes that have no scheduled maturities. At March 31, 2017 and 2016, principal balances of $46 million and $71 million, respectively, of variable-rate mortgages are presented as fixed-rate debt as the interest payments were swapped from variable to fixed. At March 31, 2017 and 2016, principal balances of £220 million ($275 million) and £357 million ($513 million) of term loans, respectively, are presented as fixed-rate debt as the interest payments were swapped from variable to fixed.

Our exposure to interest rate fluctuations related to our variable rate indebtedness is partially mitigated by our interest rate swap contracts. For a more detailed discussion of our interest rate risk, see “Quantitative and Qualitative Disclosures About Market Risk” in Item 3 below.

Depreciation and amortization expense

Depreciation and amortization expense decreased for the three months ended March 31, 2017 primarily as a result of the sale of 64 SH NNN assets and the deconsolidation of RIDEA II during the first quarter of 2017, partially offset by depreciation of assets acquired during 2016.

44

General and administrative expenses

General and administrative expenses decreased  for the three months ended March 31, 2017 primarily as a result of lower stock compensation and severance expenses.

Acquisition and pursuit costs

Acquisition and pursuit costs decreased for the three months ended March 31, 2017 as a result of lower acquisition volume compared to the first quarter of 2016.

Beginning in the first quarter of 2017, we adopted the Financial Accounting Standards Board’s Accounting Standards Update No. 2017-01, Clarifying the Definition of a Business (“ASU 2017-01”). We expect a decrease in acquisition and pursuit costs recognized within our consolidated statements of operations as a result of adopting ASU 2017-01. See Note 2 to the Consolidated Financial Statements.

Gain on sales of real estate, net

During the three months ended March 31, 2017,  we sold 64 SH NNN assets, a portfolio of four life science facilities and a 40% interest in RIDEA II, recognizing total net gain on sales of real estate of $317 million. During the three months ended March 31, 2016, there were no sales of real estate.

Other income, net

Other income, net, increased for the three months ended March 31, 2017, primarily as a result of the gain on sale of our Four Seasons Notes.

Income tax expense

The decrease in income taxes for the three months ended March 31, 2017 was primarily the result of: (i) $5 million tax benefit from the sale of a 40% interest in RIDEA II in 2017; and (ii) $4 million income tax expense associated with state built-in gain tax for the disposition of certain real estate assets during 2016. 

Equity income (loss) from unconsolidated joint ventures

The increase in equity income from unconsolidated joint ventures for the three months ended March 31, 2017 was primarily the result of income from RIDEA II in our SHOP segment.

Total discontinued operations

For the three months ended March 31, 2017, there were no discontinued operations. Discontinued operations for the three months ended March 31, 2016 relates to income from the operations of QCP.

Liquidity and Capital Resources

We anticipate that our cash flow from operations, available cash balances and cash from our various financing activities will be adequate for at least the next 12 months for purposes of: (i) funding recurring operating expenses; (ii) meeting debt service requirements including principal payments and maturities; and (iii) satisfying our distributions to our stockholders and non-controlling interest members.  

Our principal investing needs for the next 12 months are to:

· fund capital expenditures, including tenant improvements and leasing costs; and

· fund future acquisition, transactional and development activities.

We anticipate satisfying these future investing needs using one or more of the following:

· issuance of common or preferred stock;

· issuance of additional debt, including unsecured notes and mortgage debt;

45

· draws on our credit facilities; and/or

· sale or exchange of ownership interests in properties.

Access to capital markets impacts our cost of capital and ability to refinance maturing indebtedness, as well as our ability to fund future acquisitions and development through the issuance of additional securities or secured debt. Credit ratings impact our ability to access capital and directly impact our cost of capital as well. For example, as noted below, our revolving line of credit facility accrues interest at a rate per annum equal to LIBOR plus a margin that depends upon our credit ratings. We also pay a facility fee on the entire revolving commitment that depends upon our credit ratings. At April 28, 2017, we had a credit rating of BBB from Fitch, Baa2 from Moody’s and BBB from S&P Global on our senior unsecured debt securities.

Cash Flow Summary

The following summary discussion of our cash flows is based on the consolidated statements of cash flows and is not meant to be an all-inclusive discussion of the changes in our cash flows for the periods presented below.

Cash and cash equivalents were $764 million and $95 million at March 31, 2017 and December 31, 2016, respectively, representing an increase of $669 million. The following table sets forth changes in cash flows (in thousands):

	Three Months Ended March 31,
	2017		2016		Change
Net cash provided by operating activities	$	193,129	$	268,617	$	(75,488)
Net cash provided by (used in) investing activities		1,715,217		(165,757)		1,880,974
Net cash used in financing activities		(1,238,969)		(354,402)		(884,567)

The decrease in operating cash flow is primarily the result of (i) decreased income related to the QCP Spin-Off and (ii) decreased working capital, partially offset by our (i) 2016 acquisitions, (ii) annual rent increases, and (iii) decreased interest paid as a result of lower balances on our senior unsecured notes and line of credit. Our cash flow from operations is dependent upon the occupancy levels of our buildings, rental rates on leases, our tenants’ performance on their lease obligations, the level of operating expenses and other factors.

The following are significant investing and financing activities for the three months ended March 31, 2017:

· received net proceeds of $1.6 billion from the sale of real estate, including the sale and recapitalization of RIDEA II;

· received net proceeds of $185 million primarily from the sale of our Four Seasons investments and DFL repayment;

· made investments of $98 million primarily for the development of real estate;

· repaid $1.1 billion under our bank line of credit, 2012 Term Loan and mortgage debt; and

· paid dividends on common stock of $174 million.

Debt

Bank Line of Credit and Term Loans

Our $2.0 billion unsecured revolving line of credit facility (the “Facility”) matures on March 31, 2018 and contains a one-year extension option. Borrowings under the Facility accrue interest at LIBOR plus a margin that depends on our credit ratings. We pay a facility fee on the entire revolving commitment that depends on our credit ratings. Based on our credit ratings at April 28, 2017, the margin on the Facility was 1.05%, and the facility fee was 0.20%. The Facility also includes a feature that allows us to increase the borrowing capacity by an aggregate amount of up to $500 million, subject to securing additional commitments from existing lenders or new lending institutions. At March 31, 2017, we had £394 million ($492 million) outstanding under the Facility with a weighted average effective interest rate of 1.65%.

46

We have a £220 million ($275 million at March 31, 2017) four-year unsecured term loan, maturing January 12, 2019, that accrues interest at a rate of GBP LIBOR plus 1.15%, subject to adjustments based on our credit ratings.

See Note 10 in the Consolidated financial Statements for additional information about our outstanding debt.

See “2017 Transaction Overview” for further information regarding our significant financing activities during the first quarter of 2017.

Equity

At March 31, 2017, we had  468 million shares of common stock outstanding, equity totaled $6.2 billion, and our equity securities had a market value of $14.9 billion.

At March 31, 2017, non-managing members held an aggregate of 4 million units in five limited liability companies (“DownREITs”) for which we are the managing member. The DownREIT units are exchangeable for an amount of cash approximating the then-current market value of shares of our common stock or, at our option, shares of our common stock (subject to certain adjustments, such as stock splits and reclassifications).

At-The-Market Program

In June 2015, we established an at-the-market program, in connection with the renewal of our Shelf Registration Statement. Under this program, we may sell shares of our common stock from time to time having an aggregate gross sales price of up to $750 million through a consortium of banks acting as sales agents or directly to the banks acting as principals. There was no activity during the three months ended March 31, 2017 and, at March 31, 2017, shares of our common stock having an aggregate gross sales price of $676 million were available for sale under the at-the-market program. Actual future sales will depend upon a variety of factors, including but not limited to market conditions, the trading price of our common stock and our capital needs. We have no obligation to sell the remaining shares available for sale under our program.

Shelf Registration

We filed a prospectus with the SEC as part of a registration statement on Form S-3ASR, using a shelf registration process, which expires in June 2018. Under the “shelf” process, we may sell any combination of the securities described in the prospectus through one or more offerings. The securities described in the prospectus include common stock, preferred stock, depositary shares, debt securities and warrants.

Off-Balance Sheet Arrangements

We own interests in certain unconsolidated joint ventures as described in Note 7 to the Consolidated Financial Statements. Except in limited circumstances, our risk of loss is limited to our investment in the joint venture and any outstanding loans receivable. In addition, we have certain properties which serve as collateral for debt that is owed by a previous owner of certain of our facilities. Our risk of loss for these certain properties is limited to the outstanding debt balance plus penalties, if any. We have no other material off-balance sheet arrangements that we expect would materially affect our liquidity and capital resources except those included in our Annual Report on Form 10-K for the year ended December 31, 2016 in “Contractual Obligations” under “Item 7. Management’s Discussion and Analysis of Financial Condition and Results of Operations.”

Inflation

Our leases often provide for either fixed increases in base rents or indexed escalators, based on the Consumer Price Index or other measures, and/or additional rent based on increases in the tenants’ operating revenues. Most of our MOB leases require the tenant to pay a share of property operating costs such as real estate taxes, insurance and utilities. Substantially all of our senior housing, life science and remaining other leases require the tenant or operator to pay all of the property operating costs or reimburse us for all such costs. We believe that inflationary increases in expenses will be offset, in part, by the tenant or operator expense reimbursements and contractual rent increases described above.

47

Non-GAAP Financial Measures Reconciliations

The following is a reconciliation from net income applicable to common shares, the most directly comparable financial measure calculated and presented in accordance with GAAP, to FFO, FFO as adjusted and FAD (in thousands, except per share data):

	Three Months Ended March 31,
	2017		2016
Net income applicable to common shares	$	460,375	$	115,762
Depreciation and amortization of real estate, in-place lease and other intangibles		136,554		141,322
Other depreciation and amortization		3,010		2,962
Gain on sales of real estate, net		(317,258)		—
Taxes associated with real estate dispositions		(5,499)		53,177
Equity (income) loss from unconsolidated joint ventures		(3,269)		908
FFO from unconsolidated joint ventures		18,308		10,378
Noncontrolling interests’ and participating securities’ share in earnings		3,802		3,983
Noncontrolling interests’ and participating securities’ share in FFO		(7,774)		(9,226)
FFO applicable to common shares		288,249		319,266
Distributions on dilutive convertible units		2,803		3,583
Diluted FFO applicable to common shares	$	291,052	$	322,849
Weighted average shares used to calculate diluted FFO per common share		475,173		472,186

Impact of adjustments to FFO:
Transaction-related items(1)	$	1,057	$	2,518
Other impairment recovery(2)		(50,895)		—
Litigation provision		1,838		—
Foreign currency remeasurement gains		(77)		—
	$	(48,077)	$	2,518
FFO as adjusted applicable to common shares	$	240,172	$	321,784
Distributions on dilutive convertible units and other		2,877		3,579
Diluted FFO as adjusted applicable to common shares	$	243,049	$	325,363
Diluted FFO as adjusted per common share	$	0.51	$	0.69
Weighted average shares used to calculate diluted FFO as adjusted per common share		475,173		472,186

48

	Three Months Ended March 31,
	2017		2016
FFO as adjusted applicable to common shares	$	240,172	$	321,784
Amortization of deferred compensation		3,765		5,345
Amortization of deferred financing costs		3,858		5,280
Straight-line rents		(5,007)		(7,576)
Other depreciation and amortization		(3,010)		(2,962)
Leasing costs and tenant and capital improvements(3)		(23,287)		(20,482)
Lease restructure payments		540		6,294
CCRC entrance fees(4)		3,649		5,502
Deferred income taxes		(2,374)		(2,942)
Other FAD adjustments		249		(1,205)
FAD applicable to common shares	$	218,555	$	309,038
Distributions on dilutive convertible units		2,803		3,583
Diluted FAD applicable to common shares	$	221,358	$	312,621

The following is a reconciliation, on a per share basis, from net income (loss) applicable to common shares, the most directly comparable financial measure calculated and presented in accordance with GAAP, to FFO and FFO as adjusted:

	Three Months Ended March 31,
	2017		2016
Diluted earnings per common share	$	0.97	$	0.25
Depreciation and amortization		0.29		0.30
Other depreciation and amortization		0.01		0.01
Gain on sales of real estate, net		(0.67)		—
Taxes related to real estate dispositions		(0.01)		0.11
Joint venture and participating securities FFO adjustments		0.02		0.01
Diluted FFO applicable to common shares	$	0.61	$	0.68
Transaction-related items and other(1)		—		0.01
Other impairment recovery(2)		(0.10)		—
FFO as adjusted applicable to common shares	$	0.51	$	0.69

(1) On January 1, 2017, we early adopted the FASB ASU No. 2017-01, Clarifying the Definition of a Business (“ASU 2017-01”) which prospectively results in recognizing the majority of our real estate acquisitions as asset acquisitions rather than business combinations. Acquisition and pursuit costs relating to completed asset acquisitions are capitalized, including those costs incurred prior to January 1, 2017. Real estate acquisitions completed prior to January 1, 2017 were deemed business combinations and the related acquisition and pursuit costs were expense as incurred.

(2) For the three months ended March 31, 2017, the other impairment recovery relates to the sale of our Four Seasons Notes.

(3) Includes our share of leasing costs and tenant and capital improvements from unconsolidated joint ventures.

(4) Represents our 49% share of non-refundable entrance fees as the fees are collected by our CCRC JV, net of CCRC JV entrance fee amortization.

49

Critical Accounting Policies

The preparation of financial statements in conformity with U.S. GAAP requires our management to use judgment in the application of accounting policies, including making estimates and assumptions. We base estimates on the best information available to us at the time, our experience and on various other assumptions believed to be reasonable under the circumstances. These estimates affect the reported amounts of assets and liabilities, disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenue and expenses during the reporting periods. If our judgment or interpretation of the facts and circumstances relating to various transactions or other matters had been different, it is possible that different accounting would have been applied, resulting in a different presentation of our consolidated financial statements. From time to time, we re-evaluate our estimates and assumptions. In the event estimates or assumptions prove to be different from actual results, adjustments are made in subsequent periods to reflect more current estimates and assumptions about matters that are inherently uncertain. A summary of our critical accounting policies is included in our Annual Report on Form 10-K for the year ended December 31, 2016 in “Item 7. Management’s Discussion and Analysis of Financial Condition and Results of Operations” and Note 2 to the Consolidated Financial Statements. There have been no significant changes to our critical accounting policies during 2017.

Recent Accounting Pronouncements

See Note 2 to the Consolidated Financial Statements for the impact of new accounting standards.

Item 3.  Quantitative and Qualitative Disclosures About Market Risk

We are exposed to various market risks, including the potential loss arising from adverse changes in interest rates and foreign currency exchange rates, specifically the GBP. We use derivative financial instruments in the normal course of business to mitigate interest rate and foreign currency risk. We do not use derivative financial instruments for speculative or trading purposes. Derivatives are recorded on the consolidated balance sheets at fair value (see Note 19 to the Consolidated Financial Statements).

To illustrate the effect of movements in the interest rate and foreign currency markets, we performed a market sensitivity analysis on our hedging instruments. We applied various basis point spreads to the underlying interest rate curves and foreign currency exchange rates of the derivative portfolio in order to determine the change in fair value. Assuming a one percentage point change in the underlying interest rate curve and foreign currency exchange rates, the estimated change in fair value of each of the underlying derivative instruments would not exceed $2 million.

Interest Rate Risk.  At March 31, 2017, we are exposed to market risks related to fluctuations in interest rates primarily on variable rate debt. At March 31, 2017, $319 million of our variable-rate debt was hedged by interest rate swap transactions. The interest rate swaps are designated as cash flow hedges, with the objective of managing the exposure to interest rate risk by converting the interest rates on our variable-rate debt to fixed interest rates.

Interest rate fluctuations will generally not affect our future earnings or cash flows on our fixed rate debt and assets until their maturity or earlier prepayment and refinancing. If interest rates have risen at the time we seek to refinance our fixed rate debt, whether at maturity or otherwise, our future earnings and cash flows could be adversely affected by additional borrowing costs. Conversely, lower interest rates at the time of refinancing may reduce our overall borrowing costs. However, interest rate changes will affect the fair value of our fixed rate instruments. A one percentage point change in interest rates would change the fair value of our fixed rate debt and investments by approximately $55 million and $2 million, respectively, and would not materially impact earnings or cash flows. Conversely, changes in interest rates on variable rate debt and investments would change our future earnings and cash flows, but not materially impact the fair value of those instruments. Assuming a one percentage point change in the interest rate related to the variable-rate debt and variable-rate investments, and assuming no other changes in the outstanding balance at March 31, 2017, our annual interest expense and interest income would increase by approximately $6 million and $0.8 million, respectively.

Foreign Currency Risk.  At March 31, 2017, our exposure to foreign currencies primarily relates to U.K. investments in leased real estate, senior notes and related GBP denominated cash flows. Our foreign currency exposure is partially mitigated through the use of GBP denominated borrowings and foreign currency swap contracts. Based solely on our

50

operating results for the three months ended March 31, 2017, including the impact of existing hedging arrangements, if the value of the GBP relative to the U.S. dollar were to increase or decrease by 10% compared to the average exchange rate during the quarter ended March 31, 2017, our cash flows would have decreased or increased, as applicable, by less than $1 million.

Market Risk.  We have investments in marketable debt securities classified as held-to-maturity because we have the positive intent and ability to hold the securities to maturity. Held-to-maturity securities are recorded at amortized cost and adjusted for the amortization of premiums and discounts through maturity. We consider a variety of factors in evaluating an other-than-temporary decline in value, such as: the length of time and the extent to which the market value has been less than our current adjusted carrying value; the issuer’s financial condition, capital strength and near-term prospects; any recent events specific to that issuer and economic conditions of its industry; and our investment horizon in relationship to an anticipated near-term recovery in the market value, if any. At March 31, 2017, both the fair value and carrying value of marketable debt securities was $18 million.

Item 4.  Controls and Procedures

Disclosure Controls and Procedures.  We maintain disclosure controls and procedures that are designed to ensure that information required to be disclosed in our reports under the Securities Exchange Act of 1934, as amended (the “Exchange Act”), is recorded, processed, summarized and reported within the time periods specified in the SEC’s rules and forms and that such information is accumulated and communicated to our management, including our Chief Executive Officer (Principal Executive Officer) and Chief Financial Officer (Principal Financial Officer), to allow for timely decisions regarding required disclosure. In designing and evaluating the disclosure controls and procedures, management recognizes that any controls and procedures, no matter how well designed and operated, can provide only reasonable assurance of achieving the desired control objectives, and management is required to apply its judgment in evaluating the cost-benefit relationship of possible controls and procedures.

As required by Rules 13a-15(b) and 15d-15(b) of the Exchange Act, we carried out an evaluation, under the supervision and with the participation of our management, including our Chief Executive Officer (Principal Executive Officer) and Chief Financial Officer (Principal Financial Officer), of the effectiveness of the design and operation of our disclosure controls and procedures as of March 31, 2017. Based upon that evaluation, our Chief Executive Officer (Principal Executive Officer) and Chief Financial Officer (Principal Financial Officer) concluded that our disclosure controls and procedures were effective at the reasonable assurance level as of March 31, 2017.

Changes in Internal Control Over Financial Reporting.  There were no changes in our internal control over financial reporting (as such term as defined in Rules 13a-15(f) and 15d-15(f) under the Exchange Act) during the fiscal quarter to which this report relates that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.

51

PART II. OTHER INFORMATION

Item 1. Legal Proceedings

See the “Legal Proceedings” section of Note 11 to the consolidated Financial Statements for information regarding legal proceedings, which information is incorporated by reference in this Item 1.

Item 1A.  Risk Factors

In addition to the information set forth in this Form 10-Q, you should carefully consider the risk factors discussed in Part I, Item 1A of our most recent Annual Report on Form 10-K, which could materially affect our business, financial condition, or future results. The following updates the risk factors previously disclosed in our Annual Report on Form 10-K for the year ended December 31, 2016, as updated by Part II, Item 1A of our Quarterly Report on Form 10-Q for the quarter ended March 31, 2017: 

The requirements of, or changes to, governmental reimbursement programs such as Medicare or Medicaid, may adversely affect our tenants’, operators’ and borrowers’ ability to meet their financial and other contractual obligations to us.

Certain of our tenants, operators and borrowers are affected, directly or indirectly, by an extremely complex set of federal, state and local laws and regulations pertaining to governmental reimbursement programs. These laws and regulations are subject to frequent and substantial changes that are sometimes applied retroactively. See “Item 1—Business—Government Regulation, Licensing and Enforcement” above. For example, to the extent that our tenants, operators or borrowers receive a significant portion of their revenues from governmental payors, primarily Medicare and Medicaid, they are generally subject to, among other things:

· statutory and regulatory changes;

· retroactive rate adjustments;

· recovery of program overpayments or set-offs;

· federal, state and local litigation and enforcement actions;

· administrative proceedings;

· policy interpretations;

· payment or other delays by fiscal intermediaries or carriers;

· government funding restrictions (at a program level or with respect to specific facilities); and

· interruption or delays in payments due to any ongoing governmental investigations and audits at such properties.

The failure to comply with the extensive laws, regulations and other requirements applicable to their business and the operation of our properties could result in, among other challenges: (i) becoming ineligible to receive reimbursement from governmental reimbursement programs; (ii) bans on admissions of new patients or residents; (iii) civil or criminal penalties; and (iv) significant operational changes. These laws and regulations are enforced by a variety of federal, state and local agencies and can also be enforced by private litigants through, among other things, federal and state false claims acts, which allow private litigants to bring qui tam or “whistleblower” actions. For example, we have provided a loan to Tandem, a property company with ownership interests in 69 facilities totaling 6,924 beds (the “Tandem Portfolio”) (see Note 6 to the Consolidated Financial Statements for additional information). Affiliates of the sole tenant and operator of Tandem’s facilities, Consulate, are facing a qui tam or “whistleblower” action alleging that Consulate overbilled the federal government and the State of Florida (United States of America v. CMC II, LLC, et al, U.S. District Court, M.D. Florida). On February 15, 2017, a jury returned an adverse verdict against five Consulate entities as defendants, resulting in a $348 million judgment against all defendants. On March 15, 2017, the court stayed the execution of the judgment pending Consulate’s post-trial motion for judgment as a matter of law. It is unclear how the court will ultimately rule or whether the parties will reach an out-of-court settlement. A negative outcome would have a materially adverse effect on Consulate.

52

This would cause additional declines in the Tandem Portfolio’s operating performance and would likely negatively affect Consulate’s and Tandem’s ability to raise capital, which would further adversely affect Tandem’s ability to meet its debt service obligations to us. We are currently evaluating our options in respect of the Tandem Mezzanine Loan. Regardless of the ultimate outcome, our tenants, operators and borrowers could be adversely affected by the resources required to respond to an investigation or other enforcement action. In such event, the results of operations and financial condition of our tenants and the results of operations of our properties operated by those entities could be materially adversely affected, which, in turn, could have a materially adverse effect on us. We are unable to predict future federal, state and local regulations and legislation, including the Medicare and Medicaid statutes and regulations, or the intensity of enforcement efforts with respect to such regulations and legislation, and any changes in the regulatory framework could have a materially adverse effect on our tenants and operators, which, in turn, could have a materially adverse effect on us.

Sometimes, governmental payors freeze or reduce payments to healthcare providers, or provide annual reimbursement rate increases that are smaller than expected, due to budgetary and other pressures. Healthcare reimbursement will likely continue to be of significant importance to federal and state authorities. We cannot make any assessment as to the ultimate timing or the effect that any future legislative reforms may have on our tenants’, operators’ and borrowers’ costs of doing business and on the amount of reimbursement by government and other third-party payors. The failure of any of our tenants, operators or borrowers to comply with these laws and regulations, and significant limits on the scope of services reimbursed and on reimbursement rates and fees, could materially adversely affect their ability to meet their financial and contractual obligations to us.

Furthermore, executive orders and legislation may repeal the Affordable Care Act and related regulations in whole or in part. We also anticipate that Congress, state legislatures, and third-party payors may continue to review and assess alternative healthcare delivery and payment systems and may propose and adopt legislation or policy changes or implementations effecting additional fundamental changes in the healthcare system. We cannot quantify or predict the likely impact of these possible changes on our business model, prospects, financial condition or results of operations.

Item 2. Unregistered Sales of Equity Securities and Use of Proceeds

(a)

None.

(b)

None.

53

(c)

The following table sets forth information with respect to purchases of our common stock made by us or on our behalf or by any “affiliated purchaser,” as such term is defined in Rule 10b-18(a)(3) under the Exchange Act, during the three months ended March 31, 2017.

					Maximum Number (Or
				Total Number Of Shares	Approximate Dollar Value)
		Average		(Or Units) Purchased As	Of Shares (Or Units) That
	Total Number	Price		Part Of Publicly	May Yet Be Purchased
	Of Shares	Paid Per		Announced Plans Or	Under The Plans Or
Period Covered	Purchased(1)	Share		Programs	Programs
January 1-31, 2017	23,825	$	30.00	—	—
February 1-28, 2017	92,384		30.41	—	—
March 1-31, 2017	285		29.76	—	—
Total	116,494		30.33	—	—

(1) Represents shares of our common stock withheld under our equity incentive plans to offset tax withholding obligations that occur upon vesting of restricted sharesand restricted stock units. The value of the shares withheld is based on the closing price of our common stock on the last trading day prior to the date the relevant transaction occurs.

Item 5. Other Information

(a)

Election of Thomas M. Herzog as President and Chief Executive Officer 

On April 27, 2017, the Board of Directors (the “Board”) elected Thomas M. Herzog, our current Chief Executive Officer (“CEO”), as our President and Chief Executive Officer, effective June 1, 2017.

Mr. Herzog has served as CEO of HCP since January 2017, and served as Chief Financial Officer (“CFO”) of HCP from June 2016 through December 2016. From January 2013 until joining HCP in June 2016, he was CFO of UDR, Inc. (NYSE: UDR), a multifamily REIT. Mr. Herzog served as CFO of Amstar, a Denver-based real estate investment company, from August 2011 to January 2013. He previously served as CFO of HCP from April 2009 to May 2011. Mr. Herzog was Chief Accounting Officer at Apartment Investment and Management Company (NYSE: AIV), a multifamily REIT, from 2004 to 2005 and CFO from 2005 to 2009. From 2000 to 2004, he served in the roles of Chief Accounting Officer & Global Controller and Finance Technical Advisor for GE Real Estate. Prior to joining GE Real Estate, Mr. Herzog began his career in public accounting with Deloitte & Touche LLP, serving in the audit department for ten years, including a two-year national office assignment in the real estate group. He currently serves on the Board of Directors for Tier REIT, Inc. (NYSE: TIER), an office property REIT.

There are no family relationships involving Mr. Herzog that would require disclosure under Item 401(d) of Regulation S-K. There are no current or proposed transactions in which he or any member of his immediate family has, or will have, a direct or indirect material interest that would require disclosure under Item 404(a) of Regulation S-K.

(b)

None.

54

Item 6. Exhibits

31.1	Certification by Thomas M. Herzog, HCP’s Principal Executive Officer, Pursuant to Securities Exchange Act Rule 13a-14(a).*
31.2	Certification by Peter A. Scott, HCP’s Principal Financial Officer, Pursuant to Securities Exchange Act Rule 13a-14(a).*
32.1	Certification by Thomas M. Herzog, HCP’s Principal Executive Officer, Pursuant to Securities Exchange Act Rule 13a-14(b) and 18 U.S.C. Section 1350.**
32.2	Certification by Peter A. Scott, HCP’s Principal Financial Officer, Pursuant to Securities Exchange Act Rule 13a-14(b) and 18 U.S.C. Section 1350.**
101.INS	XBRL Instance Document.*
101.SCH	XBRL Taxonomy Extension Schema Document.*
101.CAL	XBRL Taxonomy Extension Calculation Linkbase Document.*
101.DEF	XBRL Taxonomy Extension Definition Linkbase Document.*
101.LAB	XBRL Taxonomy Extension Labels Linkbase Document.*
101.PRE	XBRL Taxonomy Extension Presentation Linkbase Document.*

*       Filed herewith.

**     Furnished herewith. 

55

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

Date: May 2, 2017	HCP, Inc.
	(Registrant)
	/s/ THOMAS M. HERZOG
	Thomas M. Herzog
	Chief Executive Officer
	(Principal Executive Officer)
	/s/ PETER A. SCOTT
	Peter A. Scott
	Executive Vice President and
	Chief Financial Officer
	(Principal Financial Officer)
	/s/ SCOTT A. ANDERSON
	Scott A. Anderson
	Executive Vice President and
	Chief Accounting Officer
	(Principal Accounting Officer)

56

EX-31.1

EXHIBIT 31.1

CERTIFICATION OF CHIEF EXECUTIVE OFFICER

I, Thomas M. Herzog, certify that:

1. I have reviewed this quarterly report on Form 10-Q of HCP, Inc. for the period ended March 31, 2017;

2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

4. The registrant’s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:

(a) Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

(b) Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

(c) Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

(d) Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and

5. The registrant’s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):

(a) All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and

(b) Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.

4
Date: May 2, 2017	/s/ THOMAS M. HERZOG
	Thomas M. Herzog
	Chief Executive Officer
	(Principal Executive Officer)

EX-31.2

EXHIBIT 31.2

CERTIFICATION OF PRINCIPAL FINANCIAL OFFICER

I, Peter A. Scott, certify that:

1. I have reviewed this quarterly report on Form 10-Q of HCP, Inc. for the period ended March  31, 2017;

2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

4. The registrant’s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:

(a) Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

(b) Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

(c) Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

(d) Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and

5. The registrant’s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):

(a) All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and

(b) Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.

4
Date: May 2, 2017	/s/ PETER A. SCOTT
	Peter A. Scott
	Executive Vice President and
	Chief Financial Officer
	(Principal Financial Officer)

EX-32.1

EXHIBIT 32.1

CERTIFICATION OF CHIEF EXECUTIVE OFFICER

Pursuant to 18 U.S.C. § 1350, as created by Section 906 of the Sarbanes-Oxley Act of 2002, the undersigned officer of HCP, Inc., a Maryland corporation (the “Company”), hereby certifies, to his knowledge, that:

(i) the accompanying quarterly report on Form 10-Q of the Company for the period ended March 31, 2017 (the “Report”) fully complies with the requirements of Section 13(a) or Section 15(d), as applicable, of the Securities Exchange Act of 1934, as amended; and

(ii) the information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

Date: May 2, 2017	/s/ THOMAS M. HERZOG
	Thomas M. Herzog
	Chief Executive Officer
	(Principal Executive Officer)

A signed original of this written statement required by Section 906 has been provided to the Company and will be retained by the Company and furnished to the Securities and Exchange Commission or its staff upon request. Such certification will not be deemed to be incorporated by reference into any filing under the Securities Act of 1933, as amended, or the Securities Exchange Act of 1934, as amended, except to the extent that the Company specifically incorporates it by reference.

EX-32.2

EXHIBIT 32.2

CERTIFICATION OF PRINCIPAL FINANCIAL OFFICER

Pursuant to 18 U.S.C. § 1350, as created by Section 906 of the Sarbanes-Oxley Act of 2002, the undersigned officer of HCP, Inc., a Maryland corporation (the “Company”), hereby certifies, to his knowledge, that:

(i) the accompanying quarterly report on Form 10-Q of the Company for the period ended March 31, 2017 (the “Report”) fully complies with the requirements of Section 13(a) or Section 15(d), as applicable, of the Securities Exchange Act of 1934, as amended; and

(ii) the information contained in the report fairly presents, in all material respects, the financial condition and results of operations of the Company.

Date: May 2, 2017	/s/ PETER A. SCOTT
	Peter A. Scott
	Executive Vice President and
	Chief Financial Officer
	(Principal Financial Officer)

A signed original of this written statement required by Section 906 has been provided to the Company and will be retained by the Company and furnished to the Securities and Exchange Commission or its staff upon request. Such certification will not be deemed to be incorporated by reference into any filing under the Securities Act of 1933, as amended, or the Securities Exchange Act of 1934, as amended, except to the extent that the Company specifically incorporates it by reference.

XML

Document and Entity Information - shares	3 Months Ended
	Mar. 31, 2017	Apr. 28, 2017
Document and Entity Information
Entity Registrant Name	HCP, INC.
Entity Central Index Key	0000765880
Document Type	10-Q
Document Period End Date	Mar. 31, 2017
Amendment Flag	false
Current Fiscal Year End Date	--12-31
Entity Current Reporting Status	Yes
Entity Filer Category	Large Accelerated Filer
Entity Common Stock, Shares Outstanding		468,572,028
Document Fiscal Year Focus	2017
Document Fiscal Period Focus	Q1

XML

CONSOLIDATED BALANCE SHEETS - USD ($) $ in Thousands	Mar. 31, 2017	Dec. 31, 2016
Real estate:
Buildings and improvements	$ 11,008,771	$ 11,692,654
Development costs and construction in progress	430,007	400,619
Land	1,772,174	1,881,487
Accumulated depreciation and amortization	(2,577,248)	(2,648,930)
Net real estate	10,633,704	11,325,830
Net investment in direct financing leases	712,540	752,589
Loans receivable, net	788,486	807,954
Investments in and advances to unconsolidated joint ventures	827,202	571,491
Accounts receivable, net of allowance of $3,941 and $4,459, respectively	31,500	45,116
Cash and cash equivalents	764,114	94,730
Restricted cash	60,806	42,260
Intangible assets, net	432,109	479,805
Assets held for sale, net		927,866
Other assets, net	605,407	711,624
Total assets	14,855,868	15,759,265
LIABILITIES AND EQUITY
Bank line of credit	492,421	899,718
Term loans	274,103	440,062
Senior unsecured notes	7,136,336	7,133,538
Mortgage debt	147,329	623,792
Other debt	91,263	92,385
Intangible liabilities, net	54,472	58,145
Liabilities of assets held for sale, net		3,776
Accounts payable and accrued liabilities	344,908	417,360
Deferred revenue	141,561	149,181
Total liabilities	8,682,393	9,817,957
Commitments and contingencies
Common stock, $1.00 par value: 750,000,000 shares authorized; 468,446,208 and 468,081,489 shares issued and outstanding, respectively	468,446	468,081
Additional paid-in capital	8,203,778	8,198,890
Cumulative dividends in excess of earnings	(2,802,218)	(3,089,734)
Accumulated other comprehensive loss	(28,658)	(29,642)
Total stockholders' equity	5,841,348	5,547,595
Joint venture partners	154,161	214,377
Non-managing member unitholders	177,966	179,336
Total noncontrolling interests	332,127	393,713
Total equity	6,173,475	5,941,308
Total liabilities and equity	$ 14,855,868	$ 15,759,265

XML

CONSOLIDATED BALANCE SHEETS (Parenthetical) - USD ($) $ in Thousands	Mar. 31, 2017	Dec. 31, 2016
Company's involvement with VIEs:
Development in process	$ 430,007	$ 400,619
Land	1,772,174	1,881,487
Investments in and advances to unconsolidated joint ventures	827,202	571,491
Accumulated depreciation and amortization	2,577,248	2,648,930
Accounts receivable	31,500	45,116
Cash	764,114	94,730
Restricted cash	60,806	42,260
Intangible assets, net	432,109	479,805
Other assets, net	605,407	711,624
Mortgage debt	147,329	623,792
Intangible liabilities, net	54,472	58,145
Accounts payable and accrued liabilities	344,908	417,360
Deferred Revenue	141,561	149,181
Balance Sheet Parenthetical Disclosures
Accounts receivable, allowance (in dollars)	$ 3,941	$ 4,459
Common stock, par value (in dollars per share)	$ 1.00	$ 1.00
Common stock, shares authorized	750,000,000	750,000,000
Common stock, shares issued	468,446,208	468,081,489
Common stock, shares outstanding	468,446,208	468,081,489
VIEs
Company's involvement with VIEs:
Buildings and improvements	$ 2,787,845	$ 3,522,310
Development in process	23,837	31,953
Land	214,963	327,241
Investments in and advances to unconsolidated joint ventures	3,108	3,641
Accumulated depreciation and amortization	535,012	676,276
Accounts receivable	9,609	19,996
Cash	37,005	35,844
Restricted cash	42,009	22,624
Intangible assets, net	139,281	169,027
Other assets, net	55,049	69,562
Mortgage debt	45,245	520,870
Intangible liabilities, net	8,734	8,994
Deferred Revenue	$ 16,077	$ 23,456

XML

CONSOLIDATED STATEMENTS OF OPERATIONS - USD ($) shares in Thousands, $ in Thousands	3 Months Ended
	Mar. 31, 2017	Mar. 31, 2016
Revenues:
Rental and related revenues	$ 286,218	$ 290,380
Tenant recoveries	33,675	31,375
Resident fees and services	140,232	165,763
Income from direct financing leases	13,712	14,910
Interest income	18,331	18,029
Total revenues	492,168	520,457
Costs and expenses:
Interest expense	86,718	122,062
Depreciation and amortization	136,554	139,855
Operating	159,081	175,957
General and administrative	22,478	25,451
Acquisition and pursuit costs	1,057	2,475
Total costs and expenses	405,888	465,800
Other income (expense):
Gain on sales of real estate, net	317,258
Other income, net	51,208	1,292
Total other income, net	368,466	1,292
Income before income taxes and equity (loss) income from unconsolidated joint ventures	454,746	55,949
Income tax benefit (expense)	6,162	(3,704)
Equity income (loss) from unconsolidated joint ventures	3,269	(908)
Income from continuing operations	464,177	51,337
Discontinued operations:
Income before income taxes		117,742
Income taxes expense		(49,334)
Total discontinued operations		68,408
Net income	464,177	119,745
Noncontrolling interests' share in earnings	(3,032)	(3,626)
Net income attributable to HCP, Inc.	461,145	116,119
Participating securities' share in earnings	(770)	(357)
Net income applicable to common shares	$ 460,375	$ 115,762
Basic earnings per common share:
Continuing operations (in dollars per share)	$ 0.98	$ 0.10
Discontinued operations (in dollars per share)		0.15
Net income applicable to common shares (in dollars per share)	0.98	0.25
Diluted earnings per common share:
Continuing operations (in dollars per share)	0.97	0.10
Discontinued operations (in dollars per share)		0.15
Net income applicable to common shares (in dollars per share)	$ 0.97	$ 0.25
Weighted average shares used to calculate earnings per common share:
Basic (in shares)	468,299	466,074
Diluted (in shares)	475,173	466,262
Dividends declared per common share (in dollars per share)	$ 0.37	$ 0.575

XML

CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2017	Mar. 31, 2016
CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME
Net income	$ 464,177	$ 119,745
Other comprehensive income (loss):
Change in net unrealized gains (losses) on securities	9	(15)
Change in net unrealized gains (losses) on cash flow hedges:
Unrealized losses	(302)	(690)
Reclassification adjustment realized in net income	213	169
Change in Supplemental Executive Retirement Plan obligation	74	70
Foreign currency translation adjustment	990	(737)
Total other comprehensive income (loss)	984	(1,203)
Total comprehensive income	465,161	118,542
Total comprehensive income attributable to noncontrolling interests	(3,032)	(3,626)
Total comprehensive income attributable to HCP, Inc.	$ 462,129	$ 114,916

XML

CONSOLIDATED STATEMENTS OF EQUITY - USD ($) shares in Thousands, $ in Thousands	Total Stockholders' Equity	Common Stock	Additional Paid-In Capital	Cumulative Dividends In Excess Of Earnings	Accumulated Other Comprehensive Income (Loss)	Total Noncontrolling Interests	Total
Balance at Dec. 31, 2015	$ 9,343,643	$ 465,488	$ 11,647,039	$ (2,738,414)	$ (30,470)	$ 402,674	$ 9,746,317
Balance (in shares) at Dec. 31, 2015		465,488
Increase (Decrease) in Stockholders' Equity
Net income	116,119			116,119		3,626	119,745
Other comprehensive income	(1,203)				(1,203)		(1,203)
Issuance of common stock, net	35,406	$ 1,428	33,978				35,406
Issuance of common stock, net (in shares)		1,428
Conversion of DownREIT units to common stock						(4,136)	4,136
Repurchase of common stock	(3,628)	$ (102)	(3,526)				(3,628)
Repurchase of common stock (in shares)		(102)
Exercise of stock options	2,852	$ 111	2,741				2,852
Exercise of stock options (in shares)		111
Amortization of deferred compensation	5,345		5,345				5,345
Common dividends	(268,186)			(268,186)			(268,186)
Distributions to noncontrolling interests	(36)		(36)			(4,853)	(4,889)
Issuance of noncontrolling interests						2,200	2,200
Deconsolidation of noncontrolling interests	435			435		67	502
Balance at Mar. 31, 2016	9,230,747	$ 466,925	11,685,541	(2,890,046)	(31,673)	399,578	9,630,325
Balance (in shares) at Mar. 31, 2016		466,925
Balance at Dec. 31, 2016	5,547,595	$ 468,081	8,198,890	(3,089,734)	(29,642)	393,713	5,941,308
Balance (in shares) at Dec. 31, 2016		468,081
Increase (Decrease) in Stockholders' Equity
Net income	461,145			461,145		3,032	464,177
Other comprehensive income	984				984		984
Issuance of common stock, net	3,472	$ 427	3,045				3,472
Issuance of common stock, net (in shares)		427
Conversion of DownREIT units to common stock	1,548	$ 54	1,494			(1,548)	1,548
Conversion of DownREIT units (in shares)		54
Repurchase of common stock	(3,532)	$ (116)	(3,416)				(3,532)
Repurchase of common stock (in shares)		(116)
Amortization of deferred compensation	3,765		3,765				3,765
Common dividends	(173,629)			(173,629)			(173,629)
Distributions to noncontrolling interests						(5,659)	(5,659)
Issuance of noncontrolling interests						650	650
Deconsolidation of noncontrolling interests						(58,061)	(58,061)
Balance at Mar. 31, 2017	$ 5,841,348	$ 468,446	$ 8,203,778	$ (2,802,218)	$ (28,658)	$ 332,127	$ 6,173,475
Balance (in shares) at Mar. 31, 2017		468,446

XML

CONSOLIDATED STATEMENTS OF EQUITY (Parenthetical) - $ / shares	3 Months Ended
	Mar. 31, 2017	Mar. 31, 2016
CONSOLIDATED STATEMENTS OF EQUITY
Common dividends, per share (in dollars per share)	$ 0.37	$ 0.575

XML

CONSOLIDATED STATEMENTS OF CASH FLOWS - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2017	Mar. 31, 2016
Cash flows from operating activities:
Net income	$ 464,177	$ 119,745
Adjustments to reconcile net income to net cash provided by operating activities:
Depreciation and amortization of real estate, in-place lease and other intangibles continuing operations	136,554	139,855
Depreciation and amortization of real estate, in-place lease and other intangibles discontinued operations		1,467
Amortization of deferred compensation	3,765	5,345
Amortization of deferred financing costs	3,858	5,280
Straight-line rents	(5,007)	(7,576)
Equity (income) loss from unconsolidated joint ventures	(3,269)	908
Distributions of earnings from unconsolidated joint ventures	7,842	1,589
Gain on sales of real estate, net	(317,258)
Deferred income tax (benefit) expense	(8,130)	49,156
Foreign exchange and other gains, net	(77)	(89)
Gain on sale of marketable securities	(50,895)
Other non-cash items	(583)	(922)
Changes in:
Accounts receivable, net	3,467	3,705
Other assets, net	(2,331)	(6,847)
Accounts payable and accrued liabilities	(38,984)	(42,999)
Net cash provided by operating activities	193,129	268,617
Cash flows from investing activities:
Acquisitions of real estate		(94,271)
Development of real estate	(75,166)	(99,096)
Leasing costs and tenant and capital improvements	(22,693)	(19,964)
Proceeds from sales of real estate, net	1,166,265
Contributions to unconsolidated joint ventures	(8,109)	(10,136)
Distributions in excess of earnings from unconsolidated joint ventures	870	5,336
Net proceeds from the RIDEA II transaction (Note 4)	480,613
Proceeds from the sales of Four Seasons investments	(135,538)
Principal repayments on loans receivable, direct financing leases and other	49,826	155,320
Investments in loans receivable and other	(15,000)	(117,282)
Decrease in restricted cash	3,073	14,336
Net cash provided by (used in) investing activities	1,715,217	(165,757)
Cash flows from financing activities:
Net borrowings under bank line of credit		422,897
Net repayments under bank line of credit	(375,812)
Repayment under bank line of credit	(37,032)
Repayments of term loan	(169,113)
Repayments of senior unsecured notes		(500,000)
Repayments of mortgage and other debt	(478,314)	(36,918)
Issuance of common stock and exercise of options	3,472	34,122
Repurchase of common stock	(3,532)	(3,628)
Dividends paid on common stock	(173,629)	(268,186)
Issuance of noncontrolling interests	650	2,200
Distributions to noncontrolling interests	(5,659)	(4,889)
Net cash used in financing activities	(1,238,969)	(354,402)
Effect of foreign exchange on cash and cash equivalents	7	(293)
Net increase (decrease) in cash and cash equivalents	669,384	(251,835)
Cash and cash equivalents, beginning of period	94,730	346,500
Cash and cash equivalents, end of period	764,114	94,665
Less: cash and cash equivalents of discontinued operations		(3,578)
Cash and cash equivalents, end of period	$ 764,114	$ 91,087

XML

Business

3 Months Ended

Mar. 31, 2017

Business

Business

NOTE 1.  Business

HCP, Inc., a Standard & Poor’s (“S&P”) 500 company, is a Maryland corporation that is organized to qualify as a real estate investment trust (“REIT”) which, together with its consolidated entities (collectively, “HCP” or the “Company”), invests primarily in real estate serving the healthcare industry in the United States (“U.S.”). The Company acquires, develops, leases, manages and disposes of healthcare real estate and provides financing to healthcare providers. The Company’s diverse portfolio is comprised of investments in the following reportable healthcare segments: (i) senior housing triple-net (“SH NNN”); (ii) senior housing operating portfolio (“SHOP”); (iii) life science and (iv) medical office.

XML

Summary of Significant Accounting Policies

3 Months Ended

Mar. 31, 2017

Summary of Significant Accounting Policies

Summary of Significant Accounting Policies

NOTE 2.  Summary of Significant Accounting Policies

Basis of Presentation

The accompanying unaudited consolidated financial statements have been prepared in accordance with U.S. generally accepted accounting principles (“GAAP”) for interim financial information. Management is required to make estimates and assumptions in the preparation of financial statements in conformity with GAAP. These estimates and assumptions affect the reported amounts of assets and liabilities and the disclosure of contingent assets and liabilities at the date of the consolidated financial statements and the reported amounts of revenue and expenses during the reporting period. Actual results could differ from management’s estimates.

The consolidated financial statements include the accounts of HCP, Inc., its wholly-owned subsidiaries, joint ventures (“JVs”) and VIEs that it controls through voting rights or other means. Intercompany transactions and balances have been eliminated upon consolidation. In the opinion of management, all adjustments (consisting of normal recurring adjustments) necessary to present fairly the Company’s financial position, results of operations and cash flows have been included. Operating results for the three months ended March 31, 2017 are not necessarily indicative of the results that may be expected for the year ending December 31, 2017. The accompanying unaudited interim financial information should be read in conjunction with the consolidated financial statements and notes thereto for the year ended December 31, 2016 included in the Company’s Annual Report on Form 10-K filed with the U.S. Securities and Exchange Commission (“SEC”).

Real Estate

On January 1, 2017 the Company adopted Accounting Standards Update (“ASU”) No. 2017-01, Clarifying the Definition of a Business (“ASU 2017-01”) which narrows the Financial Accounting Standards Board’s (“FASB”) definition of a business and provides a framework that gives entities a basis for making reasonable judgments about whether a transaction involves an asset, or a group of assets, or a business. ASU 2017-01 states that when substantially all of the fair value of the gross assets acquired (or disposed of) is concentrated in a single identifiable asset or group of similar identifiable assets, the set is not a business. If this initial test is not met, a set cannot be considered a business unless it includes an acquired input and a substantive process that together significantly contribute to the ability to create outputs. In addition, ASU 2017-01 clarifies the requirements for a set of activities to be considered a business and narrows the definition of an output. This ASU is to be applied prospectively and the Company expects that a majority of its future real estate acquisitions and dispositions will be deemed asset transactions rather than business combinations. As a result, for asset acquisitions the Company will record identifiable assets acquired, liabilities assumed and any associated noncontrolling interests at cost on a relative fair value basis. In addition, for such asset acquisitions, no goodwill will be recognized, third party transaction costs will be capitalized and any associated contingent consideration will be recorded when the contingency is resolved.

Segment Reporting

The Company’s reportable segments, based on how it evaluates its business and allocates resources, are as follows: (i) SH NNN, (ii) SHOP, (iii) life science and (iv) medical office.

Prior to the third quarter of 2016, the Company had five reportable segments: (i) senior housing, (ii) post-acute/skilled nursing, (iii) life science, (iv) medical office and (v) hospital. During the third quarter of 2016, primarily as a result of the planned spin-off of Quality Care Properties, Inc. (“QCP”) (NYSE:QCP), the Company revised its operating analysis structure and changed its reportable segments. The Company believes the change to its reportable segments is appropriate and consistent with how its chief operating decision makers review the Company’s operating results and determine resource allocations. Accordingly, all prior period segment information has been reclassified to conform to the current period presentation.

Reclassifications

Certain amounts in the Company’s consolidated financial statements have been reclassified for prior periods to conform to the current period presentation. Certain prior period amounts have been reclassified on consolidated statements of operations for discontinued operations (see Note 4). See Segment Reporting above for additional reclassifications.

Recent Accounting Pronouncements

In February 2017, the FASB issued ASU No. 2017-05, Clarifying the Scope of Asset Derecognition Guidance and Accounting for Partial Sales of Nonfinancial Assets (“ASU 2017-05”). The amendments in ASU 2017-05 clarify the scope of the FASB’s recently established guidance on nonfinancial asset derecognition which applies to the derecognition of all nonfinancial assets and in-substance nonfinancial assets. In addition, ASU 2017-05 clarifies the accounting for partial sales of nonfinancial assets and in-substance nonfinancial assets to align with the new revenue recognition standard (see below). ASU 2017-05 is effective for annual periods beginning after December 15, 2017, including interim periods within, and must be adopted in conjunction with the Revenue ASUs (as defined below). ASU 2017-05 can be adopted using a full retrospective approach or a modified retrospective approach, resulting in a cumulative-effect adjustment to equity as of the beginning of the fiscal year in which the guidance is effective. Under either transition election, the Company will reassess its partial sale of RIDEA II, completed in the first quarter of 2017, and record its retained 40% equity interest at fair value as of the sale completion date. The Company estimates the fair value of its retained equity investment as of the sale completion date to be approximately $107 million which upon adoption, will increase the Company’s gain on sales of real estate, net for the period ended March 31, 2017 by the same amount. See Note 4 for further information on the RIDEA II transaction.

In June 2016, the FASB issued ASU No. 2016-13, Measurement of Credit Losses on Financial Instruments (“ASU 2016-13”). ASU 2016-13 is intended to improve financial reporting by requiring timelier recognition of credit losses on loans and other financial instruments held by financial institutions and other organizations. The amendments in ASU 2016-13 eliminate the “probable” initial threshold for recognition of credit losses in current accounting guidance and, instead, reflect an entity’s current estimate of all expected credit losses over the life of the financial instrument. Previously, when credit losses were measured under current accounting guidance, an entity generally only considered past events and current conditions in measuring the incurred loss. The amendments in ASU 2016-13 broaden the information that an entity must consider in developing its expected credit loss estimate for assets measured either collectively or individually. The use of forecasted information incorporates more timely information in the estimate of expected credit loss. ASU 2016-13 is effective for fiscal years, and interim periods within, beginning after December 15, 2019. Early adoption is permitted for fiscal years, and interim periods within, beginning after December 15, 2018. A reporting entity is required to apply the amendments in ASU 2016-13 using a modified retrospective approach by recording a cumulative-effect adjustment to equity as of the beginning of the fiscal year of adoption. A prospective transition approach is required for debt securities for which an other-than-temporary impairment had been recognized before the effective date. Upon adoption of ASU 2016-13, the Company is required to reassess its financing receivables, including direct finance leases and loans receivable, and expects that application of ASU 2016-13 may result in the Company recognizing credit losses at an earlier date than would otherwise be recognized under current accounting guidance. The Company is evaluating the impact of the adoption of ASU 2016-13 on January 1, 2020 to its consolidated financial position and results of operations.

In February 2016, the FASB issued ASU No. 2016-02, Leases (“ASU 2016-02”). ASU 2016-02 amends the current accounting for leases to: (i) require lessees to put most leases on their balance sheets, but continue recognizing expenses on their income statements in a manner similar to requirements under current accounting guidance, (ii) eliminate current real estate specific lease provisions and (iii) modify the classification criteria and accounting for sales-type leases for lessors. ASU 2016-02 is effective for fiscal years, and interim periods within, beginning after December 15, 2018. Early adoption is permitted. The transition method required by ASU 2016-02 varies based on the specific amendment being adopted. As a result of adopting ASU 2016-02, the Company will recognize all of its operating leases for which it is the lessee, including corporate office leases and ground leases, on its consolidated balance sheets and will capitalize fewer legal costs related to the drafting and execution of its lease agreements. In addition, the Company expects that it will have to bifurcate lease agreements into lease components and certain non-lease components. Lease components will continue to be recognized on a straight-line basis over the lease term and certain non-lease components will be accounted for under the new revenue recognition guidance in ASU 2014-09. The Company is evaluating the impact of the adoption of ASU 2016-02 on January 1, 2019 to its consolidated financial position and results of operations.

Between May 2014 and May 2016, the FASB issued three ASUs changing the requirements for recognizing and reporting revenue (together, herein referred to as the “Revenue ASUs”): (i) ASU No. 2014-09, Revenue from Contracts with Customers (“ASU 2014-09”), (ii) ASU No. 2016-08, Principal versus Agent Considerations (Reporting Revenue Gross versus Net) (“ASU 2016-08”) and (iii) ASU No. 2016-12, Narrow-Scope Improvements and Practical Expedients (“ASU 2016-12”). ASU 2014-09 provides guidance for revenue recognition to depict the transfer of promised goods or services to customers in an amount that reflects the consideration to which the entity expects to be entitled in exchange for those goods or services. ASU 2016-08 is intended to improve the operability and understandability of the implementation guidance on principal versus agent considerations. ASU 2016-12 provides practical expedients and improvements on the previously narrow scope of ASU 2014-09. In August 2015, the FASB issued ASU No. 2015-14, Revenue from Contracts with Customers (Topic 606): Deferral of the Effective Date (“ASU 2015-14”). ASU 2015-14 defers the effective date of ASU 2014-09 by one year to fiscal years, and interim periods within, beginning after December 15, 2017. All subsequent ASUs related to ASU 2014-09, including ASU 2016-08 and ASU 2016-12, assumed the deferred effective date enforced by ASU 2015-14. Early adoption of the Revenue ASUs is permitted for annual periods, and interim periods within, beginning after December 15, 2016. A reporting entity may apply the amendments in the Revenue ASUs using either a modified retrospective approach, by recording a cumulative-effect adjustment to equity as of the beginning of the fiscal year of adoption or full retrospective approach. The Company has not yet elected a transition method and is evaluating the complete impact of the adoption of the Revenue ASUs on January 1, 2018 to its consolidated financial position, results of operations and disclosures. The Company expects to complete its evaluation of the impacts of the Revenue ASUs during the second half of 2017. As the primary source of revenue for the Company is generated through leasing arrangements, which are excluded from the Revenue ASUs,the Company expects that it will be impacted in its recognition and disclosure of non-lease revenue, such as certain resident fees in its RIDEA structures (a portion of which are not generated through leasing arrangements), non-lease components of revenue from lease agreements (upon adoption of ASU 2016-02) and its recognition of real estate sale transactions. Under ASU 2014-09, revenue recognition for real estate sales is largely based on the transfer of control versus continuing involvement under current guidance. As a result, the Company generally expects that the new guidance will result in more transactions qualifying as sales of real estate and revenue being recognized at an earlier date than under current accounting guidance.

The following ASUs have been issued, but not yet adopted, and the Company does not expect a material impact to its consolidated financial position, results of operations, cash flows, or disclosures upon adoption:

· ASU No. 2017-04, Simplifying the Test for Goodwill Impairment (“ASU 2017-04”). ASU 2017-04 is effective for fiscal years, including interim periods within, beginning after December 15, 2019 (upon the first goodwill impairment test performed during that fiscal year). Early adoption is permitted for interim or annual goodwill impairment tests performed on testing dates after January 1, 2017. A reporting entity must apply the amendments in ASU 2017-04 using a prospective approach.

· ASU No. 2016-18, Restricted Cash (“ASU 2016-18”). ASU 2016-18 is effective for fiscal years, and interim periods within, beginning after December 15, 2017. Early adoption is permitted. A reporting entity must apply the amendments in ASU 2016-18 using a full retrospective approach.

· ASU No. 2016-15, Classification of Certain Cash Receipts and Cash Payments (“ASU 2016-15”). ASU 2016-15 is effective for fiscal years, and interim periods within, beginning after December 15, 2017. Early adoption is permitted. A reporting entity must apply the amendments in ASU 2016-15 using a full retrospective approach.

· ASU No. 2016-01, Recognition and Measurement of Financial Assets and Financial Liabilities (“ASU 2016-01”). ASU 2016-01 is effective for fiscal years, and interim periods within, beginning after December 15, 2017. Early adoption is permitted only for updates to certain disclosure requirements. A reporting entity is required to apply the amendments in ASU 2016-01 using a modified retrospective approach by recording a cumulative-effect adjustment to equity as of the beginning of the fiscal year of adoption.

· ASU No. 2016-16, Intra-Entity Transfers of Assets Other Than Inventory (“ASU 2016-16”). ASU 2016-16 is effective for fiscal years, and interim periods within, beginning after December 15, 2017. Early adoption is permitted as of the first interim period presented in any year following issuance. A reporting entity must apply the amendments in ASU 2016-16 using a modified retrospective approach by recording a cumulative-effect adjustment to equity as of the beginning of the fiscal year of adoption. 

XML

Real Estate Property Investments

3 Months Ended

Mar. 31, 2017

Real Estate Property Investments

Other Real Estate Property Investments

NOTE 3.  Real Estate Property Investments

The following table summarizes the Company’s real estate acquisitions for the three months ended March 31, 2016 (in thousands):

	Consideration				Assets Acquired
	Cash Paid/		Liabilities				Net
Segment	Debt Settled		Assumed		Real Estate		Intangibles
SH NNN	$	76,362	$	1,200	$	71,875	$	5,687
Other non-reportable segments		17,909		—		16,596		1,313
	$	94,271	$	1,200	$	88,471	$	7,000

There were no real estate acquisitions for the three months ended March 31, 2017.

XML

Discontinued Operations and Dispositions of Real Estate

3 Months Ended

Mar. 31, 2017

Discontinued Operations and Dispositions of Real Estate

Discontinued Operations and Dispositions of Real Estate

NOTE 4.  Discontinued Operations and Dispositions of Real Estate

Discontinued Operations - Quality Care Properties, Inc.

On October 31, 2016, the Company completed the spin-off (the “Spin-Off”) of its subsidiary, QCP. The Spin-Off included 338 properties, primarily comprised of the HCR ManorCare, Inc. (“HCRMC”) direct financing lease (“DFL”) investments and an equity investment in HCRMC. QCP is an independent, publicly-traded, self-managed and self-administrated REIT.

In connection with the Spin-Off, the Company entered into a Transition Services Agreement (“TSA”) with QCP. Per the terms of the TSA, the Company has agreed to provide certain administrative and support services to QCP on a transitional basis for established fees. The TSA will terminate on the expiration of the term of the last service provided under the agreement, which will be on or prior to October 30, 2017. The TSA provides that QCP generally has the right to terminate a transition service upon thirty days notice to the Company. The TSA contains provisions under which the Company will, subject to certain limitations, be obligated to indemnify QCP for losses incurred by QCP resulting from the Company’s breach of the TSA.

Summarized financial information for discontinued operations for the three months ended March 31, 2016 is as follows (in thousands):

	Three Months Ended
	March 31, 2016
Revenues:
Rental and related revenues	$	6,814
Tenant recoveries		362
Income from direct financing leases		113,058
Total revenues		120,234
Costs and expenses:
Depreciation and amortization		(1,467)
Operating		(998)
General and administrative		(48)
Other income, net		21
Income before income taxes		117,742
Income tax expense		(49,334)
Net income from discontinued operations	$	68,408

HCR ManorCare, Inc.

Discontinued operations is primarily comprised of QCP’s HCRMC DFL investments. During the three months ended March 31, 2016, the Company recognized DFL income and received cash payments of $113 million from the HCRMC DFL investments.

No accretion related to its HCRMC DFL investments was recognized in 2016 due to the Company utilizing a cash basis method of accounting beginning January 1, 2016.

The Company’s acquisition of the HCRMC DFL investments in 2011 was subject to federal and state built-in gain tax of up to $2 billion, if all the assets were sold within 10 years of the acquisition date. At the time of acquisition, the Company intended to hold the assets for at least 10 years, at which time the assets would no longer be subject to the built-in gain tax. In December 2015, the U.S. Federal Government passed legislation which permanently reduced the holding period, for federal tax purposes, to five years, which the Company satisfied in April 2016. This legislation was not extended to certain states, which maintain a 10 year requirement. During the three months ended March 31, 2016, the Company determined that it may sell assets during the next five years and, therefore, recorded a deferred tax liability of $49 million representing its estimated exposure to state built-in gain tax.

Dispositions of Real Estate

Held for Sale

At December 31, 2016,  64 SH NNN facilities, four life science facilities and a SHOP facility were classified as held for sale, with an aggregate carrying value of $928 million, primarily comprised of real estate assets of $809 million. All facilities held for sale at December 31, 2016 were sold during the first quarter of 2017.

At March 31, 2017, there were no assets classified as held for sale.

2017 Dispositions

In January 2017, the Company sold four life science facilities in Salt Lake City, Utah for $76 million, resulting in a net gain on sale of $45 million.

Also in January 2017, the Company completed the contribution of its ownership interest in RIDEA II to an unconsolidated JV owned by HCP and an investor group led by Columbia Pacific Advisors, LLC (“HCP/CPA PropCo” and “HCP/CPA OpCo,” together, the “HCP/CPA JV”). In addition, RIDEA II was recapitalized with $602 million of debt, of which $360 million was provided by a third-party and $242 million was provided by HCP. In return, for both transaction elements the Company received combined proceeds of $480 million from the HCP/CPA JV and $242 million in note receivables and retained an approximately 40% beneficial interest in RIDEA II (the note receivable and 40% beneficial interest are herein referred to as the “RIDEA II Investments”). This transaction resulted in the Company deconsolidating the net assets of RIDEA II and recognizing a net gain on sale of $99 million. The RIDEA II Investments are now recognized and accounted for as equity method investments.

In March 2017, the Company sold 64 SH NNN assets, previously under triple-net leases with Brookdale Senior Living Inc. (“Brookdale”), for $1.125 billion to affiliates of Blackstone Real Estate Partners VIII, L.P., resulting in a net gain on sale of $170 million.

Subsequent Dispositions

In April 2017, the Company sold a land parcel in San Diego, California for $27 million.

XML

Net Investment in Direct Financing Leases

3 Months Ended

Mar. 31, 2017

Net Investment in Direct Financing Leases

Net Investment in Direct Financing Leases

NOTE 5.  Net Investment in Direct Financing Leases

Net investment in DFLs consisted of the following (dollars in thousands):

	March 31,		December 31,
	2017		2016
Minimum lease payments receivable	$	1,095,233	$	1,108,237
Estimated residual values		500,368		539,656
Less unearned income		(883,061)		(895,304)
Net investment in direct financing leases	$	712,540	$	752,589
Properties subject to direct financing leases		29		30

Certain DFLs contain provisions that allow the tenants to elect to purchase the properties during or at the end of the lease terms for the aggregate initial investment amount plus adjustments, if any, as defined in the lease agreements. Certain leases also permit the Company to require the tenants to purchase the properties at the end of the lease terms.

In March 2017, the Company sold a hospital in Palm Beach Gardens, Florida for $43 million to the current tenant.

Direct Financing Lease Internal Ratings

The following table summarizes the Company’s internal ratings for DFLs at March 31, 2017 (dollars in thousands):

	Carrying		Percentage of	Internal Ratings
Segment	Amount		DFL Portfolio	Performing DFLs		Watch List DFLs		Workout DFLs
SH NNN	$	627,936	88	$	268,350	$	359,586	$	—
Other non-reportable segments		84,604	12		84,604		—		—
	$	712,540	100	$	352,954	$	359,586	$	—

Beginning September 30, 2013, the Company placed a 14 property senior housing triple-net DFL (the “DFL Watchlist Portfolio”) on nonaccrual status and “Watch List” status. The Company determined that the collection of all rental payments was and continues to be no longer reasonably assured; therefore, rental revenue for the DFL Watchlist Portfolio has been recognized on a cash basis.

During both the three months ended March 31, 2017 and 2016, the Company recognized DFL income of $3 million and received cash payments of $4 million from the DFL Watchlist Portfolio. The carrying value of the DFL Watchlist Portfolio was $360 million and $361 million at March 31, 2017 and December 31, 2016, respectively.

XML

Loans Receivable

3 Months Ended

Mar. 31, 2017

Loans Receivable.

Loans Receivable

NOTE 6.  Loans Receivable

The following table summarizes the Company’s loans receivable (in thousands):

	March 31, 2017						December 31, 2016
	Real Estate		Other				Real Estate		Other
	Secured		Secured		Total		Secured		Secured		Total
Mezzanine(1) (2)	$	—	$	625,116	$	625,116	$	—	$	615,188	$	615,188
Other(3)		166,595		—		166,595		195,946		—		195,946
Unamortized discounts, fees and costs		—		(3,225)		(3,225)		413		(3,593)		(3,180)
	$	166,595	$	621,891	$	788,486	$	196,359	$	611,595	$	807,954

(1) At March 31, 2017, included £280 million ($350 million) outstanding and £2 million ($2 million) of associated unamortized discounts, fees and costs, both related to the HC-One Facility. At December 31, 2016, included £282 million ($348 million) outstanding and £2 million ($3 million) of associated unamortized discounts, fees and costs, both related to the HC-One Facility.

(2) At March 31, 2017, the Company had £29 million ($36 million) remaining under its commitments to fund development projects and capital expenditures under its United Kingdom (“U.K.”) development projects.

(3) At March 31, 2017, included £116 million ($145 million) outstanding related to Maria Mallaband loans.

Loans Receivable Internal Ratings

The following table summarizes the Company’s internal ratings for loans receivable at March 31, 2017 (dollars in thousands):

	Carrying		Percentage of	Internal Ratings
Investment Type	Amount		Loan Portfolio	Performing Loans		Watch List Loans		Workout Loans
Real estate secured	$	166,595	21	$	166,595	$	—	$	—
Other secured		621,891	79		365,318		256,573		—
	$	788,486	100	$	531,913	$	256,573	$	—

Real Estate Secured Loans

Four Seasons Health Care. In March 2017, the Company sold its investment in Four Seasons Health Care’s (“Four Seasons”) senior secured term loan at par plus accrued interest for £29 million ($35 million).

Other Secured Loans

Tandem Health Care Loan. On July 31, 2012, the Company closed a mezzanine loan facility to lend up to $205 million to Tandem Health Care (“Tandem”), as part of the recapitalization of a post-acute/skilled nursing portfolio (the “Tandem Portfolio”). The Company funded $100 million (the “First Tranche”) at closing and funded an additional $102 million (the “Second Tranche”) in June 2013. In May 2015, the Company increased and extended the mezzanine loan facility with Tandem to: (i) fund $50 million (the “Third Tranche”) and $5 million (the “Fourth Tranche”), which proceeds were used to repay a portion of Tandem’s existing senior and mortgage debt, respectively; (ii) extend its maturity to October 2018; and (iii) extend the prepayment penalty period through January 2017. The tranches (collectively, the “Tandem Mezzanine Loan”) bear interest at fixed annual rates of 12%, 14%,  6% and 6% per annum for the First, Second, Third and Fourth Tranches, respectively. The blended rate for the Tandem Mezzanine Loan is 11.5% per year. Due to a decline in the Tandem Portfolio’s operating performance, at September 30, 2016, the Company assigned an internal rating of “Watch List” to the Tandem Mezzanine Loan.At March 31, 2017, the Tandem Mezzanine Loan had an outstanding balance of $257 million and was subordinate to approximately $372 million of senior mortgage debt.

Tandem leases the entire Tandem Portfolio to Consulate Health Care (“Consulate”) under a master lease (the “Tandem and Consulate Lease”). At March 31, 2017, as a result of the Tandem Portfolio’s operating performance there are outstanding events of default under the Tandem and Consulate Lease (“Events of Default”) due to: (i) Consulate’s failure to meet certain financial covenants under the Tandem and Consulate Lease; and (ii) events of default under Consulate’s working capital facility, which, through a cross-default provision, are Events of Default. Additionally, Consulate failed to pay the full amount of its April 2017 rent under the Tandem and Consulate Lease which triggered another Event of Default. Through cross-default provisions, these Events of Default are also events of default under the Tandem Mezzanine Loan and Tandem’s senior mortgage debt (each, a “Loan Event of Default”). The Tandem Mezzanine Loan requires Tandem to pay default interest at a rate of 16.5% per year, during periods in which there is an outstanding Loan Event of Default. Tandem did not pay the additional 5% default interest rate spread above the 11.5%  and, therefore created a monetary event of default under the Tandem Mezzanine Loan.

Although Tandem continues to remain current on its non-default interest payment obligations under the Tandem Mezzanine Loan, the Company believes that it is probable it will be unable to collect all interest and principal payments according to the contractual terms of the Tandem Mezzanine Loan. Because the Tandem Mezzanine Loan is deemed collateral-dependent, and the fair value of the underlying collateral, net of the fair value of the senior mortgage debt, at March 31, 2017, exceeds the carrying amount of the Tandem Mezzanine Loan, the Company has not recorded an impairment write-down at March 31, 2017. The Company will continue to monitor the fair value of the collateral, and other factors, to determine whether it will be required to record an impairment write-down in future periods. Additionally, beginning in the first quarter of 2017, the Company elected to recognize interest income on a cash basis. During both the three months ended March 31, 2017 and 2016, the Company recognized interest income and received cash payments of $7 million from Tandem.

The Company entered into a forbearance agreement with Tandem on May 1, 2017, pursuant to which it agreed to forbear from exercising remedies, including waiving default interest, with respect to the above-described Loan Events of Default under the Tandem Mezzanine Loan until June 30, 2017, subject to the satisfaction of certain conditions. Under the forbearance terms, among other conditions, Tandem is required to make timely non-default interest payments in full for each of May and June 2017, and no additional Event of Default or Loan Event of Default may occur. The Company’s forbearance is contingent on the senior mortgage lender also agreeing to forebear from exercising remedies, including waiving default interest, with respect to the above-described Loan Events of Default under the senior mortgage debt. The Company expects Tandem and Tandem’s senior mortgage lender to enter into such forbearance agreement in the near term.  

XML

Investments in and Advances to Unconsolidated Joint Ventures

3 Months Ended

Mar. 31, 2017

Investments in and Advances to Unconsolidated Joint Ventures

Investments in and Advances to Unconsolidated Joint Ventures

NOTE 7.  Investments in and Advances to Unconsolidated Joint Ventures

The Company owns interests in the following entities that are accounted for under the equity method at March 31, 2017 (dollars in thousands):

					Carrying Amount
					March 31,		December 31,
Entity(1)	Segment	Ownership%			2017		2016
CCRC JV(2)	SHOP		49		$	434,649	$	439,449
RIDEA II(6)	SHOP		40			263,180		—
HCP Life Science(4)	Life science	50	–	63		65,490		67,879
MBK JV(3)	SHOP		50			39,088		38,909
HCP Ventures IV, LLC	Medical office		20			7,338		7,277
Vintage Park Development JV	SHOP		85			6,953		7,486
Suburban Properties, LLC	Medical office		67			4,618		4,628
MBK Development JV(3)	SHOP		50			2,464		2,463
K&Y(5)	Other non-reportable segments		80			1,380		1,342
Advances to unconsolidated JVs, net and other						2,042		2,058
					$	827,202	$	571,491

(1) These entities are not consolidated because the Company does not control, through voting rights or other means, the JVs.

(2) Includes two unconsolidated JVs in a RIDEA structure (CCRC PropCo and CCRC OpCo).

(3) Includes two unconsolidated JVs in a RIDEA structure.

(4) Includes the following unconsolidated partnerships (and the Company’s ownership percentage): (i) Torrey Pines Science Center, LP (50%); (ii) Britannia Biotech Gateway, LP (55%) and (iii) LASDK, LP (63%).

(5) Includes three unconsolidated JVs.

(6) Includes three unconsolidated JVs in a RIDEA structure (HCP/CPA PropCo, HCP/CPA OpCo, and RIDEA II PropCo).

See Note 4 for further information on the deconsolidation of RIDEA II.

XML

Intangibles

3 Months Ended

Mar. 31, 2017

Intangibles

Intangibles

NOTE 8.  Intangibles

The following tables summarize the Company’s intangible lease assets and liabilities (in thousands):

	March 31,		December 31,
Intangible lease assets	2017		2016
Gross intangible lease assets	$	841,905	$	911,697
Accumulated depreciation and amortization		(409,796)		(431,892)
Intangible assets, net	$	432,109	$	479,805

	March 31,		December 31,
Intangible lease liabilities	2017		2016
Gross intangible lease liabilities	$	151,890	$	163,924
Accumulated depreciation and amortization		(97,418)		(105,779)
Intangible liabilities, net	$	54,472	$	58,145

XML

Other Assets

3 Months Ended

Mar. 31, 2017

Other Assets.

Other Assets

NOTE 9.  Other Assets

The following table summarizes the Company’s other assets (in thousands):

	March 31,		December 31,
	2017		2016
Straight-line rent receivables, net of allowance of $25,173 and $25,059, respectively	$	316,125	$	311,776
Marketable debt securities, net		18,330		68,630
Leasing costs and inducements, net		87,553		156,820
Goodwill		47,019		42,386
Other		136,380		132,012
Total other assets	$	605,407	$	711,624

Four Seasons Health Care Senior Notes

In March 2017, pursuant to a shift in the Company’s investment strategy, the Company sold its £138.5 million par value Four Seasons senior notes (the “Four Seasons Notes”) for £83 million ($101 million). The disposition of the Four Seasons Notes generated a £42 million ($51 million) gain on sale, recognized in other income, net, as the sales price was above the previously-impaired carrying value of £41 million ($50 million).

XML

Debt

3 Months Ended

Mar. 31, 2017

Debt

Debt

NOTE 10.  Debt

Bank Line of Credit and Term Loans

The Company’s $2.0 billion unsecured revolving line of credit facility (the “Facility”) matures on March 31, 2018 and contains a committed one-year extension option, at a cost of 30 basis points. Borrowings under the Facility accrue interest at LIBOR plus a margin that depends on the Company’s credit ratings. The Company pays a facility fee on the entire revolving commitment that depends on its credit ratings. Based on the Company’s credit ratings at March 31, 2017, the margin on the Facility was 1.05% and the facility fee was 0.20%. The Facility also includes a feature that allows the Company to increase the borrowing capacity by an aggregate amount of up to $500 million, subject to securing additional commitments from existing lenders or new lending institutions. During the three months ended March 31, 2017, the Company repaid $440 million primarily using proceeds from the RIDEA II joint venture disposition (see Note 4). At March 31, 2017, the Company had £394 million ($492 million) outstanding under the Facility with a weighted average effective interest rate of 1.65%.

On July 30, 2012, the Company entered into a credit agreement with a syndicate of banks for a £137 million unsecured term loan (the “2012 Term Loan”). In March 2017, the Company repaid the 2012 Term Loan primarily using proceeds from the sale of the Four Seasons investments (see Notes 6 and 9).

On January 12, 2015, the Company entered into a credit agreement with a syndicate of banks for a £220 million ($275 million at March 31, 2017) four-year unsecured term loan (the “2015 Term Loan”) that accrues interest at a rate of GBP LIBOR plus 1.15%, subject to adjustments based on the Company’s credit ratings. The 2015 Term Loan matures on January 12, 2019 and contains a one-year committed extension option. Concurrently, the Company entered into a three-year interest rate swap contract that fixed the interest rate of the 2015 Term Loan (1.966% at March 31, 2017) (see Note 19).

The Facility and 2015 Term Loan contain certain financial restrictions and other customary requirements, including cross-default provisions to other indebtedness. Among other things, these covenants, using terms defined in the agreements: (i) limit the ratio of Consolidated Total Indebtedness to Consolidated Total Asset Value to 60%; (ii) limit the ratio of Secured Debt to Consolidated Total Asset Value to 30%; (iii) limit the ratio of Unsecured Debt to Consolidated Unencumbered Asset Value to 60%; and (iv) require a minimum Fixed Charge Coverage ratio of 1.5 times. The Facility and Term Loan also require a Minimum Consolidated Tangible Net Worth of $6.5 billion at March 31, 2017. At March 31, 2017, the Company was in compliance with each of these restrictions and requirements of the Facility and Term Loan.

Senior Unsecured Notes

At March 31, 2017, the Company had senior unsecured notes outstanding with an aggregate principal balance of $7.2 billion. The senior unsecured notes contain certain covenants including limitations on debt, maintenance of unencumbered assets, cross-acceleration provisions and other customary terms. The Company believes it was in compliance with these covenants at March 31, 2017.

The following table summarizes the Company’s senior unsecured notes payoffs for the year ended December 31, 2016 (dollars in thousands):

Date	Amount		Coupon Rate
February 1, 2016	$	500,000		3.750	%
September 15, 2016	$	400,000		6.300	%
November 30, 2016	$	500,000		6.000	%
November 30, 2016	$	600,000		6.700	%

There were no senior unsecured note payoffs for the three months ended March 31, 2017.

There were no senior unsecured notes issuances for the year ended December 31, 2016 and three months ended March 31, 2017.

Mortgage Debt

At March 31, 2017, the Company had $142 million in aggregate principal of mortgage debt outstanding, which is secured by 17 healthcare facilities (including redevelopment properties) with a carrying value of $311 million. In March 2017, the Company paid off $472 million of mortgage debt primarily using proceeds from the sale of 64 SH NNN facilities (see Note 4).

Debt Maturities

The following table summarizes the Company’s stated debt maturities and scheduled principal repayments at March 31, 2017 (in thousands):

					Senior
	Bank Line of				Unsecured		Mortgage
Year	Credit(1)		Term Loan(2)		Notes(3)		Debt(4)		Total(5)
2017 (nine months)	$	—	$	—	$	250,000	$	2,604	$	252,604
2018		492,421		—		—		3,641		496,062
2019		—		274,956		450,000		3,839		728,795
2020		—		—		800,000		3,907		803,907
2021		—		—		1,200,000		11,277		1,211,277
Thereafter		—		—		4,500,000		116,481		4,616,481
		492,421		274,956		7,200,000		141,749		8,109,126
(Discounts), premiums and debt costs, net		—		(853)		(63,664)		5,580		(58,937)
	$	492,421	$	274,103	$	7,136,336	$	147,329	$	8,050,189

(1) Represents £394 million translated into U.S. dollar (“USD”).

(2) Represents £220 million translated into USD.

(3) Effective interest rates on the notes ranged from 2.79% to 6.88% with a weighted average effective interest rate of 4.34% and a weighted average maturity of six years.

(4) Interest rates on the mortgage debt ranged from 2.99% to 7.51% with a weighted average effective interest rate of 4.24% and a weighted average maturity of 20 years.

(5) Excludes $91 million of other debt that have no scheduled maturities.

Subsequent Event

In April 2017, the Company repaid an additional £105 million of the Facility.

On May 1, 2017, the Company repaid $250 million of maturing senior unsecured notes.

XML

Commitments and Contingencies

3 Months Ended

Mar. 31, 2017

Commitments and Contingencies.

Commitments and Contingencies

NOTE 11.  Commitments and Contingencies

Commitments

HCP is the sole lender to QCP of an unsecured revolving credit facility (the "Unsecured Revolving Credit Facility") which has a total commitment of $36 million as of February 28, 2017. The Unsecured Revolving Credit Facility is available to be drawn upon by QCP through October 31, 2017 and matures on October 31, 2018. Commitments under the Unsecured Revolving Credit Facility will automatically and permanently decrease each calendar month by an amount equal to 50% of QCP's and its restricted subsidiaries’ retained cash flow for the prior calendar month. All borrowings under the Unsecured Revolving Credit Facility will be subject to the satisfaction of certain conditions, including (i) QCP’s senior secured revolving credit facility being unavailable, (ii) the failure of HCRMC to pay rent and (iii) other customary conditions, including the absence of a default and the accuracy of representations and warranties. QCP may only draw on the Unsecured Revolving Credit Facility prior to the one-year anniversary of the completion of the Spin-Off. Borrowings under the Unsecured Revolving Credit Facility will bear interest at a rate equal to LIBOR, subject to a 1.00% floor, plus an applicable margin of 6.25%. In addition to paying interest on outstanding principal under the Unsecured Revolving Credit Facility, QCP is required to pay a facility fee equal to 0.50% per annum of the unused capacity under the Unsecured Revolving Credit Facility to HCP, payable quarterly. Through March 31, 2017, no amounts had been drawn on the Unsecured Revolving Credit Facility.

Legal Proceedings

From time to time, the Company is a party to legal proceedings, lawsuits and other claims. Except as described below, the Company is not aware of any legal proceedings or claims that it believes may have, individually or taken together, a material adverse effect on the Company’s financial condition, results of operations or cash flows. The Company’s policy is to expense legal costs as they are incurred.

Class Action

On May 9, 2016, a purported stockholder of the Company filed a putative class action complaint, Boynton Beach Firefighters’ Pension Fund v. HCP, Inc., et al., Case No. 3:16-cv-01106-JJH, in the U.S. District Court for the Northern District of Ohio against the Company, certain of its officers, HCRMC, and certain of its officers, asserting violations of the federal securities laws. The suit asserts claims under sections 10(b) and 20(a) of the Securities Exchange Act of 1934 and alleges that the Company made certain false or misleading statements relating to the value of and risks concerning its investment in HCRMC by allegedly failing to disclose that HCRMC had engaged in billing fraud, as alleged by the U.S. Department of Justice in a pending suit against HCRMC arising from the False Claims Act. The plaintiff in the suit demands compensatory damages (in an unspecified amount), costs and expenses (including attorneys’ fees and expert fees), and equitable, injunctive, or other relief as the Court deems just and proper. As the Boynton Beach action is in its early stages and a lead plaintiff has not yet been named, the defendants have not yet responded to the complaint. The Company believes the suit to be without merit and intends to vigorously defend against it.

Derivative Actions

On June 16, 2016 and July 5, 2016, purported stockholders of the Company filed two derivative actions, respectively Subodh v. HCR ManorCare Inc., et al., Case No. 30-2016-00858497-CU-PT-CXC and Stearns v. HCR ManorCare, Inc., et al., Case No. 30-2016-00861646-CU-MC-CJC, in the Superior Court of California, County of Orange, against certain of the Company’s current and former directors and officers and HCRMC. The Company is named as a nominal defendant. As both derivative actions contained substantially the same allegations, they have been consolidated into a single action. The consolidated action alleges that the defendants engaged in various acts of wrongdoing, including, among other things, breaching fiduciary duties by publicly making false or misleading statements of fact regarding HCRMC’s finances and prospects, and failing to maintain adequate internal controls. As the Subodh/Stearns action is in the early stages, defendants have not yet responded to the complaint. On April 18, 2017, the Court approved the parties’ stipulation staying the action pending further developments, including in the related securities class action litigation. The Court also adjourned the status conference scheduled for April 27, 2017 to January 10, 2018.

On April 10, 2017, a purported stockholder of the Company filed a derivative action, Weldon v. Martin et al., Case No. 3:17-cv-755, in federal court in the Northern District of Ohio, Western Division, against certain of the Company’s current and former directors and officers and HCRMC. The Company is named as a nominal defendant. The Weldon complaint asserts similar claims to those asserted in the California derivative actions. In addition, the complaint asserts a claim under Section 14(a) of the Securities Exchange Act of 1934, alleging that the Company made false statements in its 2016 proxy statement by not disclosing that the Company’s performance issues in 2015 were the direct result of billing fraud at HCRMC. On April 18, 2017, the Court re-assigned and transferred this action to the judge presiding over the related federal securities class action. Defendants have not yet been served or responded to the complaint.

The Company is unable to estimate the ultimate individual or aggregate amount of monetary liability or financial impact amount of loss or range of reasonable possible losses with respect to matters discussed above at March 31, 2017.

XML

Equity

3 Months Ended

Mar. 31, 2017

Equity

Equity

NOTE 12.  Equity

Accumulated Other Comprehensive Loss

The following table summarizes the Company’s accumulated other comprehensive loss (in thousands):

	March 31,		December 31,
	2017		2016
Cumulative foreign currency translation adjustment	$	(21,827)	$	(22,817)
Unrealized losses on cash flow hedges, net		(3,731)		(3,642)
Supplemental Executive Retirement Plan minimum liability		(3,055)		(3,129)
Unrealized losses on available for sale securities		(45)		(54)
Total accumulated other comprehensive loss	$	(28,658)	$	(29,642)

XML

Segment Disclosures

3 Months Ended

Mar. 31, 2017

Segment Disclosures

Segment Disclosures

NOTE 13.  Segment Disclosures

The Company evaluates its business and allocates resources based on its reportable business segments: (i) SH NNN, (ii) SHOP, (iii) life science and (iv) medical office. Under the medical office segment, the Company invests through the acquisition and development of MOBs, which generally require a greater level of property management. Otherwise, the Company primarily invests, through the acquisition and development of real estate, in single tenant and operator properties. The Company has non-reportable segments that are comprised primarily of the Company’s debt investments, hospital properties and U.K. care homes. The accounting policies of the segments are the same as those in Note 2 to the Consolidated Financial Statements in the Company’s 2016 Annual Report on Form 10-K filed with the SEC, as amended by Note 2 herein. During the year ended December 31, 2016, 17 SH NNN facilities were transitioned to a RIDEA structure (reported in the Company’s SHOP segment). During the three months ended March 31, 2017, one SH NNN facility was transitioned to a RIDEA structure. The Company evaluates performance based upon: (i) property net operating income from continuing operations (“NOI”) and (ii) adjusted NOI of the combined consolidated and unconsolidated investments in each segment.

Non-segment assets consist primarily of corporate assets, including cash and cash equivalents, restricted cash, accounts receivable, net, marketable equity securities and, if any, real estate held for sale. Interest expense, depreciation and amortization, and non-property specific revenues and expenses are not allocated to individual segments in evaluating the Company’s segment-level performance. See Note 17 for other information regarding concentrations of credit risk.

The following tables summarize information for the reportable segments (in thousands):

For the three months ended March 31, 2017:

					Life		Medical		Other		Corporate
	SH NNN		SHOP		Science		Office		Non-reportable		Non-segment		Total
Rental revenues(1)	$	100,034	$	140,228	$	85,321	$	118,371	$	29,883	$	—	$	473,837
HCP share of unconsolidated JV revenues		—		76,364		1,940		489		418		—		79,211
Operating expenses		(1,111)		(94,539)		(17,319)		(44,864)		(1,248)		—		(159,081)
HCP share of unconsolidated JV operating expenses		—		(59,527)		(371)		(142)		(19)		—		(60,059)
NOI		98,923		62,526		69,571		73,854		29,034		—		333,908
Adjustments to NOI(2)		(1,839)		3,508		(256)		(969)		(1,012)		—		(568)
Adjusted NOI		97,084		66,034		69,315		72,885		28,022		—		333,340
Addback adjustments		1,839		(3,508)		256		969		1,012		—		568
Interest income		—		—		—		—		18,331		—		18,331
Interest expense		(627)		(4,596)		(104)		(129)		(1,997)		(79,265)		(86,718)
Depreciation and amortization		(26,411)		(26,358)		(33,791)		(42,729)		(7,265)		—		(136,554)
General and administrative		—		—		—		—		—		(22,478)		(22,478)
Acquisition and pursuit costs		—		—		—		—		—		(1,057)		(1,057)
Gain on sales of real estate, net		268,464		366		44,633		—		3,795		—		317,258
Other income, net		—		—		—		—		—		51,208		51,208
Income tax benefit		—		—		—		—		—		6,162		6,162
Less: HCP share of unconsolidated JV NOI		—		(16,837)		(1,569)		(347)		(399)		—		(19,152)
Equity income in unconsolidated JVs		—		1,993		770		269		237		—		3,269
Net income (loss)	$	340,349	$	17,094	$	79,510	$	30,918	$	41,736	$	(45,430)	$	464,177

For the three months ended March 31, 2016:

					Life		Medical		Other		Corporate
	SH NNN		SHOP		Science		Office		Non-reportable		Non-segment		Total
Rental revenues(1)	$	106,889	$	165,763	$	88,948	$	108,023	$	32,805	$	—	$	502,428
HCP share of unconsolidated JV revenues		—		52,277		1,810		479		407		—		54,973
Operating expenses		(2,074)		(114,003)		(16,743)		(41,949)		(1,188)		—		(175,957)
HCP share of unconsolidated JV operating expenses		—		(42,088)		(374)		(149)		(3)		—		(42,614)
NOI		104,815		61,949		73,641		66,404		32,021		—		338,830
Adjustments to NOI(2)		(5,443)		5,032		(673)		(795)		(571)		—		(2,450)
Adjusted NOI		99,372		66,981		72,968		65,609		31,450		—		336,380
Addback adjustments		5,443		(5,032)		673		795		571		—		2,450
Interest income		—		—		—		—		18,029		—		18,029
Interest expense		(4,166)		(7,855)		(638)		(1,665)		(2,327)		(105,411)		(122,062)
Depreciation and amortization		(33,506)		(26,297)		(33,596)		(38,719)		(7,737)		—		(139,855)
General and administrative		—		—		—		—		—		(25,451)		(25,451)
Acquisition and pursuit costs		—		—		—		—		—		(2,475)		(2,475)
Other income, net		—		—		—		—		—		1,292		1,292
Income tax expense		—		—		—		—		—		(3,704)		(3,704)
Less: HCP share of unconsolidated JV NOI		—		(10,189)		(1,436)		(330)		(404)		—		(12,359)
Equity (loss) income in unconsolidated JVs		—		(2,478)		709		658		203		—		(908)
Discontinued operations		—		—		—		—		—		68,408		68,408
Net income (loss)	$	67,143	$	15,130	$	38,680	$	26,348	$	39,785	$	(67,341)	$	119,745

(1) Represents rental and related revenues, tenant recoveries, resident fees and services, and income from DFLs.

(2) Represents straight-line rents, DFL non-cash interest, amortization of market lease intangibles, net, lease termination fees and non-refundable entrance fees as the fees are collected by the Company’s CCRC JV, net of CCRC JV entrance fee amortization.

The following table summarizes the Company’s revenues by segment (in thousands):

	Three Months Ended March 31,
Segment	2017		2016
SH NNN	$	100,034	$	106,889
SHOP		140,228		165,763
Life science		85,321		88,948
Medical office		118,371		108,023
Other non-reportable segments		48,214		50,834
Total revenues	$	492,168	$	520,457

See Notes 3 and 4 for significant transactions impacting the Company’s segment assets during the periods presented.

XML

Earnings Per Common Share

3 Months Ended

Mar. 31, 2017

Earnings Per Common Share

Earnings Per Common Share

NOTE 14.  Earnings Per Common Share

The following table illustrates the computation of basic and diluted earnings per share (in thousands, except per share amounts):

	Three Months Ended March 31,
	2017		2016
Numerator
Net income from continuing operations	$	464,177	$	51,337
Noncontrolling interests’ share in earnings		(3,032)		(3,626)
Net income attributable to HCP, Inc.		461,145		47,711
Participating securities’ share in earnings		(770)		(357)
Income from continuing operations applicable to common shares		460,375		47,354
Discontinued operations		—		68,408
Net income applicable to common shares	$	460,375	$	115,762
Numerator - Dilutive
Net income applicable to common shares	$	460,375	$	115,762
Add: distributions on dilutive convertible units		2,803		—
Dilutive net income available to common shares	$	463,178	$	115,762
Denominator
Basic weighted average common shares		468,299		466,074
Dilutive potential common shares - equity awards		229		188
Dilutive potential common shares - DownREIT units		6,645		—
Diluted weighted average common shares		475,173		466,262
Basic earnings per common share
Continuing operations	$	0.98	$	0.10
Discontinued operations		—		0.15
Net income applicable to common shares	$	0.98	$	0.25
Diluted earnings per common share
Continuing operations	$	0.97	$	0.10
Discontinued operations		—		0.15
Net income applicable to common shares	$	0.97	$	0.25

Restricted stock and certain performance restricted stock units are considered participating securities, because dividend payments are not forfeited even if the underlying award does not vest, and require use of the two-class method when computing basic and diluted earnings per share.

Options to purchase 1 million shares of common stock were excluded from the computation of diluted earnings per share for both the three months ended March 31, 2017 and 2016 because they are anti-dilutive. Additionally, 6 million shares, issuable upon conversion of 4 million DownREIT units during the three months ended March 31, 2016, were not included because they are anti-dilutive.

XML

Supplemental Cash Flow Information

3 Months Ended

Mar. 31, 2017

Supplemental Cash Flow Information

Supplemental Cash Flow Information

NOTE 15.  Supplemental Cash Flow Information

The following table provides supplemental cash flow information (in thousands):

	Three Months Ended March 31,
	2017		2016
Supplemental cash flow information:
Interest paid, net of capitalized interest	$	108,232	$	171,422
Income taxes paid		1,105		1,213
Capitalized interest		3,090		3,128
Supplemental schedule of non-cash investing and financing activities:
Accrued construction costs		51,498		56,972
Non-cash acquisitions and dispositions settled with receivables and restricted cash held in connection with Section 1031 transactions		39,991		91,605
Tenant-funded tenant improvements owned by HCP		3,120		9,178
Vesting of restricted stock units		293		248
Conversion of non-managing member units into common stock		1,548		4,136
Mortgages and other liabilities assumed with real estate acquisitions		—		1,200
Unrealized losses on available-for-sale securities and derivatives designated as cash flow hedges, net		(45)		(705)

XML

Variable Interest Entities

3 Months Ended

Mar. 31, 2017

Variable Interest Entities

Variable Interest Entities

NOTE 16.  Variable Interest Entities

Unconsolidated Variable Interest Entities

At March 31, 2017,  the Company had investments in: (i) four unconsolidated VIE JVs, (ii) 48 properties leased to VIE tenants, (iii) marketable debt securities of one VIE and (iv) two loans to VIE borrowers. The Company has determined that it is not the primary beneficiary of and therefore does not consolidate these VIEs because it does not have the ability to control the activities that most significantly impact their economic performance. Except for the Company’s equity interest in the unconsolidated JVs (CCRC OpCo, RIDEA II PropCo, Vintage Park Development JV and the LLC investment discussed below), it has no formal involvement in these VIEs beyond its investments.

The Company holds a 49% ownership interest in CCRC OpCo, a joint venture entity formed in August 2014 that operates senior housing properties in a RIDEA structure and has been identified as a VIE (see Note 7). The equity members of CCRC OpCo “lack power” because they share certain operating rights with Brookdale, as manager of the CCRCs. The assets of CCRC OpCo primarily consist of the CCRCs that it owns and leases, resident fees receivable, notes receivable, and cash and cash equivalents; its obligations primarily consist of operating lease obligations to CCRC PropCo, debt service payments and capital expenditures for the properties, and accounts payable and expense accruals associated with the cost of its CCRCs’ operations. Assets generated by the CCRC operations (primarily rents from CCRC residents) of CCRC OpCo may only be used to settle its contractual obligations (primarily from debt service payments, capital expenditures, and rental costs and operating expenses incurred to manage such facilities).

In January 2017, as a result of the partial sale of its interest in RIDEA II, the Company concluded that it should deconsolidate RIDEA II as it is no longer the primary beneficiary of the joint venture. The HCP/CPA JV is the primary beneficiary of both RIDEA II PropCo and RIDEA II OpCo as it controls the significant activities of RIDEA II PropCo and, of the group that controls the significant activities of RIDEA II OpCo, is most closely associated to the entity. Furthermore, control over the HCP/CPA JV is shared between HCP and CPA, and as such, the Company does not consolidate the HCP/CPA JV. Subsequent to the partial sale of its interest in RIDEA II, the Company continues to hold a direct investment in RIDEA II PropCo, which has been identified as a VIE as Brookdale, the non-managing member, does not have any substantive participating rights or kick-out rights over the managing member, HCP/CPA PropCo (see Notes 4 and 7). The assets of RIDEA II PropCo primarily consist of leased properties (net real estate), rents receivable, and cash and cash equivalents; its obligations primarily consist of a combination of third-party and HCP debt (see Note 4). Assets generated by RIDEA II PropCo (primarily from RIDEA II OpCo lease payments) may only be used to settle its contractual obligations (primarily debt service payments on the third-party and HCP debt).

The Company holds an 85% ownership interest in Vintage Park Development JV (see Note 7), which has been identified as a VIE as power is shared with a member that does not have a substantive equity investment at risk. The assets of Vintage Park Development JV primarily consist of an in-progress independent living facility development project that it owns and cash and cash equivalents; its obligations primarily consist of accounts payable and expense accruals associated with the cost of its development obligations. Any assets generated by Vintage Park Development JV may only be used to settle its contractual obligations (primarily development expenses and debt service payments).

The Company holds a limited partner ownership interest in an unconsolidated LLC that has been identified as a VIE. The Company’s involvement in the entity is limited to its equity investment as a limited partner, and it does not have any substantive participating rights or kick-out rights over the general partner. The assets and liabilities of the entity primarily consist of those associated with its senior housing real estate and development activities. Any assets generated by the entity may only be used to settle its contractual obligations (primarily development expenses and debt service payments).

The Company leases 48 properties to a total of seven tenants that have also been identified as VIEs (“VIE tenants”). These VIE tenants are “thinly capitalized” entities that rely on the operating cash flows generated from the senior housing facilities to pay operating expenses, including the rent obligations under their leases.

The Company holds commercial mortgage-backed securities (“CMBS”) issued by Federal Home Loan Mortgage Corporation (commonly referred to as Freddie MAC) through a special purpose entity that has been identified as a VIE because it is “thinly capitalized.” The CMBS issued by the VIE are backed by mortgage debt obligations on real estate assets.

The Company provided a £105 million ($131 million at closing) bridge loan to Maria Mallaband Care Group Ltd. (“MMCG”) to fund the acquisition of a portfolio of care homes in the U.K. MMCG created a special purpose entity to acquire the portfolio and funded it entirely using the Company’s bridge loan. As such, the special purpose entity has been identified as a VIE because it is “thinly capitalized.” The Company retains a three-year call option to acquire all the shares of the special purpose entity, which it can only exercise upon the occurrence of certain events.

The Company provided seller financing of $10 million related to its sale of seven SH NNN facilities. The financing was provided in the form of a secured five-year mezzanine loan to a “thinly capitalized” borrower created to acquire the facilities.

The classification of the related assets and liabilities and the maximum loss exposure as a result of the Company’s involvement with these VIEs at March 31, 2017 was as follows (in thousands):

		Maximum Loss
		Exposure
		and Carrying
VIE Type	Asset/Liability Type	Amount(1)
VIE tenants—DFLs(2)	Net investment in DFLs	$	600,348
VIE tenants—operating leases(2)	Lease intangibles, net and straight-line rent receivables		6,721
CCRC OpCo	Investments in unconsolidated JVs		217,655
RIDEA II PropCo	Investments in unconsolidated JVs		257,534
Vintage Park Development JV	Investments in unconsolidated JVs		6,953
Loan—senior secured	Loans receivable, net		131,916
Loan—seller financing	Loans receivable, net		10,000
CMBS and LLC investment	Marketable debt and cost method investment		33,391

(1) The Company’s maximum loss exposure represents the aggregate carrying amount of such investments (including accrued interest).

(2) The Company’s maximum loss exposure may be mitigated by re-leasing the underlying properties to new tenants upon an event of default. 

At March 31, 2017, the Company had not provided, and is not required to provide, financial support through a liquidity arrangement or otherwise, to its unconsolidated VIEs, including circumstances in which it could be exposed to further losses (e.g., cash shortfalls). See Notes 4, 6, and 7 for additional descriptions of the nature, purpose and operating activities of the Company’s unconsolidated VIEs and interests therein.

Consolidated Variable Interest Entities

HCP, Inc.’s consolidated total assets and total liabilities at March 31, 2017 and December 31, 2016 include certain assets of variable interest entities (“VIEs”) that can only be used to settle the liabilities of the related VIE. The VIE creditors do not have recourse to HCP, Inc. Total assets at March 31, 2017 and December 31, 2016 include VIE assets as follows (in thousands):

	March 31, 2017		December 31, 2016
Assets
Buildings and improvements	$	2,787,845	$	3,522,310
Development costs and construction in progress		23,837		31,953
Land		214,963		327,241
Accumulated depreciation and amortization		(535,012)		(676,276)
Net real estate		2,491,633		3,205,228
Investments in and advances to unconsolidated joint ventures		3,108		3,641
Accounts receivable		9,609		19,996
Cash and cash equivalents		37,005		35,844
Restricted cash		42,009		22,624
Intangible assets, net		139,281		169,027
Other assets, net		55,049		69,562
Total assets	$	2,777,694	$	3,525,922
Liabilities
Mortgage debt		45,245		520,870
Intangible liabilities, net		8,734		8,994
Liabilities of assets held for sale, net		92,640		120,719
Deferred revenue		16,077		23,456
Total liabilities	$	162,696	$	674,039

RIDEA I.  The Company holds a 90% ownership interest in JV entities formed in September 2011 that own and operate senior housing properties in a RIDEA structure (“RIDEA I”). The Company has historically classified RIDEA I OpCo as a VIE and, as a result of the adoption of ASU No. 2015-02, Amendments to the Consolidation Analysis (“ASU 2015-02”), also classifies RIDEA I PropCo as a VIE due to the non-managing member lacking substantive participation rights in the management of RIDEA I PropCo or kick-out rights over the managing member. The Company consolidates RIDEA I PropCo and RIDEA I OpCo as the primary beneficiary because it has the ability to control the activities that most significantly impact these VIEs’ economic performance. The assets of RIDEA I PropCo primarily consist of leased properties (net real estate), rents receivable, and cash and cash equivalents; its obligations primarily consist of notes payable to a non-VIE consolidated subsidiary of the Company. The assets of RIDEA I OpCo primarily consist of leasehold interests in senior housing facilities (operating leases), resident fees receivable, and cash and cash equivalents; its obligations primarily consist of lease payments to RIDEA I PropCo and operating expenses of its senior housing facilities (accounts payable and accrued expenses). Assets generated by the senior housing operations (primarily from senior housing resident rents) of the RIDEA I structure may only be used to settle its contractual obligations (primarily from the rental costs, operating expenses incurred to manage such facilities and debt costs).

RIDEA III.  The Company holds a 90% ownership interest in JV entities formed in June 2015 that own and operate senior housing properties in a RIDEA structure. The Company has historically classified RIDEA III OpCo as a VIE and, as a result of the adoption of ASU 2015-02, also classifies RIDEA III PropCo as a VIE due to the non-managing member lacking substantive participation rights in the management of RIDEA III PropCo or kick-out rights over the managing member. The Company consolidates RIDEA III PropCo and RIDEA III OpCo as the primary beneficiary because it has the ability to control the activities that most significantly impact these VIEs’ economic performance. The assets of RIDEA III PropCo primarily consist of leased properties (net real estate), rents receivable, and cash and cash equivalents; its obligations primarily consist of a note payable to a non-VIE consolidated subsidiary of the Company. The assets of RIDEA III OpCo primarily consist of leasehold interests in senior housing facilities (operating leases), resident fees receivable, and cash and cash equivalents; its obligations primarily consist of lease payments to RIDEA III PropCo and operating expenses of its senior housing facilities (accounts payable and accrued expenses). Assets generated by the senior housing operations (primarily from senior housing resident rents) of the RIDEA III structure may only be used to settle its contractual obligations (primarily from the rental costs, operating expenses incurred to manage such facilities and debt costs).

HCP Ventures V, LLC.  The Company holds a 51% ownership interest in and is the managing member of a JV entity formed in October 2015 that owns and leases MOBs (“HCP Ventures V”). Upon adoption of ASU 2015-02, the Company classified HCP Ventures V as a VIE due to the non-managing member lacking substantive participation rights in the management of HCP Ventures V or kick-out rights over the managing member. The Company consolidates HCP Ventures V as the primary beneficiary because it has the ability to control the activities that most significantly impact the VIE’s economic performance. The assets of HCP Ventures V primarily consist of leased properties (net real estate), rents receivable, and cash and cash equivalents; its obligations primarily consist of capital expenditures for the properties. Assets generated by HCP Ventures V may only be used to settle its contractual obligations (primarily from capital expenditures).

Vintage Park JV.  The Company holds a 90% ownership interest in a JV entity formed in January 2015 that owns an 85% interest in an unconsolidated development VIE (“Vintage Park JV”). Upon adoption of ASU 2015-02, the Company classified Vintage Park JV as a VIE due to the non-managing member lacking substantive participation rights in the management of the Vintage Park JV or kick-out rights over the managing member. The Company consolidates Vintage Park JV as the primary beneficiary because it has the ability to control the activities that most significantly impact the VIE’s economic performance. The assets of Vintage Park JV primarily consist of an investment in the Vintage Park Development JV and cash and cash equivalents; its obligations primarily consist of funding the ongoing development of the Vintage Park Development JV. Assets generated by the Vintage Park JV may only be used to settle its contractual obligations (primarily from the funding of the Vintage Park Development JV).

DownREITs.  The Company holds a controlling ownership interest in and is the managing member of five DownREITs. Upon adoption of ASU 2015-02, the Company classified the DownREITs as VIEs due to the non-managing members lacking substantive participation rights in the management of the DownREITs or kick-out rights over the managing member. The Company consolidates the DownREITs as the primary beneficiary because it has the ability to control the activities that most significantly impact these VIEs’ economic performance. The assets of the DownREITs primarily consist of leased properties (net real estate), rents receivable, and cash and cash equivalents; their obligations primarily consist of debt service payments and capital expenditures for the properties. Assets generated by the DownREITs (primarily from resident rents) may only be used to settle their contractual obligations (primarily from debt service and capital expenditures).

Other Consolidated Real Estate Partnerships.  The Company holds a controlling ownership interest in and is the general partner (or managing member) of multiple partnerships that own and lease real estate assets (the “Partnerships”). Upon adoption of ASU 2015-02, the Company classified the Partnerships as VIEs due to the limited partners (non-managing members) lacking substantive participation rights in the management of the Partnerships or kick-out rights over the general partner (managing member). The Company consolidates the Partnerships as the primary beneficiary because it has the ability to control the activities that most significantly impact these VIEs’ economic performance. The assets of the Partnerships primarily consist of leased properties (net real estate), rents receivable, and cash and cash equivalents; their obligations primarily consist of debt service payments and capital expenditures for the properties. Assets generated by the Partnerships (primarily from resident rents) may only be used to settle their contractual obligations (primarily from debt service and capital expenditures).

Other consolidated VIEs.  The Company made a loan to an entity that entered into a tax credit structure (“Tax Credit Subsidiary”) and a loan to an entity that made an investment in a development JV (“Development JV”) both of which are considered VIEs. The Company consolidates the Tax Credit Subsidiary and Development JV as the primary beneficiary because it has the ability to control the activities that most significantly impact the VIEs’ economic performance. The assets and liabilities of the Tax Credit Subsidiary and Development JV substantially consist of a development in progress, notes receivable, prepaid expenses, notes payable, and accounts payable and accrued liabilities generated from their operating activities. Any assets generated by the operating activities of the Tax Credit Subsidiary and Development JV may only be used to settle their contractual obligations.

XML

Concentration of Credit Risk

3 Months Ended

Mar. 31, 2017

Concentration of Credit Risk

Concentration of Credit Risk

NOTE 17.  Concentration of Credit Risk

Concentrations of credit risk arise when one or more tenants, operators or obligors related to the Company’s investments are engaged in similar business activities, or activities in the same geographic region, or have similar economic features that would cause their ability to meet contractual obligations, including those to the Company, to be similarly affected by changes in economic conditions. The Company regularly monitors various segments of its portfolio to assess potential concentrations of credit risks. The Company does not have significant foreign operations.

The following tables provide information regarding the Company’s concentrations with respect to certain tenants:

	Percentage of Gross Assets				Percentage of Revenues
	Total Company		SH NNN		Total Company		SH NNN
	March 31,	December 31,	March 31,	December 31,	Three Months Ended March 31,		Three Months Ended March 31,
Tenant	2017	2016	2017	2016	2017	2016	2017	2016
Brookdale(1)	11	17	42	69	12	12	60	58

(1) Includes revenues from 64 SH NNN facilities that were classified as held for sale at December 31, 2016 and sold in March 2017.   

At March 31, 2017 and December 31, 2016, Brookdale managed or operated, in the Company’s SHOP segment,  approximately 13% and 18%, respectively, of the Company’s real estate investments based on gross assets. Because an operator manages the Company’s facilities in exchange for the receipt of a management fee, the Company is not directly exposed to the credit risk of its operators in the same manner or to the same extent as its triple-net tenants. At March 31, 2017,  Brookdale provided comprehensive facility management and accounting services with respect to 59 of the Company’s SHOP facilities and 65 SHOP facilities owned by its unconsolidated joint ventures, for which the Company or joint venture pay annual management fees pursuant to long-term management agreements. Most of the management agreements have terms ranging from 10 to 15 years, with three to four 5-year renewal periods. The base management fees are 4.5% to 5.0% of gross revenues (as defined) generated by the RIDEA facilities. In addition, there are incentive management fees payable to Brookdale if operating results of the RIDEA properties exceed pre-established EBITDAR (as defined) thresholds.

Brookdale is subject to the registration and reporting requirements of the SEC and is required to file with the SEC annual reports containing audited financial information and quarterly reports containing unaudited financial information. The information related to Brookdale contained or referred to in this report has been derived from SEC filings made by Brookdale or other publicly available information, or was provided to the Company by Brookdale, and the Company has not verified this information through an independent investigation or otherwise. The Company has no reason to believe that this information is inaccurate in any material respect, but the Company cannot assure the reader of its accuracy. The Company is providing this data for informational purposes only, and encourages the reader to obtain Brookdale’s publicly available filings, which can be found on the SEC’s website at www.sec.gov.

To mitigate the credit risk of leasing properties to certain senior housing and post-acute/skilled nursing operators, leases with operators are often combined into portfolios that contain cross-default terms, so that if a tenant of any of the properties in a portfolio defaults on its obligations under its lease, the Company may pursue its remedies under the lease with respect to any of the properties in the portfolio. Certain portfolios also contain terms whereby the net operating profits of the properties are combined for the purpose of securing the funding of rental payments due under each lease.

XML

Fair Value Measurements

3 Months Ended

Mar. 31, 2017

Fair Value Measurements

Fair Value Measurements

NOTE 18.  Fair Value Measurements

Financial assets and liabilities measured at fair value on a recurring basis at March 31, 2017 in the consolidated balance sheets are immaterial.

The table below summarizes the carrying amounts and fair values of the Company’s financial instruments (in thousands):

	March 31, 2017(4)				December 31, 2016(4)
	Carrying				Carrying
	Value		Fair Value		Value		Fair Value
Loans receivable, net(2)	$	788,486	$	787,067	$	807,954	$	807,505
Marketable debt securities(2)		18,330		18,330		68,630		68,630
Marketable equity securities(1)		85		85		76		76
Warrants(3)		39		39		19		19
Bank line of credit(2)		492,421		492,421		899,718		899,718
Term loans(2)		274,103		274,103		440,062		440,062
Senior unsecured notes(1)		7,136,336		7,445,519		7,133,538		7,386,149
Mortgage debt(2)		147,329		134,605		623,792		609,374
Other debt(2)		91,263		91,263		92,385		92,385
Interest-rate swap liabilities(2)		4,163		4,163		4,857		4,857
Currency swap asset(2)		1,924		1,924		2,920		2,920

(1) Level 1: Fair value calculated based on quoted prices in active markets.  

(2) Level 2: Fair value based on (i) for marketable debt securities, quoted prices for similar or identical instruments in active or inactive markets, respectively, or (ii) or for loans receivable, net, mortgage debt, and swaps, calculated utilizing standardized pricing models in which significant inputs or value drivers are observable in active markets. For bank line of credit, term loans and other debt, the carrying values are a reasonable estimate of fair value because the borrowings are primarily based on market interest rates and the Company’s credit rating.

(3) Level 3: Fair value determined based on significant unobservable market inputs using standardized derivative pricing models.

(4) During the three months ended March 31, 2017 and year ended December 31, 2016, there were no material transfers of financial assets or liabilities within the fair value hierarchy.

XML

Derivative Financial Instruments

3 Months Ended

Mar. 31, 2017

Derivative Financial Instruments

Derivative Financial Instruments

NOTE 19.  Derivative Financial Instruments

The following table summarizes the Company’s outstanding interest-rate and foreign currency swap contracts at March 31, 2017 (dollars and GBP in thousands):

			Fixed
		Hedge	Rate/Buy			Floating/Exchange	Notional/
Date Entered	Maturity Date	Designation	Amount			Rate Index	Sell Amount		Fair Value(1)
Interest rate:
July 2005(2)	July 2020	Cash Flow		3.82	%	BMA Swap Index	$	44,300	$	(3,301)
January 2015(3)	October 2017	Cash Flow		1.79	%	1 Month GBP LIBOR+0.975%	£	220,000	$	(862)
Foreign currency:
January 2015(4)	October 2017	Cash Flow	$	11,300		Buy USD/Sell GBP	£	7,500	$	1,924

(1) Derivative assets are recorded in other assets, net and derivative liabilities are recorded in accounts payable and accrued liabilities on the consolidated balance sheets.

(2) Represents three interest-rate swap contracts, which hedge fluctuations in interest payments on variable-rate secured debt due to overall changes in hedged cash flows.

(3) Hedges fluctuations in interest payments on variable-rate unsecured debt due to fluctuations in the underlying benchmark interest rate.

(4) Currency swap contract (buy USD/sell GBP) hedges the foreign currency exchange risk related to the Company’s forecasted GBP denominated interest receipts on its HC-One Facility. Represents a currency swap to sell approximately £1.1 million monthly at a rate of 1.5149 through October 2017. 

The Company uses derivative instruments to mitigate the effects of interest rate and foreign currency fluctuations on specific forecasted transactions as well as recognized financial obligations or assets. Utilizing derivative instruments allows the Company to manage the risk of fluctuations in interest and foreign currency rates related to the potential impact these changes could have on future earnings and forecasted cash flows. The Company does not use derivative instruments for speculative or trading purposes. Assuming a one percentage point change in the underlying interest rate curve and foreign currency exchange rates, the estimated change in fair value of each of the underlying derivative instruments would not exceed $2 million.

At March 31, 2017, £219 million of the Company’s GBP-denominated borrowings under the Facility and 2015 Term Loan are designated as a hedge of a portion of the Company’s net investments in GBP-functional subsidiaries to mitigate its exposure to fluctuations in the GBP to USD exchange rate. For instruments that are designated and qualify as net investment hedges, the variability in the foreign currency to USD exchange rate of the instrument is recorded as part of the cumulative translation adjustment component of accumulated other comprehensive income (loss). Accordingly, the remeasurement value of the designated £219 million GBP-denominated borrowings due to fluctuations in the GBP to USD exchange rate are reported in accumulated other comprehensive income (loss) as the hedging relationship is considered to be effective. The cumulative balance of the remeasurement value will be reclassified to earnings when the hedged investment is sold or substantially liquidated.

XML

Summary of Significant Accounting Policies (Policies)

3 Months Ended

Mar. 31, 2017

Summary of Significant Accounting Policies

Basis of Presentation

Basis of Presentation

The accompanying unaudited consolidated financial statements have been prepared in accordance with U.S. generally accepted accounting principles (“GAAP”) for interim financial information. Management is required to make estimates and assumptions in the preparation of financial statements in conformity with GAAP. These estimates and assumptions affect the reported amounts of assets and liabilities and the disclosure of contingent assets and liabilities at the date of the consolidated financial statements and the reported amounts of revenue and expenses during the reporting period. Actual results could differ from management’s estimates.

The consolidated financial statements include the accounts of HCP, Inc., its wholly-owned subsidiaries, joint ventures (“JVs”) and VIEs that it controls through voting rights or other means. Intercompany transactions and balances have been eliminated upon consolidation. In the opinion of management, all adjustments (consisting of normal recurring adjustments) necessary to present fairly the Company’s financial position, results of operations and cash flows have been included. Operating results for the three months ended March 31, 2017 are not necessarily indicative of the results that may be expected for the year ending December 31, 2017. The accompanying unaudited interim financial information should be read in conjunction with the consolidated financial statements and notes thereto for the year ended December 31, 2016 included in the Company’s Annual Report on Form 10-K filed with the U.S. Securities and Exchange Commission (“SEC”).

Real Estate

Real Estate

On January 1, 2017 the Company adopted Accounting Standards Update (“ASU”) No. 2017-01, Clarifying the Definition of a Business (“ASU 2017-01”) which narrows the Financial Accounting Standards Board’s (“FASB”) definition of a business and provides a framework that gives entities a basis for making reasonable judgments about whether a transaction involves an asset, or a group of assets, or a business. ASU 2017-01 states that when substantially all of the fair value of the gross assets acquired (or disposed of) is concentrated in a single identifiable asset or group of similar identifiable assets, the set is not a business. If this initial test is not met, a set cannot be considered a business unless it includes an acquired input and a substantive process that together significantly contribute to the ability to create outputs. In addition, ASU 2017-01 clarifies the requirements for a set of activities to be considered a business and narrows the definition of an output. This ASU is to be applied prospectively and the Company expects that a majority of its future real estate acquisitions and dispositions will be deemed asset transactions rather than business combinations. As a result, for asset acquisitions the Company will record identifiable assets acquired, liabilities assumed and any associated noncontrolling interests at cost on a relative fair value basis. In addition, for such asset acquisitions, no goodwill will be recognized, third party transaction costs will be capitalized and any associated contingent consideration will be recorded when the contingency is resolved.

Segment Reporting

Segment Reporting

The Company’s reportable segments, based on how it evaluates its business and allocates resources, are as follows: (i) SH NNN, (ii) SHOP, (iii) life science and (iv) medical office.

Prior to the third quarter of 2016, the Company had five reportable segments: (i) senior housing, (ii) post-acute/skilled nursing, (iii) life science, (iv) medical office and (v) hospital. During the third quarter of 2016, primarily as a result of the planned spin-off of Quality Care Properties, Inc. (“QCP”) (NYSE:QCP), the Company revised its operating analysis structure and changed its reportable segments. The Company believes the change to its reportable segments is appropriate and consistent with how its chief operating decision makers review the Company’s operating results and determine resource allocations. Accordingly, all prior period segment information has been reclassified to conform to the current period presentation.

Reclassifications

Reclassifications

Certain amounts in the Company’s consolidated financial statements have been reclassified for prior periods to conform to the current period presentation. Certain prior period amounts have been reclassified on consolidated statements of operations for discontinued operations (see Note 4). See Segment Reporting above for additional reclassifications.

Recent Accounting Pronouncements

Recent Accounting Pronouncements

In February 2017, the FASB issued ASU No. 2017-05, Clarifying the Scope of Asset Derecognition Guidance and Accounting for Partial Sales of Nonfinancial Assets (“ASU 2017-05”). The amendments in ASU 2017-05 clarify the scope of the FASB’s recently established guidance on nonfinancial asset derecognition which applies to the derecognition of all nonfinancial assets and in-substance nonfinancial assets. In addition, ASU 2017-05 clarifies the accounting for partial sales of nonfinancial assets and in-substance nonfinancial assets to align with the new revenue recognition standard (see below). ASU 2017-05 is effective for annual periods beginning after December 15, 2017, including interim periods within, and must be adopted in conjunction with the Revenue ASUs (as defined below). ASU 2017-05 can be adopted using a full retrospective approach or a modified retrospective approach, resulting in a cumulative-effect adjustment to equity as of the beginning of the fiscal year in which the guidance is effective. Under either transition election, the Company will reassess its partial sale of RIDEA II, completed in the first quarter of 2017, and record its retained 40% equity interest at fair value as of the sale completion date. The Company estimates the fair value of its retained equity investment as of the sale completion date to be approximately $107 million which upon adoption, will increase the Company’s gain on sales of real estate, net for the period ended March 31, 2017 by the same amount. See Note 4 for further information on the RIDEA II transaction.

In June 2016, the FASB issued ASU No. 2016-13, Measurement of Credit Losses on Financial Instruments (“ASU 2016-13”). ASU 2016-13 is intended to improve financial reporting by requiring timelier recognition of credit losses on loans and other financial instruments held by financial institutions and other organizations. The amendments in ASU 2016-13 eliminate the “probable” initial threshold for recognition of credit losses in current accounting guidance and, instead, reflect an entity’s current estimate of all expected credit losses over the life of the financial instrument. Previously, when credit losses were measured under current accounting guidance, an entity generally only considered past events and current conditions in measuring the incurred loss. The amendments in ASU 2016-13 broaden the information that an entity must consider in developing its expected credit loss estimate for assets measured either collectively or individually. The use of forecasted information incorporates more timely information in the estimate of expected credit loss. ASU 2016-13 is effective for fiscal years, and interim periods within, beginning after December 15, 2019. Early adoption is permitted for fiscal years, and interim periods within, beginning after December 15, 2018. A reporting entity is required to apply the amendments in ASU 2016-13 using a modified retrospective approach by recording a cumulative-effect adjustment to equity as of the beginning of the fiscal year of adoption. A prospective transition approach is required for debt securities for which an other-than-temporary impairment had been recognized before the effective date. Upon adoption of ASU 2016-13, the Company is required to reassess its financing receivables, including direct finance leases and loans receivable, and expects that application of ASU 2016-13 may result in the Company recognizing credit losses at an earlier date than would otherwise be recognized under current accounting guidance. The Company is evaluating the impact of the adoption of ASU 2016-13 on January 1, 2020 to its consolidated financial position and results of operations.

In February 2016, the FASB issued ASU No. 2016-02, Leases (“ASU 2016-02”). ASU 2016-02 amends the current accounting for leases to: (i) require lessees to put most leases on their balance sheets, but continue recognizing expenses on their income statements in a manner similar to requirements under current accounting guidance, (ii) eliminate current real estate specific lease provisions and (iii) modify the classification criteria and accounting for sales-type leases for lessors. ASU 2016-02 is effective for fiscal years, and interim periods within, beginning after December 15, 2018. Early adoption is permitted. The transition method required by ASU 2016-02 varies based on the specific amendment being adopted. As a result of adopting ASU 2016-02, the Company will recognize all of its operating leases for which it is the lessee, including corporate office leases and ground leases, on its consolidated balance sheets and will capitalize fewer legal costs related to the drafting and execution of its lease agreements. In addition, the Company expects that it will have to bifurcate lease agreements into lease components and certain non-lease components. Lease components will continue to be recognized on a straight-line basis over the lease term and certain non-lease components will be accounted for under the new revenue recognition guidance in ASU 2014-09. The Company is evaluating the impact of the adoption of ASU 2016-02 on January 1, 2019 to its consolidated financial position and results of operations.

Between May 2014 and May 2016, the FASB issued three ASUs changing the requirements for recognizing and reporting revenue (together, herein referred to as the “Revenue ASUs”): (i) ASU No. 2014-09, Revenue from Contracts with Customers (“ASU 2014-09”), (ii) ASU No. 2016-08, Principal versus Agent Considerations (Reporting Revenue Gross versus Net) (“ASU 2016-08”) and (iii) ASU No. 2016-12, Narrow-Scope Improvements and Practical Expedients (“ASU 2016-12”). ASU 2014-09 provides guidance for revenue recognition to depict the transfer of promised goods or services to customers in an amount that reflects the consideration to which the entity expects to be entitled in exchange for those goods or services. ASU 2016-08 is intended to improve the operability and understandability of the implementation guidance on principal versus agent considerations. ASU 2016-12 provides practical expedients and improvements on the previously narrow scope of ASU 2014-09. In August 2015, the FASB issued ASU No. 2015-14, Revenue from Contracts with Customers (Topic 606): Deferral of the Effective Date (“ASU 2015-14”). ASU 2015-14 defers the effective date of ASU 2014-09 by one year to fiscal years, and interim periods within, beginning after December 15, 2017. All subsequent ASUs related to ASU 2014-09, including ASU 2016-08 and ASU 2016-12, assumed the deferred effective date enforced by ASU 2015-14. Early adoption of the Revenue ASUs is permitted for annual periods, and interim periods within, beginning after December 15, 2016. A reporting entity may apply the amendments in the Revenue ASUs using either a modified retrospective approach, by recording a cumulative-effect adjustment to equity as of the beginning of the fiscal year of adoption or full retrospective approach. The Company has not yet elected a transition method and is evaluating the complete impact of the adoption of the Revenue ASUs on January 1, 2018 to its consolidated financial position, results of operations and disclosures. The Company expects to complete its evaluation of the impacts of the Revenue ASUs during the second half of 2017. As the primary source of revenue for the Company is generated through leasing arrangements, which are excluded from the Revenue ASUs,the Company expects that it will be impacted in its recognition and disclosure of non-lease revenue, such as certain resident fees in its RIDEA structures (a portion of which are not generated through leasing arrangements), non-lease components of revenue from lease agreements (upon adoption of ASU 2016-02) and its recognition of real estate sale transactions. Under ASU 2014-09, revenue recognition for real estate sales is largely based on the transfer of control versus continuing involvement under current guidance. As a result, the Company generally expects that the new guidance will result in more transactions qualifying as sales of real estate and revenue being recognized at an earlier date than under current accounting guidance.

The following ASUs have been issued, but not yet adopted, and the Company does not expect a material impact to its consolidated financial position, results of operations, cash flows, or disclosures upon adoption:

· ASU No. 2017-04, Simplifying the Test for Goodwill Impairment (“ASU 2017-04”). ASU 2017-04 is effective for fiscal years, including interim periods within, beginning after December 15, 2019 (upon the first goodwill impairment test performed during that fiscal year). Early adoption is permitted for interim or annual goodwill impairment tests performed on testing dates after January 1, 2017. A reporting entity must apply the amendments in ASU 2017-04 using a prospective approach.

· ASU No. 2016-18, Restricted Cash (“ASU 2016-18”). ASU 2016-18 is effective for fiscal years, and interim periods within, beginning after December 15, 2017. Early adoption is permitted. A reporting entity must apply the amendments in ASU 2016-18 using a full retrospective approach.

· ASU No. 2016-15, Classification of Certain Cash Receipts and Cash Payments (“ASU 2016-15”). ASU 2016-15 is effective for fiscal years, and interim periods within, beginning after December 15, 2017. Early adoption is permitted. A reporting entity must apply the amendments in ASU 2016-15 using a full retrospective approach.

· ASU No. 2016-01, Recognition and Measurement of Financial Assets and Financial Liabilities (“ASU 2016-01”). ASU 2016-01 is effective for fiscal years, and interim periods within, beginning after December 15, 2017. Early adoption is permitted only for updates to certain disclosure requirements. A reporting entity is required to apply the amendments in ASU 2016-01 using a modified retrospective approach by recording a cumulative-effect adjustment to equity as of the beginning of the fiscal year of adoption.

· ASU No. 2016-16, Intra-Entity Transfers of Assets Other Than Inventory (“ASU 2016-16”). ASU 2016-16 is effective for fiscal years, and interim periods within, beginning after December 15, 2017. Early adoption is permitted as of the first interim period presented in any year following issuance. A reporting entity must apply the amendments in ASU 2016-16 using a modified retrospective approach by recording a cumulative-effect adjustment to equity as of the beginning of the fiscal year of adoption. 

XML

Real Estate Property Investments (Tables)

3 Months Ended

Mar. 31, 2017

Real Estate Property Investments

Schedule of real estate acquisitions (in thousands)

The following table summarizes the Company’s real estate acquisitions for the three months ended March 31, 2016 (in thousands):

	Consideration				Assets Acquired
	Cash Paid/		Liabilities				Net
Segment	Debt Settled		Assumed		Real Estate		Intangibles
SH NNN	$	76,362	$	1,200	$	71,875	$	5,687
Other non-reportable segments		17,909		—		16,596		1,313
	$	94,271	$	1,200	$	88,471	$	7,000

XML

Discontinued Operations and Dispositions of Real Estate (Tables)

3 Months Ended

Mar. 31, 2017

Spinoff

Summary of financial information for discontinued operations

Summarized financial information for discontinued operations for the three months ended March 31, 2016 is as follows (in thousands):

	Three Months Ended
	March 31, 2016
Revenues:
Rental and related revenues	$	6,814
Tenant recoveries		362
Income from direct financing leases		113,058
Total revenues		120,234
Costs and expenses:
Depreciation and amortization		(1,467)
Operating		(998)
General and administrative		(48)
Other income, net		21
Income before income taxes		117,742
Income tax expense		(49,334)
Net income from discontinued operations	$	68,408

XML

Net Investment in Direct Financing Leases (Tables)

3 Months Ended

Mar. 31, 2017

Loans Receivable:

Schedule of components of net investment in DFLs (dollars in thousands)

Net investment in DFLs consisted of the following (dollars in thousands):

	March 31,		December 31,
	2017		2016
Minimum lease payments receivable	$	1,095,233	$	1,108,237
Estimated residual values		500,368		539,656
Less unearned income		(883,061)		(895,304)
Net investment in direct financing leases	$	712,540	$	752,589
Properties subject to direct financing leases		29		30

DFL Watchlist Portfolio

Loans Receivable:

Summary of the Company's internal ratings for DFLs (dollars in thousands)

The following table summarizes the Company’s internal ratings for DFLs at March 31, 2017 (dollars in thousands):

	Carrying		Percentage of	Internal Ratings
Segment	Amount		DFL Portfolio	Performing DFLs		Watch List DFLs		Workout DFLs
SH NNN	$	627,936	88	$	268,350	$	359,586	$	—
Other non-reportable segments		84,604	12		84,604		—		—
	$	712,540	100	$	352,954	$	359,586	$	—

XML

Loans Receivable (Tables) - Loans receivable

3 Months Ended

Mar. 31, 2017

Loans Receivable:

Schedule of loans receivable (in thousands)

The following table summarizes the Company’s loans receivable (in thousands):

	March 31, 2017						December 31, 2016
	Real Estate		Other				Real Estate		Other
	Secured		Secured		Total		Secured		Secured		Total
Mezzanine(1) (2)	$	—	$	625,116	$	625,116	$	—	$	615,188	$	615,188
Other(3)		166,595		—		166,595		195,946		—		195,946
Unamortized discounts, fees and costs		—		(3,225)		(3,225)		413		(3,593)		(3,180)
	$	166,595	$	621,891	$	788,486	$	196,359	$	611,595	$	807,954

(1) At March 31, 2017, included £280 million ($350 million) outstanding and £2 million ($2 million) of associated unamortized discounts, fees and costs, both related to the HC-One Facility. At December 31, 2016, included £282 million ($348 million) outstanding and £2 million ($3 million) of associated unamortized discounts, fees and costs, both related to the HC-One Facility.

(2) At March 31, 2017, the Company had £29 million ($36 million) remaining under its commitments to fund development projects and capital expenditures under its United Kingdom (“U.K.”) development projects.

(3) At March 31, 2017, included £116 million ($145 million) outstanding related to Maria Mallaband loans.

Summary of the Company's internal ratings for loans receivable (dollars in thousands)

The following table summarizes the Company’s internal ratings for loans receivable at March 31, 2017 (dollars in thousands):

	Carrying		Percentage of	Internal Ratings
Investment Type	Amount		Loan Portfolio	Performing Loans		Watch List Loans		Workout Loans
Real estate secured	$	166,595	21	$	166,595	$	—	$	—
Other secured		621,891	79		365,318		256,573		—
	$	788,486	100	$	531,913	$	256,573	$	—

XML

Investments in and Advances to Unconsolidated Joint Ventures (Tables)

3 Months Ended

Mar. 31, 2017

Investments in and Advances to Unconsolidated Joint Ventures

Company owned interests in entities, accounted under equity method (dollars in thousands)

The Company owns interests in the following entities that are accounted for under the equity method at March 31, 2017 (dollars in thousands):

					Carrying Amount
					March 31,		December 31,
Entity(1)	Segment	Ownership%			2017		2016
CCRC JV(2)	SHOP		49		$	434,649	$	439,449
RIDEA II(6)	SHOP		40			263,180		—
HCP Life Science(4)	Life science	50	–	63		65,490		67,879
MBK JV(3)	SHOP		50			39,088		38,909
HCP Ventures IV, LLC	Medical office		20			7,338		7,277
Vintage Park Development JV	SHOP		85			6,953		7,486
Suburban Properties, LLC	Medical office		67			4,618		4,628
MBK Development JV(3)	SHOP		50			2,464		2,463
K&Y(5)	Other non-reportable segments		80			1,380		1,342
Advances to unconsolidated JVs, net and other						2,042		2,058
					$	827,202	$	571,491

(1) These entities are not consolidated because the Company does not control, through voting rights or other means, the JVs.

(2) Includes two unconsolidated JVs in a RIDEA structure (CCRC PropCo and CCRC OpCo).

(3) Includes two unconsolidated JVs in a RIDEA structure.

(4) Includes the following unconsolidated partnerships (and the Company’s ownership percentage): (i) Torrey Pines Science Center, LP (50%); (ii) Britannia Biotech Gateway, LP (55%) and (iii) LASDK, LP (63%).

(5) Includes three unconsolidated JVs.

(6) Includes three unconsolidated JVs in a RIDEA structure (HCP/CPA PropCo, HCP/CPA OpCo, and RIDEA II PropCo).

See Note 4 for further information on the deconsolidation of RIDEA II.

XML

Intangibles (Tables)

3 Months Ended

Mar. 31, 2017

Intangibles

Schedule of intangible lease assets

The following tables summarize the Company’s intangible lease assets and liabilities (in thousands):

	March 31,		December 31,
Intangible lease assets	2017		2016
Gross intangible lease assets	$	841,905	$	911,697
Accumulated depreciation and amortization		(409,796)		(431,892)
Intangible assets, net	$	432,109	$	479,805

Schedule of intangible lease liabilities

	March 31,		December 31,
Intangible lease liabilities	2017		2016
Gross intangible lease liabilities	$	151,890	$	163,924
Accumulated depreciation and amortization		(97,418)		(105,779)
Intangible liabilities, net	$	54,472	$	58,145

XML

Other Assets (Tables)

3 Months Ended

Mar. 31, 2017

Other Assets.

Schedule of other assets (in thousands)

The following table summarizes the Company’s other assets (in thousands):

	March 31,		December 31,
	2017		2016
Straight-line rent receivables, net of allowance of $25,173 and $25,059, respectively	$	316,125	$	311,776
Marketable debt securities, net		18,330		68,630
Leasing costs and inducements, net		87,553		156,820
Goodwill		47,019		42,386
Other		136,380		132,012
Total other assets	$	605,407	$	711,624

XML

Debt (Tables)

3 Months Ended

Mar. 31, 2017

Debt

Summary of senior notes issuances (dollars in thousands)

The following table summarizes the Company’s senior unsecured notes payoffs for the year ended December 31, 2016 (dollars in thousands):

Date	Amount		Coupon Rate
February 1, 2016	$	500,000		3.750	%
September 15, 2016	$	400,000		6.300	%
November 30, 2016	$	500,000		6.000	%
November 30, 2016	$	600,000		6.700	%

Summary of stated debt maturities and scheduled principal repayments (in thousands)

The following table summarizes the Company’s stated debt maturities and scheduled principal repayments at March 31, 2017 (in thousands):

					Senior
	Bank Line of				Unsecured		Mortgage
Year	Credit(1)		Term Loan(2)		Notes(3)		Debt(4)		Total(5)
2017 (nine months)	$	—	$	—	$	250,000	$	2,604	$	252,604
2018		492,421		—		—		3,641		496,062
2019		—		274,956		450,000		3,839		728,795
2020		—		—		800,000		3,907		803,907
2021		—		—		1,200,000		11,277		1,211,277
Thereafter		—		—		4,500,000		116,481		4,616,481
		492,421		274,956		7,200,000		141,749		8,109,126
(Discounts), premiums and debt costs, net		—		(853)		(63,664)		5,580		(58,937)
	$	492,421	$	274,103	$	7,136,336	$	147,329	$	8,050,189

(1) Represents £394 million translated into U.S. dollar (“USD”).

(2) Represents £220 million translated into USD.

(3) Effective interest rates on the notes ranged from 2.79% to 6.88% with a weighted average effective interest rate of 4.34% and a weighted average maturity of six years.

(4) Interest rates on the mortgage debt ranged from 2.99% to 7.51% with a weighted average effective interest rate of 4.24% and a weighted average maturity of 20 years.

(5) Excludes $91 million of other debt that have no scheduled maturities.

XML

Equity (Tables)

3 Months Ended

Mar. 31, 2017

Equity

Schedule of accumulated other comprehensive loss (in thousands)

The following table summarizes the Company’s accumulated other comprehensive loss (in thousands):

	March 31,		December 31,
	2017		2016
Cumulative foreign currency translation adjustment	$	(21,827)	$	(22,817)
Unrealized losses on cash flow hedges, net		(3,731)		(3,642)
Supplemental Executive Retirement Plan minimum liability		(3,055)		(3,129)
Unrealized losses on available for sale securities		(45)		(54)
Total accumulated other comprehensive loss	$	(28,658)	$	(29,642)

XML

Segment Disclosures (Tables)

3 Months Ended

Mar. 31, 2017

Segment Disclosures

Summary financial information of reportable segment (in thousands)

The following tables summarize information for the reportable segments (in thousands):

For the three months ended March 31, 2017:

					Life		Medical		Other		Corporate
	SH NNN		SHOP		Science		Office		Non-reportable		Non-segment		Total
Rental revenues(1)	$	100,034	$	140,228	$	85,321	$	118,371	$	29,883	$	—	$	473,837
HCP share of unconsolidated JV revenues		—		76,364		1,940		489		418		—		79,211
Operating expenses		(1,111)		(94,539)		(17,319)		(44,864)		(1,248)		—		(159,081)
HCP share of unconsolidated JV operating expenses		—		(59,527)		(371)		(142)		(19)		—		(60,059)
NOI		98,923		62,526		69,571		73,854		29,034		—		333,908
Adjustments to NOI(2)		(1,839)		3,508		(256)		(969)		(1,012)		—		(568)
Adjusted NOI		97,084		66,034		69,315		72,885		28,022		—		333,340
Addback adjustments		1,839		(3,508)		256		969		1,012		—		568
Interest income		—		—		—		—		18,331		—		18,331
Interest expense		(627)		(4,596)		(104)		(129)		(1,997)		(79,265)		(86,718)
Depreciation and amortization		(26,411)		(26,358)		(33,791)		(42,729)		(7,265)		—		(136,554)
General and administrative		—		—		—		—		—		(22,478)		(22,478)
Acquisition and pursuit costs		—		—		—		—		—		(1,057)		(1,057)
Gain on sales of real estate, net		268,464		366		44,633		—		3,795		—		317,258
Other income, net		—		—		—		—		—		51,208		51,208
Income tax benefit		—		—		—		—		—		6,162		6,162
Less: HCP share of unconsolidated JV NOI		—		(16,837)		(1,569)		(347)		(399)		—		(19,152)
Equity income in unconsolidated JVs		—		1,993		770		269		237		—		3,269
Net income (loss)	$	340,349	$	17,094	$	79,510	$	30,918	$	41,736	$	(45,430)	$	464,177

For the three months ended March 31, 2016:

					Life		Medical		Other		Corporate
	SH NNN		SHOP		Science		Office		Non-reportable		Non-segment		Total
Rental revenues(1)	$	106,889	$	165,763	$	88,948	$	108,023	$	32,805	$	—	$	502,428
HCP share of unconsolidated JV revenues		—		52,277		1,810		479		407		—		54,973
Operating expenses		(2,074)		(114,003)		(16,743)		(41,949)		(1,188)		—		(175,957)
HCP share of unconsolidated JV operating expenses		—		(42,088)		(374)		(149)		(3)		—		(42,614)
NOI		104,815		61,949		73,641		66,404		32,021		—		338,830
Adjustments to NOI(2)		(5,443)		5,032		(673)		(795)		(571)		—		(2,450)
Adjusted NOI		99,372		66,981		72,968		65,609		31,450		—		336,380
Addback adjustments		5,443		(5,032)		673		795		571		—		2,450
Interest income		—		—		—		—		18,029		—		18,029
Interest expense		(4,166)		(7,855)		(638)		(1,665)		(2,327)		(105,411)		(122,062)
Depreciation and amortization		(33,506)		(26,297)		(33,596)		(38,719)		(7,737)		—		(139,855)
General and administrative		—		—		—		—		—		(25,451)		(25,451)
Acquisition and pursuit costs		—		—		—		—		—		(2,475)		(2,475)
Other income, net		—		—		—		—		—		1,292		1,292
Income tax expense		—		—		—		—		—		(3,704)		(3,704)
Less: HCP share of unconsolidated JV NOI		—		(10,189)		(1,436)		(330)		(404)		—		(12,359)
Equity (loss) income in unconsolidated JVs		—		(2,478)		709		658		203		—		(908)
Discontinued operations		—		—		—		—		—		68,408		68,408
Net income (loss)	$	67,143	$	15,130	$	38,680	$	26,348	$	39,785	$	(67,341)	$	119,745

(1) Represents rental and related revenues, tenant recoveries, resident fees and services, and income from DFLs.

(2) Represents straight-line rents, DFL non-cash interest, amortization of market lease intangibles, net, lease termination fees and non-refundable entrance fees as the fees are collected by the Company’s CCRC JV, net of CCRC JV entrance fee amortization.

Reconciliation of company's revenues to total revenues (in thousands)

	Three Months Ended March 31,
Segment	2017		2016
SH NNN	$	100,034	$	106,889
SHOP		140,228		165,763
Life science		85,321		88,948
Medical office		118,371		108,023
Other non-reportable segments		48,214		50,834
Total revenues	$	492,168	$	520,457

XML

Earnings Per Common Share (Tables)

3 Months Ended

Mar. 31, 2017

Earnings Per Common Share

Computation of basic and diluted earnings per share (in thousands, except per share amounts)

The following table illustrates the computation of basic and diluted earnings per share (in thousands, except per share amounts):

	Three Months Ended March 31,
	2017		2016
Numerator
Net income from continuing operations	$	464,177	$	51,337
Noncontrolling interests’ share in earnings		(3,032)		(3,626)
Net income attributable to HCP, Inc.		461,145		47,711
Participating securities’ share in earnings		(770)		(357)
Income from continuing operations applicable to common shares		460,375		47,354
Discontinued operations		—		68,408
Net income applicable to common shares	$	460,375	$	115,762
Numerator - Dilutive
Net income applicable to common shares	$	460,375	$	115,762
Add: distributions on dilutive convertible units		2,803		—
Dilutive net income available to common shares	$	463,178	$	115,762
Denominator
Basic weighted average common shares		468,299		466,074
Dilutive potential common shares - equity awards		229		188
Dilutive potential common shares - DownREIT units		6,645		—
Diluted weighted average common shares		475,173		466,262
Basic earnings per common share
Continuing operations	$	0.98	$	0.10
Discontinued operations		—		0.15
Net income applicable to common shares	$	0.98	$	0.25
Diluted earnings per common share
Continuing operations	$	0.97	$	0.10
Discontinued operations		—		0.15
Net income applicable to common shares	$	0.97	$	0.25

XML

Supplemental Cash Flow Information (Tables)

3 Months Ended

Mar. 31, 2017

Supplemental Cash Flow Information

Supplemental cash flow information (in thousands)

The following table provides supplemental cash flow information (in thousands):

	Three Months Ended March 31,
	2017		2016
Supplemental cash flow information:
Interest paid, net of capitalized interest	$	108,232	$	171,422
Income taxes paid		1,105		1,213
Capitalized interest		3,090		3,128
Supplemental schedule of non-cash investing and financing activities:
Accrued construction costs		51,498		56,972
Non-cash acquisitions and dispositions settled with receivables and restricted cash held in connection with Section 1031 transactions		39,991		91,605
Tenant-funded tenant improvements owned by HCP		3,120		9,178
Vesting of restricted stock units		293		248
Conversion of non-managing member units into common stock		1,548		4,136
Mortgages and other liabilities assumed with real estate acquisitions		—		1,200
Unrealized losses on available-for-sale securities and derivatives designated as cash flow hedges, net		(45)		(705)

XML

Variable Interest Entities (Tables)

3 Months Ended

Mar. 31, 2017

Variable Interest Entities

Schedule of Variable Interest Entities (in thousands)

The classification of the related assets and liabilities and the maximum loss exposure as a result of the Company’s involvement with these VIEs at March 31, 2017 was as follows (in thousands):

		Maximum Loss
		Exposure
		and Carrying
VIE Type	Asset/Liability Type	Amount(1)
VIE tenants—DFLs(2)	Net investment in DFLs	$	600,348
VIE tenants—operating leases(2)	Lease intangibles, net and straight-line rent receivables		6,721
CCRC OpCo	Investments in unconsolidated JVs		217,655
RIDEA II PropCo	Investments in unconsolidated JVs		257,534
Vintage Park Development JV	Investments in unconsolidated JVs		6,953
Loan—senior secured	Loans receivable, net		131,916
Loan—seller financing	Loans receivable, net		10,000
CMBS and LLC investment	Marketable debt and cost method investment		33,391

(1) The Company’s maximum loss exposure represents the aggregate carrying amount of such investments (including accrued interest).

(2) The Company’s maximum loss exposure may be mitigated by re-leasing the underlying properties to new tenants upon an event of default. 

Schedule Of Variable Interest Entities Included In The Balance Sheet

	March 31, 2017		December 31, 2016
Assets
Buildings and improvements	$	2,787,845	$	3,522,310
Development costs and construction in progress		23,837		31,953
Land		214,963		327,241
Accumulated depreciation and amortization		(535,012)		(676,276)
Net real estate		2,491,633		3,205,228
Investments in and advances to unconsolidated joint ventures		3,108		3,641
Accounts receivable		9,609		19,996
Cash and cash equivalents		37,005		35,844
Restricted cash		42,009		22,624
Intangible assets, net		139,281		169,027
Other assets, net		55,049		69,562
Total assets	$	2,777,694	$	3,525,922
Liabilities
Mortgage debt		45,245		520,870
Intangible liabilities, net		8,734		8,994
Liabilities of assets held for sale, net		92,640		120,719
Deferred revenue		16,077		23,456
Total liabilities	$	162,696	$	674,039

XML

Concentration of Credit Risk (Tables)

3 Months Ended

Mar. 31, 2017

Tenants

Schedule of concentration of credit risk

	Percentage of Gross Assets				Percentage of Revenues
	Total Company		SH NNN		Total Company		SH NNN
	March 31,	December 31,	March 31,	December 31,	Three Months Ended March 31,		Three Months Ended March 31,
Tenant	2017	2016	2017	2016	2017	2016	2017	2016
Brookdale(1)	11	17	42	69	12	12	60	58

(1) Includes revenues from 64 SH NNN facilities that were classified as held for sale at December 31, 2016 and sold in March 2017.   

XML

Fair Value Measurements (Tables)

3 Months Ended

Mar. 31, 2017

Fair Value Measurements

Summary of the carrying values and fair values of financial instruments (in thousands)

The table below summarizes the carrying amounts and fair values of the Company’s financial instruments (in thousands):

	March 31, 2017(4)				December 31, 2016(4)
	Carrying				Carrying
	Value		Fair Value		Value		Fair Value
Loans receivable, net(2)	$	788,486	$	787,067	$	807,954	$	807,505
Marketable debt securities(2)		18,330		18,330		68,630		68,630
Marketable equity securities(1)		85		85		76		76
Warrants(3)		39		39		19		19
Bank line of credit(2)		492,421		492,421		899,718		899,718
Term loans(2)		274,103		274,103		440,062		440,062
Senior unsecured notes(1)		7,136,336		7,445,519		7,133,538		7,386,149
Mortgage debt(2)		147,329		134,605		623,792		609,374
Other debt(2)		91,263		91,263		92,385		92,385
Interest-rate swap liabilities(2)		4,163		4,163		4,857		4,857
Currency swap asset(2)		1,924		1,924		2,920		2,920

(1) Level 1: Fair value calculated based on quoted prices in active markets.  

(2) Level 2: Fair value based on (i) for marketable debt securities, quoted prices for similar or identical instruments in active or inactive markets, respectively, or (ii) or for loans receivable, net, mortgage debt, and swaps, calculated utilizing standardized pricing models in which significant inputs or value drivers are observable in active markets. For bank line of credit, term loans and other debt, the carrying values are a reasonable estimate of fair value because the borrowings are primarily based on market interest rates and the Company’s credit rating.

(3) Level 3: Fair value determined based on significant unobservable market inputs using standardized derivative pricing models.

(4) During the three months ended March 31, 2017 and year ended December 31, 2016, there were no material transfers of financial assets or liabilities within the fair value hierarchy.

XML

Derivative Financial Instruments (Tables)

3 Months Ended

Mar. 31, 2017

Derivative Financial Instruments

Schedule of derivative instruments (dollars and GBP in thousands)

The following table summarizes the Company’s outstanding interest-rate and foreign currency swap contracts at March 31, 2017 (dollars and GBP in thousands):

			Fixed
		Hedge	Rate/Buy			Floating/Exchange	Notional/
Date Entered	Maturity Date	Designation	Amount			Rate Index	Sell Amount		Fair Value(1)
Interest rate:
July 2005(2)	July 2020	Cash Flow		3.82	%	BMA Swap Index	$	44,300	$	(3,301)
January 2015(3)	October 2017	Cash Flow		1.79	%	1 Month GBP LIBOR+0.975%	£	220,000	$	(862)
Foreign currency:
January 2015(4)	October 2017	Cash Flow	$	11,300		Buy USD/Sell GBP	£	7,500	$	1,924

(1) Derivative assets are recorded in other assets, net and derivative liabilities are recorded in accounts payable and accrued liabilities on the consolidated balance sheets.

(2) Represents three interest-rate swap contracts, which hedge fluctuations in interest payments on variable-rate secured debt due to overall changes in hedged cash flows.

(3) Hedges fluctuations in interest payments on variable-rate unsecured debt due to fluctuations in the underlying benchmark interest rate.

(4) Currency swap contract (buy USD/sell GBP) hedges the foreign currency exchange risk related to the Company’s forecasted GBP denominated interest receipts on its HC-One Facility. Represents a currency swap to sell approximately £1.1 million monthly at a rate of 1.5149 through October 2017. 

XML

Summary of Significant Accounting Policies (Details) $ in Millions	6 Months Ended
	Jun. 30, 2016 segment	Mar. 31, 2017 USD ($)
Number of reportable segments | segment	5
Accounting Standards Update 2017-05
Investment ownership percentage		40.00%
Retained equity investment at estimated fair value | $		$ 107

XML

Real Estate Property Investments (Details) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2016	Mar. 31, 2017
Real estate acquisitions
Consideration, Cash Paid/Debt Settled	$ 94,271
Consideration, Liabilities assumed	1,200
Assets Acquired, Real Estate	88,471	$ 0
Assets Acquired, Net Intangibles	7,000
SH NNN
Real estate acquisitions
Consideration, Cash Paid/Debt Settled	76,362
Consideration, Liabilities assumed	1,200
Assets Acquired, Real Estate	71,875
Assets Acquired, Net Intangibles	5,687
Other Non-reportable segments
Real estate acquisitions
Consideration, Cash Paid/Debt Settled	17,909
Assets Acquired, Real Estate	16,596
Assets Acquired, Net Intangibles	$ 1,313

XML

Discontinued Operations and Dispositions of Real Estate - QCP (Details) $ in Thousands	3 Months Ended
	Mar. 31, 2016 USD ($)	Oct. 31, 2016 property
Costs and expenses:
Depreciation and amortization	$ (1,467)
Income taxes expense	(49,334)
QCP | Discontinued Operations, Held-for-sale
Revenue:
Rental and related revenues	6,814
Tenant recoveries	362
Income from direct financing leases	113,058
Total revenues	120,234
Costs and expenses:
Depreciation and amortization	(1,467)
Operating	(998)
General and administrative	(48)
Other income (expense), net	21
Income before income taxes	117,742
Income taxes expense	(49,334)
Net income from discontinued operations	$ 68,408
QCP | Spinoff
Dispositions of Real Estate
Number of properties | property		338

XML

Discontinued Operations and Dispositions of Real Estate - HCR ManorCare, Inc. (Details)	1 Months Ended			3 Months Ended		6 Months Ended	12 Months Ended
	Apr. 30, 2017 USD ($)	Jan. 31, 2017 USD ($) facility	Dec. 31, 2015	Mar. 31, 2017 USD ($) property facility	Mar. 31, 2016 USD ($)	Jun. 30, 2016 USD ($)	Dec. 31, 2011 USD ($)	Dec. 31, 2016 USD ($) property facility
Dispositions of Real Estate
DFL income				$ 13,712,000	$ 14,910,000
Real estate and other related assets, net								$ 809,000,000
Gain on sales of real estate, net				317,258,000
California
Dispositions of Real Estate
Total consideration for disposition of real estate	$ 27,000,000
Maximum
Dispositions of Real Estate
Federal and state built-in gain tax from assets sold							$ 2,000,000,000
HCRMC
Dispositions of Real Estate
DFL income						$ 113,000,000
DFL accretion				$ 0
Federal and state built-in gain tax from assets sold, term							10 years
Intended To Hold The Assets, Term							10 years
Federal built-in gain tax from assets sold, federal term			5 years
State built-in gain from assets sold					$ 49,000,000
SH NNN
Dispositions of Real Estate
Number of properties classified as held for sale | property				64				64
Life science
Dispositions of Real Estate
Number of properties classified as held for sale | facility								4
Number of properties disposed | facility		4
Total consideration for disposition of real estate		$ 76,000,000
Gain on sales of real estate, net		45,000,000
SHOP
Dispositions of Real Estate
Number of properties classified as held for sale | facility								1
Brookdale Senior Living | SH NNN
Dispositions of Real Estate
Number of properties disposed | facility				64
Total consideration for disposition of real estate				$ 1,125,000,000
Gain on sales of real estate, net				$ 170,000,000
HCP/CPA/Brookdale JV
Dispositions of Real Estate
Debt provided		602,000,000
Debt provided by third-party		360,000,000
Debt provided by entity		242,000,000
Proceeds from issuance of debt, net		480,000,000
Proceeds from note receivable		242,000,000
RIDEA II | HCP/CPA/Brookdale JV
Dispositions of Real Estate
Gain on sales of real estate, net		$ 99,000,000
Investment ownership percentage		40.00%

XML

Net Investment in Direct Financing Leases (Details) $ in Thousands	1 Months Ended	3 Months Ended		6 Months Ended
	Mar. 31, 2017 USD ($) property item	Mar. 31, 2017 USD ($) property item	Mar. 31, 2016 USD ($)	Jun. 30, 2016 USD ($)	Dec. 31, 2016 USD ($) property
Net Investment in Direct Financing Leases
Minimum lease payments receivable	$ 1,095,233	$ 1,095,233			$ 1,108,237
Estimated residual values	500,368	500,368			539,656
Less unearned income	(883,061)	(883,061)			(895,304)
Net investment in direct financing leases	$ 712,540	$ 712,540			$ 752,589
Properties subject to direct financing leases | property	29	29			30
Percentage of DFL Portfolio	100.00%	100.00%
DFL income		$ 13,712	$ 14,910
HCRMC
Net Investment in Direct Financing Leases
DFL income				$ 113,000
DFL Watchlist Portfolio
Net Investment in Direct Financing Leases
DFL income		3,000
Cash payments received		4,000
Performing Loans
Net Investment in Direct Financing Leases
Net investment in direct financing leases	$ 352,954	352,954
Watch List Loans
Net Investment in Direct Financing Leases
Net investment in direct financing leases	359,586	359,586
SH NNN
Net Investment in Direct Financing Leases
Net investment in direct financing leases	$ 627,936	$ 627,936
Percentage of DFL Portfolio	88.00%	88.00%
SH NNN | DFL Watchlist Portfolio
Net Investment in Direct Financing Leases
Net investment in direct financing leases	$ 360,000	$ 360,000			$ 361,000
Properties subject to direct financing leases | item	14	14
SH NNN | Performing Loans
Net Investment in Direct Financing Leases
Net investment in direct financing leases	$ 268,350	$ 268,350
SH NNN | Watch List Loans
Net Investment in Direct Financing Leases
Net investment in direct financing leases	359,586	359,586
Other Non-reportable segments
Net Investment in Direct Financing Leases
Net investment in direct financing leases	$ 84,604	$ 84,604
Percentage of DFL Portfolio	12.00%	12.00%
Other Non-reportable segments | Performing Loans
Net Investment in Direct Financing Leases
Net investment in direct financing leases	$ 84,604	$ 84,604
Florida
Net Investment in Direct Financing Leases
Proceeds from sale of leased assets	$ 43,000

XML

Loans Receivable (Details) $ in Thousands, £ in Millions	3 Months Ended
	Mar. 31, 2017 GBP (£)	Mar. 31, 2017 USD ($)	Mar. 31, 2017 USD ($)	Dec. 31, 2016 GBP (£)	Dec. 31, 2016 USD ($)
Loans Receivable:
Mezzanine			$ 625,116		$ 615,188
Mezzanine	£ 280		350,000	£ 282	348,000
Loans receivable, other			166,595		195,946
Maria Mallaband Loans			145,000
Maria Mallaband Loans | £	116
Unamortized premiums (discounts), fees and costs			(3,225)		(3,180)
Unamortized premiums (discounts), fees and costs | £	2			£ 2
Loans receivable, net			$ 788,486		807,954
Remaining commitments to fund development projects	£ 29	$ 36,000
Percentage of Loan Portfolio	100.00%		100.00%
Performing Loans
Loans Receivable:
Loans receivable, net			$ 531,913
Watch List Loans
Loans Receivable:
Loans receivable, net			256,573
Real Estate Secured
Loans Receivable:
Loans receivable, other			166,595		195,946
Unamortized premiums (discounts), fees and costs					413
Loans receivable, net			$ 166,595		196,359
Percentage of Loan Portfolio	21.00%		21.00%
Real Estate Secured | Performing Loans
Loans Receivable:
Loans receivable, net			$ 166,595
Other Secured
Loans Receivable:
Mezzanine			625,116		615,188
Unamortized premiums (discounts), fees and costs			(3,225)		(3,593)
Loans receivable, net			$ 621,891		611,595
Percentage of Loan Portfolio	79.00%		79.00%
Other Secured | Performing Loans
Loans Receivable:
Loans receivable, net			$ 365,318
Other Secured | Watch List Loans
Loans Receivable:
Loans receivable, net			256,573
HC-One Facility
Loans Receivable:
Unamortized premiums (discounts), fees and costs			$ 2,000		$ 3,000

XML

Loans Receivable - Other Secured Loans (Details) £ in Millions	3 Months Ended
	Mar. 31, 2017 GBP (£)	Mar. 31, 2017 USD ($)	Mar. 31, 2016 USD ($)	Dec. 31, 2016 USD ($)	May 31, 2015 USD ($)	Jun. 30, 2013 USD ($)	Jul. 31, 2012 USD ($)
Loans Receivable:
Loans receivable, other		$ 166,595,000		$ 195,946,000
Tandem Mezzanine Loan
Loans Receivable:
Loans receivable, other		257,000,000
Cash payments received from borrower		$ 7,000,000	$ 7,000,000
Loan receivable, blended annual rate (as a percent)		11.50%
Loan receivable, default rate (as a percent)		$ 16.5
Loans receivable, additional interest upaid	5.00%	5.00%
Loan receivable subordinated to senior mortgage debt		$ 372,000,000
Tandem Mezzanine Loan | Maximum
Loans Receivable:
Loans receivable, other							$ 205,000,000
Tandem Health Care Loan - First Tranche
Loans Receivable:
Loans receivable, other						$ 100,000,000
Loan receivable, interest rate payable (as a percent)		12.00%
Tandem Health Care Loan - Second Tranche
Loans Receivable:
Loans receivable, other						$ 102,000,000
Loan receivable, interest rate payable (as a percent)		14.00%
Tandem Health Care Loan Third Tranche
Loans Receivable:
Loans receivable, other					$ 50,000,000
Loan receivable, interest rate payable (as a percent)		6.00%
Tandem Health Care Loan Fourth Tranche
Loans Receivable:
Loans receivable, other					$ 5,000,000
Loan receivable, interest rate payable (as a percent)		6.00%
Four Seasons
Loans Receivable:
Payment to purchase senior secured term loan	£ 29	$ 35,000,000

XML

Investments in and Advances to Unconsolidated Joint Ventures - Equity Method Investments (Details) $ in Thousands	3 Months Ended
	Mar. 31, 2017 USD ($) item	Dec. 31, 2016 USD ($)
Company owned interests in entities, accounted under equity method:
Investments in and advances to unconsolidated joint ventures	$ 827,202	$ 571,491
CCRC JV | SHOP
Company owned interests in entities, accounted under equity method:
Number of unconsolidated joint ventures | item	2
CCRC JV | SHOP
Company owned interests in entities, accounted under equity method:
Investments in and advances to unconsolidated joint ventures	$ 434,649	439,449
Investment ownership percentage	49.00%
RIDEA II | SHOP
Company owned interests in entities, accounted under equity method:
Investments in and advances to unconsolidated joint ventures	$ 263,180
Investment ownership percentage	40.00%
MBK JV | SHOP
Company owned interests in entities, accounted under equity method:
Investments in and advances to unconsolidated joint ventures	$ 39,088	38,909
Investment ownership percentage	50.00%
MBK Development JV | SHOP
Company owned interests in entities, accounted under equity method:
Investments in and advances to unconsolidated joint ventures	$ 2,464	2,463
Investment ownership percentage	50.00%
MBK JV and MBK Development JV | SHOP
Company owned interests in entities, accounted under equity method:
Number of unconsolidated joint ventures | item	2
HCP Ventures IV, LLC | Medical office
Company owned interests in entities, accounted under equity method:
Investments in and advances to unconsolidated joint ventures	$ 7,338	7,277
Investment ownership percentage	20.00%
HCP Life Science | Life science
Company owned interests in entities, accounted under equity method:
Investments in and advances to unconsolidated joint ventures	$ 65,490	67,879
Number of unconsolidated joint ventures | item	3
HCP Life Science | Life science | Minimum
Company owned interests in entities, accounted under equity method:
Investment ownership percentage	50.00%
HCP Life Science | Life science | Maximum
Company owned interests in entities, accounted under equity method:
Investment ownership percentage	63.00%
Torrey Pines Science Center, LP | Life science
Company owned interests in entities, accounted under equity method:
Investment ownership percentage	50.00%
Britannia Biotech Gateway, LP | Life science
Company owned interests in entities, accounted under equity method:
Investment ownership percentage	55.00%
LASDK, LP | Life science
Company owned interests in entities, accounted under equity method:
Investment ownership percentage	63.00%
Vintage Park Development JV | SHOP
Company owned interests in entities, accounted under equity method:
Investments in and advances to unconsolidated joint ventures	$ 6,953	7,486
Investment ownership percentage	85.00%
Suburban Properties, LLC | Medical office
Company owned interests in entities, accounted under equity method:
Investments in and advances to unconsolidated joint ventures	$ 4,618	4,628
Investment ownership percentage	67.00%
K&Y
Company owned interests in entities, accounted under equity method:
Number of unconsolidated joint ventures | item	3
K&Y | Other Non-reportable segments
Company owned interests in entities, accounted under equity method:
Investments in and advances to unconsolidated joint ventures	$ 1,380	1,342
Investment ownership percentage	80.00%
Advances to unconsolidated joint ventures, net
Company owned interests in entities, accounted under equity method:
Investments in and advances to unconsolidated joint ventures	$ 2,042	$ 2,058

XML

Intangibles Lease Assets (Details) - USD ($) $ in Thousands	Mar. 31, 2017	Dec. 31, 2016
Intangibles
Gross intangible lease assets	$ 841,905	$ 911,697
Accumulated depreciation and amortization	(409,796)	(431,892)
Intangible assets, net	$ 432,109	$ 479,805

XML

Intangibles Lease Liabilities (Details) - USD ($) $ in Thousands	Mar. 31, 2017	Dec. 31, 2016
Intangibles
Gross intangible lease liabilities	$ 151,890	$ 163,924
Accumulated depreciation and amortization	(97,418)	(105,779)
Net intangible lease liabilities	$ 54,472	$ 58,145

XML

Other Assets (Details) $ in Thousands, £ in Millions	3 Months Ended
	Mar. 31, 2017 GBP (£)	Mar. 31, 2017 USD ($)	Mar. 31, 2017 USD ($)	Dec. 31, 2016 USD ($)
Other assets
Straight-line rent receivables, net of allowance			$ 316,125	$ 311,776
Allowance on straight-line rent receivables			25,173	25,059
Marketable debt securities, net			18,330	68,630
Leasing costs and inducements, net			87,553	156,820
Goodwill			47,019	42,386
Other			136,380	132,012
Total other assets			605,407	$ 711,624
Four Seasons
Other assets
Market debt security, carrying value	£ 41.0		50,000
Marketable debt security, par value	138.5		$ 101,000
Marketable debt security, par value, discounted | £	83.0
Four Seasons | Other Income
Other assets
Gain on sale	£ 42.0	$ 51,000

XML

Debt - Bank Line of Credit and Term Loans (Details) $ in Thousands, £ in Millions		1 Months Ended	3 Months Ended
	Jan. 12, 2012	Apr. 30, 2017 GBP (£)	Mar. 31, 2017 USD ($)	Mar. 31, 2017 GBP (£)	Mar. 31, 2017 USD ($)	Dec. 31, 2016 USD ($)	Jan. 12, 2015 GBP (£)	Jun. 30, 2012 GBP (£)
Debt Instrument
Debt instrument, variable rate basis			30.0
Net repayment under bank line of credit			$ 375,812
Bank line of credit					$ 492,421	$ 899,718
Debt					8,050,189
Senior unsecured notes					$ 7,136,336	$ 7,133,538
Line of Credit and Term Loan
Debt Instrument
Debt instrument, covenant debt to assets (as a percent)				60.00%	60.00%
Debt instrument, covenant secured debt to assets (as a percent)				30.00%	30.00%
Debt instrument, covenant unsecured debt to unencumbered assets (as a percent)				60.00%	60.00%
Debt instrument, covenant minimum fixed charge coverage ratio				1.5	1.5
Debt instrument, covenant net worth					$ 6,500,000
Bank Line of Credit
Debt Instrument
Line of credit facility, maximum borrowing capacity					2,000,000
Debt instrument, variable rate basis			LIBOR
Length of debt instrument extension period			1 year
Debt instrument, basis spread on variable rate (as a percent)			1.05%
Debt instrument, facility fee (as a percent)			0.20%
Line of credit facility additional aggregate amount, maximum			$ 500,000
Net repayment under bank line of credit		£ 105.0	$ 440,000
Line of Credit Portion Denominated in Foreign Currency				£ 394.0	$ 492,000
Weighted-average interest rate (as a percent)				1.65%	1.65%
Debt					$ 492,421
2012 Term Loan
Debt Instrument
Debt | £								£ 137.0
2015 Term Loan
Debt Instrument
Length of debt instrument extension period	1 year
Debt instrument, basis spread on variable rate (as a percent)	1.15%
Derivative, fixed interest rate (as a percent)				1.966%	1.966%
Term of the interest rate swap agreement	3 years
Maturity period of debt instruments	4 years
Senior unsecured notes					$ 275,000		£ 220.0

XML

Debt - Senior Unsecured Notes (Details) - USD ($) $ in Thousands	Nov. 30, 2016	Sep. 15, 2016	Feb. 01, 2016	Mar. 31, 2017	Dec. 31, 2016
Debt Instrument
Total debt before discount, net				$ 8,109,126
Senior unsecured notes				7,136,336	$ 7,133,538
Unsecured Debt.
Debt Instrument
Total debt before discount, net				7,200,000
Senior unsecured notes				$ 0	$ 0
Senior Unsecured Debt 3.75 Percent Incepted February 1 2016
Debt Instrument
Debt Instrument, Interest Rate, Stated Percentage (as a percent)			3.75%
Repayment of senior unsecured notes			$ 500,000
Senior Unsecured Debt 6.30 Percent Incepted September 15 2016
Debt Instrument
Debt Instrument, Interest Rate, Stated Percentage (as a percent)		6.30%
Repayment of senior unsecured notes		$ 400,000
Senior Unsecured Debt 6.000 Percent Incepted November 30 2016
Debt Instrument
Debt Instrument, Interest Rate, Stated Percentage (as a percent)	6.00%
Repayment of senior unsecured notes	$ 500,000
Senior Unsecured Debt 6.700 Percent Incepted November 30 2016
Debt Instrument
Debt Instrument, Interest Rate, Stated Percentage (as a percent)	6.70%
Repayment of senior unsecured notes	$ 600,000

XML

Debt - Mortgage Debt (Details) $ in Thousands, £ in Millions		1 Months Ended	3 Months Ended
	May 01, 2017 USD ($)	Apr. 30, 2017 GBP (£)	Mar. 31, 2017 USD ($)	Mar. 31, 2016 USD ($)	Mar. 31, 2017 GBP (£) property item	Mar. 31, 2017 USD ($) property item	Dec. 31, 2016 USD ($) property
Debt Instrument
Total debt before discount, net						$ 8,109,126
(Discounts), premiums and debt costs, net						(58,937)
Debt instruments, carrying amount						8,050,189
Other debt						91,263	$ 92,385
Net repayment under bank line of credit			$ 375,812
Repayment of senior unsecured notes			478,314	$ 36,918
Debt maturing in 2017
Debt Instrument
2017						252,604
Debt maturing in 2018
Debt Instrument
2018						496,062
Debt maturing in 2019
Debt Instrument
2019						728,795
Debt maturing in 2020
Debt Instrument
2020						803,907
Debt maturing in 2021
Debt Instrument
2021						1,211,277
Thereafter
Debt Instrument
Thereafter						4,616,481
Bank Line of Credit
Debt Instrument
Total debt before discount, net						492,421
Debt instruments, carrying amount						492,421
Line of credit, portion denominated in GBP					£ 394	$ 492,000
Weighted-average interest rate (as a percent)					1.65%	1.65%
Net repayment under bank line of credit		£ 105	$ 440,000
Bank Line of Credit | Debt maturing in 2018
Debt Instrument
2018						$ 492,421
Term loans
Debt Instrument
Total debt before discount, net						274,956
(Discounts), premiums and debt costs, net						(853)
Debt instruments, carrying amount						274,103
Term loans, portion denominated in GBP | £					£ 220
Term loans | Debt maturing in 2019
Debt Instrument
2019						274,956
Unsecured Debt.
Debt Instrument
Total debt before discount, net						7,200,000
(Discounts), premiums and debt costs, net						(63,664)
Debt instruments, carrying amount						$ 7,136,336
Weighted-average interest rate (as a percent)					4.34%	4.34%
Weighted-average maturity			6 years
Unsecured Debt. | Minimum
Debt Instrument
Debt Instrument, Interest Rate, Stated Percentage (as a percent)					2.79%	2.79%
Unsecured Debt. | Maximum
Debt Instrument
Debt Instrument, Interest Rate, Stated Percentage (as a percent)					6.88%	6.88%
Unsecured Debt. | Debt maturing in 2017
Debt Instrument
2017						$ 250,000
Unsecured Debt. | Debt maturing in 2019
Debt Instrument
2019						450,000
Unsecured Debt. | Debt maturing in 2020
Debt Instrument
2020						800,000
Unsecured Debt. | Debt maturing in 2021
Debt Instrument
2021						1,200,000
Unsecured Debt. | Thereafter
Debt Instrument
Thereafter						$ 4,500,000
Mortgage Debt
Debt Instrument
Number of healthcare facilities used to secure debt | item					17	17
Debt instrument, collateral, healthcare facilities carrying value						$ 311,000
Cash distribution			$ 472,000
Total debt before discount, net						141,749
(Discounts), premiums and debt costs, net						5,580
Debt instruments, carrying amount						$ 147,329
Weighted-average interest rate (as a percent)					4.24%	4.24%
Weighted-average maturity			20 years
Mortgage Debt | Minimum
Debt Instrument
Debt Instrument, Interest Rate, Stated Percentage (as a percent)					2.99%	2.99%
Mortgage Debt | Maximum
Debt Instrument
Debt Instrument, Interest Rate, Stated Percentage (as a percent)					7.51%	7.51%
Mortgage Debt | Debt maturing in 2017
Debt Instrument
2017						$ 2,604
Mortgage Debt | Debt maturing in 2018
Debt Instrument
2018						3,641
Mortgage Debt | Debt maturing in 2019
Debt Instrument
2019						3,839
Mortgage Debt | Debt maturing in 2020
Debt Instrument
2020						3,907
Mortgage Debt | Debt maturing in 2021
Debt Instrument
2021						11,277
Mortgage Debt | Thereafter
Debt Instrument
Thereafter						116,481
Life Care Bonds and Demand Notes
Debt Instrument
Other debt						$ 91,000
SH NNN
Debt Instrument
Number of properties classified as held for sale | property					64	64	64
Subsequent event | Unsecured Debt.
Debt Instrument
Repayment of senior unsecured notes	$ 250,000

XML

Commitments and Contingencies (Details) £ in Millions	1 Months Ended		3 Months Ended
	Oct. 31, 2017	Oct. 31, 2016 USD ($)	Mar. 31, 2017 USD ($)	Feb. 28, 2017 GBP (£)	Dec. 31, 2016 USD ($)
Commitments and Contingencies
Loan amount outstanding			$ 492,421,000		$ 899,718,000
QCP | Unsecured Revolving Credit Facility
Commitments and Contingencies
Permanent decrease in commitments for each month equal to retained cash flow (as a percent)			50.00%
Debt Instrument, Term	1 year
Debt instrument, facility fee (as a percent)		0.50%
Loan amount outstanding		$ 0		£ 36
QCP | LIBOR | Unsecured Revolving Credit Facility
Commitments and Contingencies
Debt instrument , floor rate (as a percent)		1.00%
Debt instrument, basis spread on variable rate (as a percent)		6.25%

XML

Equity (Details) - USD ($) $ in Thousands	Mar. 31, 2017	Dec. 31, 2016
Accumulated Other Comprehensive Loss
Cumulative foreign currency translation adjustment	$ (21,827)	$ (22,817)
Unrealized losses on cash flow hedges, net	(3,731)	(3,642)
Supplemental Executive Retirement Plan minimum liability	(3,055)	(3,129)
Unrealized gains (losses) on available for sale securities	(45)	(54)
Total accumulated other comprehensive loss	$ (28,658)	$ (29,642)

XML

Segment Disclosures - Summary Information for the Reportable Segments (Details) - USD ($)	1 Months Ended	3 Months Ended		12 Months Ended
	Jan. 31, 2017	Mar. 31, 2017	Mar. 31, 2016	Dec. 31, 2016
Segment reporting information, revenues
Rental Revenues		$ 473,837,000	$ 502,428,000
HCP's share of earnings		3,269,000	(908,000)
Operating expenses		(159,081,000)	(175,957,000)
Segment NOI		333,908,000	338,830,000
Adjustments to NOI		(568,000)	(2,450,000)
Adjusted NOI		333,340,000	336,380,000
Addback adjustments		568,000	2,450,000
Interest income		18,331,000	18,029,000
Interest expense		(86,718,000)	(122,062,000)
Depreciation and amortization		(136,554,000)	(139,855,000)
General and administrative		(22,478,000)	(25,451,000)
Acquisition and pursuit costs		(1,057,000)	(2,475,000)
Gain on sales of real estate, net		317,258,000
Other income, net		51,208,000	1,292,000
Income tax expense		6,162,000	(3,704,000)
Less: HCP share of unconsolidated joint venture NOI		(19,152,000)	(12,359,000)
Equity income in unconsolidated JVs		3,269,000	(908,000)
Discontinued operations			68,408,000
Net income		464,177,000	119,745,000
Corporate and other assets
Segment reporting information, revenues
Interest expense		(79,265,000)	(105,411,000)
General and administrative		(22,478,000)	(25,451,000)
Acquisition and pursuit costs		(1,057,000)	(2,475,000)
Other income, net		51,208,000	1,292,000
Income tax expense		6,162,000	(3,704,000)
Discontinued operations			68,408,000
Net income		(45,430,000)	(67,341,000)
Intersegment Eliminations
Segment reporting information, revenues
Operating expenses		(60,059,000)	(42,614,000)
Parent Company
Segment reporting information, revenues
HCP's share of earnings		79,211,000	54,973,000
SH NNN
Segment reporting information, revenues
Intersegment sales or transfers		1		$ 17
SH NNN | Operating segment
Segment reporting information, revenues
Rental Revenues		100,034,000	106,889,000
Operating expenses		(1,111,000)	(2,074,000)
Segment NOI		98,923,000	104,815,000
Adjustments to NOI		(1,839,000)	(5,443,000)
Adjusted NOI		97,084,000	99,372,000
Addback adjustments		1,839,000	5,443,000
Interest expense		(627,000)	(4,166,000)
Depreciation and amortization		(26,411,000)	(33,506,000)
Gain on sales of real estate, net		268,464,000
Net income		340,349,000	67,143,000
SHOP | Operating segment
Segment reporting information, revenues
Rental Revenues		140,228,000	165,763,000
Operating expenses		(94,539,000)	(114,003,000)
Segment NOI		62,526,000	61,949,000
Adjustments to NOI		3,508,000	5,032,000
Adjusted NOI		66,034,000	66,981,000
Addback adjustments		(3,508,000)	(5,032,000)
Interest expense		(4,596,000)	(7,855,000)
Depreciation and amortization		(26,358,000)	(26,297,000)
Gain on sales of real estate, net		366,000
Less: HCP share of unconsolidated joint venture NOI		(16,837,000)	(10,189,000)
Equity income in unconsolidated JVs		1,993,000	(2,478,000)
Net income		17,094,000	15,130,000
SHOP | Intersegment Eliminations
Segment reporting information, revenues
Operating expenses		(59,527,000)	(42,088,000)
SHOP | Parent Company | Operating segment
Segment reporting information, revenues
HCP's share of earnings		76,364,000	52,277,000
Life science
Segment reporting information, revenues
Gain on sales of real estate, net	$ 45,000,000
Life science | Operating segment
Segment reporting information, revenues
Rental Revenues		85,321,000	88,948,000
Operating expenses		(17,319,000)	(16,743,000)
Segment NOI		69,571,000	73,641,000
Adjustments to NOI		(256,000)	(673,000)
Adjusted NOI		69,315,000	72,968,000
Addback adjustments		256,000	673,000
Interest expense		(104,000)	(638,000)
Depreciation and amortization		(33,791,000)	(33,596,000)
Gain on sales of real estate, net		44,633,000
Less: HCP share of unconsolidated joint venture NOI		(1,569,000)	(1,436,000)
Equity income in unconsolidated JVs		770,000	709,000
Net income		79,510,000	38,680,000
Life science | Intersegment Eliminations
Segment reporting information, revenues
Operating expenses		(371,000)	(374,000)
Life science | Parent Company | Operating segment
Segment reporting information, revenues
HCP's share of earnings		1,940,000	1,810,000
Medical office | Operating segment
Segment reporting information, revenues
Rental Revenues		118,371,000	108,023,000
Operating expenses		(44,864,000)	(41,949,000)
Segment NOI		73,854,000	66,404,000
Adjustments to NOI		(969,000)	(795,000)
Adjusted NOI		72,885,000	65,609,000
Addback adjustments		969,000	795,000
Interest expense		(129,000)	(1,665,000)
Depreciation and amortization		(42,729,000)	(38,719,000)
Less: HCP share of unconsolidated joint venture NOI		(347,000)	(330,000)
Equity income in unconsolidated JVs		269,000	658,000
Net income		30,918,000	26,348,000
Medical office | Intersegment Eliminations
Segment reporting information, revenues
Operating expenses		(142,000)	(149,000)
Medical office | Parent Company | Operating segment
Segment reporting information, revenues
HCP's share of earnings		489,000	479,000
Other Non-reportable segments | Operating segment
Segment reporting information, revenues
Rental Revenues		29,883,000	32,805,000
Operating expenses		(1,248,000)	(1,188,000)
Segment NOI		29,034,000	32,021,000
Adjustments to NOI		(1,012,000)	(571,000)
Adjusted NOI		28,022,000	31,450,000
Addback adjustments		1,012,000	571,000
Interest income		18,331,000	18,029,000
Interest expense		(1,997,000)	(2,327,000)
Depreciation and amortization		(7,265,000)	(7,737,000)
Gain on sales of real estate, net		3,795,000
Less: HCP share of unconsolidated joint venture NOI		(399,000)	(404,000)
Equity income in unconsolidated JVs		237,000	203,000
Net income		41,736,000	39,785,000
Other Non-reportable segments | Intersegment Eliminations
Segment reporting information, revenues
Operating expenses		(19,000)	(3,000)
Other Non-reportable segments | Parent Company | Operating segment
Segment reporting information, revenues
HCP's share of earnings		$ 418,000	$ 407,000

XML

Segment Disclosures - Revenues and Assets by Segment (Details) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2017	Mar. 31, 2016
Segment Disclosure
Total revenues	$ 492,168	$ 520,457
Operating segment
Segment Disclosure
Total revenues	492,168	520,457
Operating segment | SH NNN
Segment Disclosure
Total revenues	100,034	106,889
Operating segment | SHOP
Segment Disclosure
Total revenues	140,228	165,763
Operating segment | Life science
Segment Disclosure
Total revenues	85,321	88,948
Operating segment | Medical office
Segment Disclosure
Total revenues	118,371	108,023
Operating segment | Other Non-reportable segments
Segment Disclosure
Total revenues	$ 48,214	$ 50,834

XML

Earnings Per Common Share (Details) - USD ($) $ / shares in Units, shares in Thousands, $ in Thousands	3 Months Ended
	Mar. 31, 2017	Mar. 31, 2016
Numerator - Basic
Net income from continuing operations	$ 464,177	$ 51,337
Noncontrolling interests' share in earnings	(3,032)	(3,626)
Net income attributable to HCP, Inc.	461,145	47,711
Participating securities' share in earnings	(770)	(357)
Income from continuing operations applicable to common shares	460,375	47,354
Discontinued operations		68,408
Net income applicable to common shares	460,375	115,762
Numerator - Dilutive
Net income applicable to common shares	460,375	115,762
Add: distributions on dilutive convertible units	2,803
Dilutive net income available to common shares	$ 463,178	$ 115,762
Denominator
Basic weighted average common shares	468,299	466,074
Diluted weighted average common shares	475,173	466,262
Basic earnings per common share:
Continuing operations (in dollars per share)	$ 0.98	$ 0.10
Discontinued operations (in dollars per share)		0.15
Net income applicable to common shares (in dollars per share)	0.98	0.25
Diluted earnings per common share
Continuing operations (in dollars per share)	0.97	0.10
Discontinued operations (in dollars per share)		0.15
Net income applicable to common shares (in dollars per share)	$ 0.97	$ 0.25
Common Stock Options
Diluted earnings per common share
Shares of anti-dilutive securities excluded from earnings per share calculation	1,000
Equity awards
Denominator
Dilutive potential common shares	229	188
Down REIT
Denominator
Dilutive potential common shares	6,645
Diluted earnings per common share
Shares of anti-dilutive securities excluded from earnings per share calculation		6,000
DownREIT LLCs, non-managing member units outstanding		4,000

XML

Supplemental Cash Flow Information (Details) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2017	Mar. 31, 2016
Supplemental cash flow information:
Interest paid, net of capitalized interest	$ 108,232	$ 171,422
Income taxes paid	1,105	1,213
Capitalized interest	3,090	3,128
Supplemental schedule of non-cash investing and financing activities:
Accrued construction costs	51,498	56,972
Non-cash acquisitions and dispositions settled with receivables and restricted cash held in connection with Section 1031 transactions	39,991	91,605
Tenant funded tenant improvements owned by HCP	3,120	9,178
Vesting of restricted stock units	293	248
Conversion of non-managing member units into common stock	1,548	4,136
Mortgages and other liabilities assumed with real estate acquisitions		1,200
Unrealized gains (losses) on available-for-sale securities and derivatives designated as cash flow hedges, net	$ (45)	$ (705)

XML

Variable Interest Entities (Details) $ in Thousands, £ in Millions	3 Months Ended
	Mar. 31, 2017 GBP (£) property loan facility item	Mar. 31, 2017 USD ($) property loan item	Dec. 31, 2016 USD ($)	Aug. 29, 2014
Company's involvement with VIEs:
Mezzanine		$ 625,116	$ 615,188
Unconsolidated Variable Interest Entities
Company's involvement with VIEs:
Number of unconsolidated joint ventures | item	4
Number of properties leased | property	48	48
Number of VIE borrowers with marketable debt securities | item	1	1
Number of loans to VIE borrowers | loan	2	2
CCRC OpCo
Company's involvement with VIEs:
Joint Venture Ownership Percentage				49.00%
Maximum Loss Exposure		$ 217,655
Vintage Park Development JV
Company's involvement with VIEs:
Ownership percentage (as a percent)	85.00%
Maximum Loss Exposure		$ 6,953
VIE tenants-operating leases
Company's involvement with VIEs:
Number of properties leased | property	48	48
Number of VIE tenants | item	7	7
Maximum Loss Exposure		$ 6,721
VIE tenants-DFLs
Company's involvement with VIEs:
Maximum Loss Exposure		600,348
Loan-senior secured
Company's involvement with VIEs:
Maximum Loss Exposure		131,916
Loan-seller financing
Company's involvement with VIEs:
Maximum Loss Exposure		10,000
Loan-seller financing | SH NNN
Company's involvement with VIEs:
Mezzanine		10,000
Number of properties sold | facility	7
Term of facility	5 years
CMBS and LLC investment
Company's involvement with VIEs:
Maximum Loss Exposure		33,391
MMCG | Bridge Loan
Company's involvement with VIEs:
Loan amount	£ 105	131,000
Period of call-option retained	3 years
RIDEA JV
Company's involvement with VIEs:
Ownership percentage (as a percent)	90.00%
RIDEA II
Company's involvement with VIEs:
Maximum Loss Exposure		$ 257,534
RIDEA III
Company's involvement with VIEs:
Ownership percentage (as a percent)	90.00%
HCP Ventures V
Company's involvement with VIEs:
Ownership percentage (as a percent)	51.00%
Vintage Park Development JV
Company's involvement with VIEs:
Ownership percentage (as a percent)	90.00%
DownREIT Partnerships
Company's involvement with VIEs:
Number of controlling ownership interest entities as a managing member | item	5

XML

Variable Interest Entities - Consolidated Variable Interest Entities (Details) - USD ($) $ in Thousands	Mar. 31, 2017	Dec. 31, 2016	Mar. 31, 2016
ASSETS
Development costs and construction in progress	$ 430,007	$ 400,619
Land	1,772,174	1,881,487
Accumulated depreciation and amortization	(2,577,248)	(2,648,930)
Net real estate	10,633,704	11,325,830
Investments in and advances to unconsolidated joint ventures	827,202	571,491
Accounts receivable	31,500	45,116
Cash and cash equivalents	764,114	94,730	$ 91,087
Restricted cash	60,806	42,260
Intangible assets, net	432,109	479,805
Other assets, net	605,407	711,624
Total assets	14,855,868	15,759,265
LIABILITIES AND EQUITY
Mortgage debt	147,329	623,792
Intangible liabilities, net	54,472	58,145
Liabilities of assets held for sale, net		3,776
Deferred Revenue	141,561	149,181
Total liabilities	8,682,393	9,817,957
VIEs
ASSETS
Buildings and improvements	2,787,845	3,522,310
Development costs and construction in progress	23,837	31,953
Land	214,963	327,241
Accumulated depreciation and amortization	(535,012)	(676,276)
Net real estate	2,491,633	3,205,228
Investments in and advances to unconsolidated joint ventures	3,108	3,641
Accounts receivable	9,609	19,996
Cash and cash equivalents	37,005	35,844
Restricted cash	42,009	22,624
Intangible assets, net	139,281	169,027
Other assets, net	55,049	69,562
Total assets	2,777,694	3,525,922
LIABILITIES AND EQUITY
Mortgage debt	45,245	520,870
Intangible liabilities, net	8,734	8,994
Liabilities of assets held for sale, net	92,640	120,719
Deferred Revenue	16,077	23,456
Total liabilities	$ 162,696	$ 674,039

XML

Concentration of Credit Risk (Details)	3 Months Ended		12 Months Ended
	Mar. 31, 2017 property item	Mar. 31, 2016	Dec. 31, 2016 property facility
Brookdale Senior Living | Minimum
Concentration of risk
Percentage of EDITDAR payable as base management fee	4.50%
Brookdale Senior Living | Maximum
Concentration of risk
Percentage of EDITDAR payable as base management fee	5.00%
Senior housing | Management and Accounting Services | Brookdale Senior Living
Concentration of risk
Investments in Joint Ventures Senior Housing Facilities Number	59
SH NNN
Concentration of risk
Properties Held for Sale, Number | property	64		64
SHOP
Concentration of risk
Properties Held for Sale, Number | facility			1
SHOP | Management and Accounting Services | Brookdale Senior Living
Concentration of risk
Number of facilities owned by RIDEA joint ventures	65
Management and Accounting Services | Senior housing | Brookdale Senior Living
Concentration of risk
Management agreement renewal term (in years)	5 years
Management and Accounting Services | Senior housing | Brookdale Senior Living | Minimum
Concentration of risk
Management agreement term (in years)	10 years
Management Agreement Number of Renewals	3
Management and Accounting Services | Senior housing | Brookdale Senior Living | Maximum
Concentration of risk
Management agreement term (in years)	15 years
Management Agreement Number of Renewals	4
Total Assets | SHOP | Brookdale Senior Living
Concentration of risk
Concentration risk (as a percent)	13.00%		18.00%
Tenants and Operators | Total Assets | Brookdale Senior Living
Concentration of risk
Concentration risk (as a percent)	11.00%		17.00%
Tenants and Operators | Total Assets | SH NNN | Brookdale Senior Living
Concentration of risk
Concentration risk (as a percent)	42.00%		69.00%
Tenants and Operators | Revenue | Brookdale Senior Living
Concentration of risk
Concentration risk (as a percent)	12.00%	12.00%
Tenants and Operators | Revenue | SH NNN | Brookdale Senior Living
Concentration of risk
Concentration risk (as a percent)	60.00%	58.00%

XML

Fair Value Measurements - Summary of the Carrying Amounts and Fair Values of the Financial Instruments (Details) - USD ($) $ in Thousands	Mar. 31, 2017	Dec. 31, 2016
Summary of financial instruments
Bank line of credit	$ 492,421	$ 899,718
Senior unsecured notes	7,136,336	7,133,538
Mortgage debt	147,329	623,792
Other debt	91,263	92,385
Carrying Value
Summary of financial instruments
Loans receivable, net	788,486	807,954
Marketable debt securities	18,330	68,630
Marketable equity securities	85	76
Bank line of credit	492,421	899,718
Term loans	274,103	440,062
Senior unsecured notes	7,136,336	7,133,538
Mortgage debt	147,329	623,792
Other debt	91,263	92,385
Carrying Value | Warrants
Summary of financial instruments
Derivative assets	39	19
Carrying Value | Interest-rate swap contracts
Summary of financial instruments
Derivative liabilities	4,163	4,857
Carrying Value | Currency Swap | Level 2
Summary of financial instruments
Derivative assets	1,924	2,920
Fair Value | Level 1
Summary of financial instruments
Marketable equity securities	85	76
Senior unsecured notes	7,445,519	7,386,149
Fair Value | Level 2
Summary of financial instruments
Loans receivable, net	787,067	807,505
Marketable debt securities	18,330	68,630
Bank line of credit	492,421	899,718
Term loans	274,103	440,062
Mortgage debt	134,605	609,374
Other debt	91,263	92,385
Fair Value | Warrants | Level 3
Summary of financial instruments
Derivative assets	39	19
Fair Value | Interest-rate swap contracts | Level 2
Summary of financial instruments
Derivative liabilities	4,163	4,857
Fair Value | Currency Swap | Level 2
Summary of financial instruments
Derivative assets	$ 1,924	$ 2,920

XML

Derivative Financial Instruments (Details) £ in Thousands, $ in Thousands	3 Months Ended
	Mar. 31, 2017 USD ($)	Mar. 31, 2017 GBP (£) item	Mar. 31, 2017 USD ($) item
Maximum
Derivative
Estimate change in fair value of derivative for assumption of one percentage point change in the interest rate	$ 2,000
Net Investment Hedging | Facility and 2015 Term Loan
Derivative
Borrowings designated as hedge of net investment | £		£ 219,000
Interest rate swap, entered in July 2005, maturity in July 2020 | BMA Swap Index
Derivative
Notional amount			$ 44,300
Fair value of interest rate hedge, liabilities			$ (3,301)
Interest rate swap, entered in July 2005, maturity in July 2020 | Cash flow hedge
Derivative
Number of interest-rate swap contracts | item		3	3
Interest rate swap, entered in July 2005, maturity in July 2020 | Cash flow hedge | BMA Swap Index
Derivative
Fixed Rate/Buy Amount (as a percent)		3.82%	3.82%
Interest rate swap, entered in January 2015, maturity in October 2017 | GBP LIBOR
Derivative
Notional amount | £		£ 220,000
Fair value of interest rate hedge, liabilities			$ (862)
Interest rate swap, entered in January 2015, maturity in October 2017 | Cash flow hedge
Derivative
Exchange rate GBP/USD		1.5149	1.5149
Interest rate swap, entered in January 2015, maturity in October 2017 | Cash flow hedge | GBP LIBOR
Derivative
Fixed Rate/Buy Amount (as a percent)		1.79%	1.79%
Floating/Exchange Rate Index, percentage		0.975%	0.975%
Currency swap, entered in January 2015, maturity in October 2017
Derivative
Notional amount | £		£ 7,500
Fair value of foreign currency hedge, assets			$ 1,924
Currency swap, entered in January 2015, maturity in October 2017 | Cash flow hedge
Derivative
Buy (sell) amount | £		£ 1,100
Monthly buy (sell) amount			$ 11,300